tag:blogger.com,1999:blog-64491507575054258062024-03-14T08:04:08.740+01:00Onco-ActuCe bulletin signale des articles du web anglophone portant sur les divers champs d'intervention de l'Institut national du cancer. <br>La publication se fait sur un rythme quotidien.OVEhttp://www.blogger.com/profile/16701670533772026788noreply@blogger.comBlogger1129125tag:blogger.com,1999:blog-6449150757505425806.post-90937867280925987302020-06-30T11:16:00.001+02:002020-06-30T11:16:44.057+02:00Onco Actu du 30 juin 2020<i><span style="font-family: Verdana, sans-serif;">Message de service : ce billet est le dernier numéro d'Onco Actu rédigé par son créateur. Fidèles lecteurs, sachez que je pars à la retraite fier d'avoir contribué, durant toutes ces années, à la lutte contre les cancers en France.</span></i><br />
<i><span style="font-family: Verdana, sans-serif;">Gérard Chevalier</span></i><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">PRÉVENTION - TABAC - CIGARETTES ÉLECTRONIQUES</span></b></div>
<span style="font-family: Verdana, sans-serif;"><b><a href="https://theconversation.com/why-the-ban-on-nicotine-vape-fluid-will-do-more-harm-than-good-141365" target="_blank">Why the ban on nicotine vape fluid will do more harm than good [The Conversation]</a></b> </span><br />
<span style="font-family: Verdana, sans-serif;">Last week the federal government’s Office of Drug Control announced changes to the importation of nicotine-containing electronic cigarette fluids that will seriously affect the estimated 227,000 regular e-cigarette users in Australia.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">TRAITEMENTS - ESSAIS</span></b></div>
<span style="font-family: Verdana, sans-serif;"><b><a href="https://medicine.yale.edu/news-article/25646/" target="_blank">Yale Cancer Center Study Validates Combination Therapy for Aggressive Endometrial Cancer [Yale]</a></b> </span><br />
<span style="font-family: Verdana, sans-serif;">Yale Cancer Center (YCC) scientists have found that combining the targeted drug trastuzumab with chemotherapy significantly improves survival rates for women with a rare, aggressive form of endometrial cancer. These results may help to change the standard of care worldwide for the disease. The findings are published today in the journal Clinical Cancer Research.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">IMMUNOTHÉRAPIES - AMM</span></b></div>
<b><span style="font-family: Verdana, sans-serif;"><a href="https://www.fda.gov/news-events/press-announcements/fda-approves-first-line-immunotherapy-patients-msi-hdmmr-metastatic-colorectal-cancer" target="_blank">FDA Approves First-Line Immunotherapy for Patients with MSI-H/dMMR Metastatic Colorectal Cancer [FDA]</a> </span></b><br />
<span style="font-family: Verdana, sans-serif;">The FDA’s approval for this indication was based on the results of one multicenter, international, open-label, active-controlled, randomized trial that compared Keytruda with chemotherapy treatment in 307 patients with MSI-H or dMMR metastatic colorectal cancer.</span><br />
<br />
<b><span style="font-family: Verdana, sans-serif;"><a href="https://www.mrknewsroom.com/newsroom/news-releases/news-details/2020/FDA-Approves-Mercks-KEYTRUDA-pembrolizumab-for-First-Line-Treatment-of-Patients-With-Unresectable-or-Metastatic-MSI-H-or-dMMR-Colorectal-Cancer/default.aspx" target="_blank">FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for First-Line Treatment of Patients With Unresectable or Metastatic MSI-H or dMMR Colorectal Cancer [Merck]</a> </span></b><br />
<span style="font-family: Verdana, sans-serif;">Approval Received Less Than One Month Following Submission of sBLA Application Based on Results of KEYNOTE-177.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES, …</span></b></div>
<b><span style="font-family: Verdana, sans-serif;"><a href="https://news.illinois.edu/view/6367/1083499516" target="_blank">Engineered immune cells recognize, attack human and mouse solid-tumor cancer cells [University of Illinois]</a> </span></b><br />
<span style="font-family: Verdana, sans-serif;">“We realized that because this receptor binds both to the protein and the sugar on the surface of the cancer cell, there might be room to change the antibody so that it can bind to more than one protein attached to the short sugar,” Sharma said. “This could make it broadly reactive to different kinds of cancers.”</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">PHARMA</span></b></div>
<span style="font-family: Verdana, sans-serif;"><b><a href="https://investor.seattlegenetics.com/press-releases/news-details/2020/Seattle-Genetics-Announces-Positive-Topline-Results-from-Phase-2-Clinical-Trial-of-Tisotumab-Vedotin-in-Recurrent-or-Metastatic-Cervical-Cancer/default.aspx" target="_blank">Seattle Genetics Announces Positive Topline Results from Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer [Seattle Genetics]</a></b> </span><br />
<span style="font-family: Verdana, sans-serif;">Full Data to be Presented at an Upcoming Medical Meeting.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">FDA, EMA, ...</span></b></div>
<span style="font-family: Verdana, sans-serif;"><b><a href="https://www.statnews.com/2020/06/29/what-to-expect-from-modernizing-the-fdas-data-strategy-meeting" target="_blank">What to expect from ‘Modernizing the FDA’s Data Strategy’ meeting [STAT]</a></b> </span><br />
<span style="font-family: Verdana, sans-serif;">There will also be many implications for the agency when the European Union’s General Data Protection Regulation and other similar regulations come into play. Privacy must be paramount as the data modernization strategy progresses. </span><br />
<br />
<span style="font-family: Verdana, sans-serif;"><b><a href="https://www.raps.org/news-and-articles/news-articles/2020/6/ema-revises-methodological-guidance-for-trials-imp" target="_blank">EMA revises methodological guidance for trials impacted by COVID-19 [RAPS]</a></b> </span><br />
<span style="font-family: Verdana, sans-serif;">The agency also says it will extend its decision to hold all upcoming committee and working party meetings virtually through September 2020. The agency adds that it will continue its practice of holding stakeholder events virtually or postponing them.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">TRAITEMENTS - AMM</span></b></div>
<b><span style="font-family: Verdana, sans-serif;"><a href="https://www.fda.gov/news-events/press-announcements/fda-approves-breast-cancer-treatment-can-be-administered-home-health-care-professional" target="_blank">FDA Approves Breast Cancer Treatment That Can Be Administered At Home By Health Care Professional [FDA]</a> </span></b><br />
<span style="font-family: Verdana, sans-serif;">Today, the U.S. Food and Drug Administration approved Phesgo—a combination of pertuzumab, trastuzumab and hyaluronidase–zzxf—for injection under the skin to treat adult patients with HER2-positive breast cancer that has spread to other parts of the body, and for treatment of adult patients with early HER2-positive breast cancer.</span><br />
<br />
<span style="font-family: Verdana, sans-serif;"><b><a href="https://www.roche.com/media/releases/med-cor-2020-06-29c.htm" target="_blank">FDA approves Roche’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for HER2-positive breast cancer [Roche]</a></b> </span><br />
<span style="font-family: Verdana, sans-serif;">Data showed that 85% of patients preferred Phesgo compared to standard intravenous administration.</span><br />
<br />
<span style="font-family: Verdana, sans-serif;"><b><a href="https://www.reuters.com/article/us-roche-hldg-fda/roches-combo-therapy-for-advanced-breast-cancer-gets-u-s-fda-approval-idUSKBN240297" target="_blank">Roche's combo therapy for advanced breast cancer gets U.S. FDA approval [Reuters]</a></b> </span><br />
<span style="font-family: Verdana, sans-serif;">The therapy, which is initially used in combination with chemotherapy, can continue to be administered at home by a qualified healthcare professional after the patient is finished with the chemotherapy regimen.</span><br />
<br />
<span style="font-family: Verdana, sans-serif;"><b><a href="https://xconomy.com/san-diego/2020/06/29/roche-gets-fda-ok-for-injectable-version-of-breast-cancer-drug/" target="_blank">Roche Gets FDA OK for Injectable Version of Breast Cancer Drug [Xconomy]</a></b> </span><br />
<span style="font-family: Verdana, sans-serif;">The newly approved drug, Phesgo, is a fixed-dose mix of pertuzumab (Perjeta) and trastuzumab (Herceptin) that uses technology developed by San Diego’s Halozyme Therapeutics.</span><br />
<br />
<span style="font-family: Verdana, sans-serif;"><b><a href="https://www.novartis.com/news/media-releases/novartis-announces-met-inhibitor-tabrecta-approved-japan-advanced-non-small-cell-lung-cancer-metex14" target="_blank">Novartis announces MET inhibitor Tabrecta™ approved in Japan for advanced non-small cell lung cancer with METex14 [Novartis]</a></b> </span><br />
<span style="font-family: Verdana, sans-serif;">Lung cancer is the most common type of cancer in Japan and approximately 3,000 patients are diagnosed with METex14 metastatic NSCLC, a particularly aggressive form of the disease, in Japan each year.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">TRAITEMENTS - ÉCONOMIE</span></b></div>
<span style="font-family: Verdana, sans-serif;"><b><a href="http://www.pharmafile.com/news/552423/nice-knocks-back-janssens-zytiga-combo-newly-diagnosed-hormone-sensitive-metastatic-pros" target="_blank">NICE knocks back Janssen's Zytiga combo for newly diagnosed, hormone-sensitive metastatic prostate cancer [Pharmafile]</a></b> </span><br />
<span style="font-family: Verdana, sans-serif;">This is despite trial data supplied in support of the NICE application showing that patients receiving the Zytiga combo survived for a median of 53.3 months overall, compared to 36.5 months with placebo plus ADT.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">LUTTE CONTRE LES CANCERS - COVID19</span></b></div>
<span style="font-family: Verdana, sans-serif;"><b><a href="https://www.cancer.gov/news-events/cancer-currents-blog/2020/covid-19-cancer-clinical-trials" target="_blank">Responding to Coronavirus, Cancer Researchers Reimagine Clinical Trials [NCI]</a></b> </span><br />
<span style="font-family: Verdana, sans-serif;">A greater use of telemedicine has emerged as one of the positive changes to cancer clinical trials that could be continued after the pandemic has passed, according to the results of two surveys of clinical trial investigators and a series of recent commentaries by leaders of clinical trials. </span><br />
<br />
<b><span style="font-family: Verdana, sans-serif;"><a href="https://www.cancerresearchuk.org/about-us/cancer-news/press-release/2020-06-29-scotlands-lifeline-cancer-trials-must-be-restarted-urgently" target="_blank">Scotland's lifeline cancer trials must be restarted urgently [Cancer Research UK]</a> </span></b><br />
<span style="font-family: Verdana, sans-serif;">A report to the Scottish Parliament’s Cross Party Group on Cancer, which meets online today, has also highlighted a 95% drop* in new patients entering clinical trials, which has left people with cancer with fewer options for treatment. Coronavirus has also delayed research into drugs that could potentially be effective in the future.</span>OVEhttp://www.blogger.com/profile/16701670533772026788noreply@blogger.comtag:blogger.com,1999:blog-6449150757505425806.post-39558565493275138252020-06-29T11:23:00.000+02:002020-06-29T11:23:24.095+02:00Onco Actu du 29 juin 2020<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">BIOLOGIE - TECHNOS, MODÈLES</span></b></div>
<span style="font-family: Verdana, sans-serif;"><b><a href="https://www.stjude.org/media-resources/news-releases/2020-medicine-science-news/st-jude-cloud-portal-expands-access-to-treasure-trove-of-pediatric-solid-tumor-data.html" target="_blank">St. Jude Cloud portal expands access to treasure trove of pediatric solid tumor data [St. Jude Children’s Research Hospital]</a></b> </span><br />
<span style="font-family: Verdana, sans-serif;">The CSTN includes wide-ranging data on 170 patient-derived samples representing 21 different childhood solid tumors, including neuroblastoma, rhabdomyosarcoma and rare tumors. The samples are orthotopic patient-derived xenografts, meaning the human tumor samples are implanted and grown in the corresponding location in mice.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">DÉP., DIAG. & PRONO. - GÉNOME</span></b></div>
<b><span style="font-family: Verdana, sans-serif;"><a href="https://eurekalert.org/pub_releases/2020-06/dmc-rgp062620.php" target="_blank">Rapid genomic profiling of colon cancers can improve therapy selection for patients [EurekAlert!]</a> </span></b><br />
<span style="font-family: Verdana, sans-serif;">In a new multicenter study, researchers compared a new cartridge-based laboratory testing device called the IdyllaTM automated system (Biocartis) to current standard-of-care testing methods. They found that average turnaround time for test results could be cut by more than 65% from 15 days to 5 days, with some results available in a single day.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">DÉP., DIAG. & PRONO. - COLON-RECTUM</span></b></div>
<span style="font-family: Verdana, sans-serif;"><b><a href="https://medicalxpress.com/news/2020-06-complications-colonoscopy-aged.html" target="_blank">Complications after colonoscopy up for those aged ≥ 75 [Medical XPress]</a></b> </span><br />
<span style="font-family: Verdana, sans-serif;">For individuals undergoing outpatient colonoscopy, the risk of 30-day postcolonoscopy complications is increased for those aged ≥75 years, according to a study published online June 25 in JAMA Network Open.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">DÉP., DIAG. & PRONO. - BIOPSIES LIQUIDES</span></b></div>
<span style="font-family: Verdana, sans-serif;"><b><a href="https://www.genomeweb.com/liquid-biopsy/brain-and-kidney-cancer-studies-lay-path-clinical-application-epigenetic-liquid-biopsy" target="_blank">Brain and Kidney Cancer Studies Lay Path for Clinical Application of Epigenetic Liquid Biopsy Method [Genome Web]</a></b> </span><br />
<span style="font-family: Verdana, sans-serif;">Two publications piloting different potential clinical applications appeared in Nature Medicine this week.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">DÉP., DIAG. & PRONO. - IMAGERIE</span></b></div>
<b><span style="font-family: Verdana, sans-serif;"><a href="https://www.icr.ac.uk/news-archive/mri-scan-used-for-heart-disease-could-also-pick-out-aggressive-cancers" target="_blank">MRI scan used for heart disease could also pick out aggressive cancers [Institute of Cancer Research]</a> </span></b><br />
<span style="font-family: Verdana, sans-serif;">Researchers showed that the MRI imaging technique, known as T1-mapping, could offer crucial insights into the biology of childhood cancers and give an early warning of how effective targeted treatments were likely to be.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">TRAITEMENTS - PRÉ-CLINIQUE</span></b></div>
<b><span style="font-family: Verdana, sans-serif;"><a href="http://news.mit.edu/2020/how-cancer-drugs-find-their-targets-could-lead-new-drug-development-toolset-0626" target="_blank">How cancer drugs find their targets [MIT]</a> </span></b><br />
<span style="font-family: Verdana, sans-serif;">“We used to think that drugs come to the right place because their targets are there, but in our in vitro system, the target is not there. That’s really informative — it shows the drug is actually being concentrated in a different way than we thought.”</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">TRAITEMENTS - ESSAIS</span></b></div>
<b><span style="font-family: Verdana, sans-serif;"><a href="https://www.cancerresearchuk.org/about-us/cancer-news/news-report/2020-06-25-targeted-drug-improves-survival-for-children-with-non-hodgkin-lymphoma" target="_blank">Targeted drug improves survival for children with non-Hodgkin lymphoma [Cancer Research UK]</a> </span></b><br />
<span style="font-family: Verdana, sans-serif;">The latest clinical trial analysis, published in the New England Journal of Medicine, involved 328 children and young people aged between 2 and 18 years, with recruitment in 12 different countries. The trial tested the benefits of adding 6 doses of rituximab to standard chemotherapy treatment.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">IMMUNOTHÉRAPIES - BIOTECH</span></b></div>
<b><span style="font-family: Verdana, sans-serif;"><a href="https://endpts.com/novartis-backed-poseida-is-packing-in-the-cash-for-its-next-gen-car-t-work-adding-a-110m-venture-raise-on-top-of-its-newly-refiled-ipo/" target="_blank">Novartis-backed Poseida is packing in the cash for its next-gen CAR-T work, adding a $110M venture raise on top of its newly-refiled IPO [EndPoints]</a> </span></b><br />
<span style="font-family: Verdana, sans-serif;">Poseida’s big idea involves the use of a non-viral DNA tech that they say can be used to gather a bigger concentration of stem cell memory T cells that can avoid the exhaustion that limits the efficacy of the pioneers — a central theme in cell therapy 2.0. </span><br />
<br />
<b><span style="font-family: Verdana, sans-serif;"><a href="https://www.fiercebiotech.com/biotech/natural-killer-biotech-artiva-launches-78m-and-cancer-biotech-veterans" target="_blank">Natural killer biotech Artiva launches with $78M, industry veterans [Fierce Biotech]</a> </span></b><br />
<span style="font-family: Verdana, sans-serif;">The company plans to enter the clinic this year with AB-101 in combination with an anti-CD20 monoclonal antibody for the treatment of relapsed refractory B-cell lymphoma.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">IMMUNOTHÉRAPIES - AMM</span></b></div>
<span style="font-family: Verdana, sans-serif;"><b><a href="https://www.esmo.org/oncology-news/fda-approves-pembrolizumab-for-cutaneous-squamous-cell-carcinoma" target="_blank">FDA Approves Pembrolizumab for Cutaneous Squamous Cell Carcinoma [ESMO]</a></b> </span><br />
<span style="font-family: Verdana, sans-serif;">Efficacy was investigated in KEYNOTE-629 (NCT03284424), a multicentre, multi-cohort, non-randomised, open-label trial. The trial excluded patients who had previously received therapy with an anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody and those with autoimmune disease or a medical condition that required immunosuppression.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">IMMUNOTHÉRAPIES - PRÉ-CLINIQUE</span></b></div>
<span style="font-family: Verdana, sans-serif;"><b><a href="https://www.hopkinsmedicine.org/news/newsroom/news-releases/research-story-tip-immune-cells-hampered-when-fighting-soft-tissue-and-bone-sarcomas" target="_blank">Immune Cells Hampered When Fighting Soft Tissue and Bone Sarcomas [Johns Hopkins]</a></b> </span><br />
<span style="font-family: Verdana, sans-serif;">Immunotherapies such as checkpoint inhibitors that enhance the body’s natural ability to fight cancer have been only minimally successful in treating sarcomas — rare cancers that grow in the soft tissues and bones. In a new study, Johns Hopkins Kimmel Cancer Center researchers have teased out the tumor microenvironment in these cancers to look for reasons why.</span><br />
<br />
<span style="font-family: Verdana, sans-serif;"><b><a href="https://www.fiercebiotech.com/research/manipulating-proteins-to-turn-cold-tumors-responsive-to-immunotherapies" target="_blank">Manipulating proteins to make 'cold' tumors responsive to immunotherapies [Fierce Biotech]</a></b> </span><br />
<span style="font-family: Verdana, sans-serif;">In mice with a variety of cancers, DR-18 significantly reduced tumor growth compared with wild-type IL-18. It also completely cleared tumors in many of the animals.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES, …</span></b></div>
<span style="font-family: Verdana, sans-serif;"><b><a href="https://www.cellectis.com/en/press/cellectis-published-streamlined-manufacturing-method-to-generate-ultrapure-allogeneic-car-t-cell-therapies/" target="_blank">Cellectis Published Streamlined Manufacturing Method to Generate Ultrapure Allogeneic CAR T-Cell Therapies [Cellectis]</a></b> </span><br />
<span style="font-family: Verdana, sans-serif;">This article describes an innovative and easy-to-implement procedure which will streamline the manufacturing of allogeneic ‘off-the-shelf’ CAR T-cell therapies.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">PHARMA</span></b></div>
<span style="font-family: Verdana, sans-serif;"><b><a href="https://endpts.com/sanofi-preps-another-round-of-layoffs-as-new-execs-look-to-slim-down-the-global-pharma-in-an-ongoing-reorganization-report/" target="_blank">Sanofi preps another round of layoffs as new execs look to slim down the global pharma in an ongoing reorganization — report [EndPoints]</a></b> </span><br />
<span style="font-family: Verdana, sans-serif;">Since Hudson’s arrival in Paris, the company has dumped its diabetes work, focusing on cancer and specialty care. There’s long been considerable tension between the European side of Sanofi and the US-based research ops, where Reed is based.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">FDA, EMA, ... </span></b></div>
<span style="font-family: Verdana, sans-serif;"><b><a href="https://www.ema.europa.eu/en/news/emer-cooke-nominated-new-ema-executive-director" target="_blank">Emer Cooke nominated as new EMA Executive Director [EMA]</a></b> </span><br />
<span style="font-family: Verdana, sans-serif;">Ms Cooke has 30 years’ experience in international regulatory affairs, 18 years of which were in leadership roles. She worked for the pharmaceutical unit of the European Commission from 1998 to 2002 and at EMA between 2002 and 2016. </span><br />
<br />
<span style="font-family: Verdana, sans-serif;"><b><a href="https://endpts.com/ema-nominates-emer-cooke-as-executive-director-to-replace-guido-rasi/" target="_blank">EMA nominates Emer Cooke as executive director to replace Guido Rasi [EndPoints]</a></b> </span><br />
<span style="font-family: Verdana, sans-serif;">Cooke
is currently the director of the Regulation and Prequalification
Department at the WHO, where she leads the international agency’s work
on health technology regulation, standards, prequalification and
regulatory systems strengthening.</span><br />
<br />
<span style="font-family: Verdana, sans-serif;"><b><a href="https://www.fiercebiotech.com/biotech/ema-picks-who-s-cooke-to-replace-rasi-as-executive-director" target="_blank">EMA picks WHO's Cooke to replace Rasi as executive director [Fierce Biotech]</a></b> </span><br />
<span style="font-family: Verdana, sans-serif;">In nominating Cooke, the management board has turned to an EMA insider to lead the agency.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">TRAITEMENTS - AMM</span></b></div>
<b><span style="font-family: Verdana, sans-serif;"><a href="https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-june-2020" target="_blank">Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 June 2020 [EMA]</a> </span></b><br />
<span style="font-family: Verdana, sans-serif;">The CHMP adopted a negative opinion recommending the refusal of a marketing authorisation for Turalio (pexidartinib). Turalio was expected to be used to treat tenosynovial giant cell tumours.</span><br />
<br />
<b><span style="font-family: Verdana, sans-serif;"><a href="https://www.samsungbioepis.com/en/newsroom/newsroomView.do?idx=177" target="_blank">Samsung Bioepis Receives Positive CHMP Opinion for AYBINTIO® (Bevacizumab) [Samsung]</a> </span></b><br />
<span style="font-family: Verdana, sans-serif;">AYBINTIO® is recommended for the treatment of the same types of cancer as reference bevacizumab.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">TRAITEMENTS - ÉCONOMIE</span></b></div>
<span style="font-family: Verdana, sans-serif;"><b><a href="https://www.cancerresearchuk.org/about-us/cancer-news/news-report/2020-06-26-prostate-cancer-hormone-therapy-not-recommended-for-nhs-in-england" target="_blank">Prostate cancer hormone therapy not recommended for NHS in England [Cancer Research UK]</a></b> </span><br />
<span style="font-family: Verdana, sans-serif;">In addition to the uncertainties about the drug’s effectiveness, NHS England and the manufacturer were unable to agree a pricing arrangement that would make abiraterone a cost-effective use of NHS resources.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">LUTTE CONTRE LES CANCERS - OBSERVATION</span></b></div>
<span style="font-family: Verdana, sans-serif;"><b><a href="https://healthcare.utah.edu/huntsmancancerinstitute/news/2020/06/a-study-of-early-onset-colorectal-cancer-in-young-adult-men-reveals-hotspots-of-death-in-the-united-states.php" target="_blank">A Study Of Early-onset Colorectal Cancer In Young Adult Men Reveals “Hotspots” Of Death In The United States [Huntsman Cancer Institute]</a></b> </span><br />
<span style="font-family: Verdana, sans-serif;">Rogers and his colleagues developed an analysis of counties with a high rate of early-onset colorectal cancer using data from Centers for Disease Control and Prevention during the years 1999 to 2017. They then linked this to Surveillance, Epidemiology, and End Results (SEER) Program data from the National Cancer Institute for men aged 15 to 49.</span><br />
OVEhttp://www.blogger.com/profile/16701670533772026788noreply@blogger.comtag:blogger.com,1999:blog-6449150757505425806.post-52641463358798756382020-06-26T11:47:00.000+02:002020-06-26T11:47:52.857+02:00Onco Actu du 26 juin 2020<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">BIOLOGIE</span></b></div>
<span style="font-family: Verdana, sans-serif;"><b><a href="https://news.vanderbilt.edu/2020/06/24/discovery-of-aggressive-cancer-cell-types-by-vanderbilt-researchers-made-possible-with-machine-learning-techniques/" target="_blank">Discovery of aggressive cancer cell types by Vanderbilt researchers made possible with machine learning techniques [Vanderbilt]</a></b> </span><br />
<span style="font-family: Verdana, sans-serif;">“We’re able to find the needles in the haystack without searching the entire haystack. This technology lets us devote our attention to better understanding the most dangerous cancer cells and to get closer to ultimately curing brain cancer.”</span><br />
<br />
<span style="font-family: Verdana, sans-serif;"><b><a href="https://www.sloankettering.edu/blog/metabolic-enzyme-drives-lymphoma-and-potential-drug-target" target="_blank">A Metabolic Enzyme Drives Lymphoma and Is a Potential Drug Target [Memorial Sloan Kettering Cancer Center]</a></b> </span><br />
<span style="font-family: Verdana, sans-serif;">“We find that increased activity of a normal metabolic enzyme, called SHMT2, is sufficient to transform normal B cells into B cell lymphomas,” says Sara Parsa. The paper was published in the journal Nature Cancer.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">BIOLOGIE - TECHNOS, MODÈLES</span></b></div>
<span style="font-family: Verdana, sans-serif;"><b><a href="https://www.nature.com/articles/d41586-020-01906-4" target="_blank">CRISPR gene editing in human embryos wreaks chromosomal mayhem [Nature]</a></b> </span><br />
<span style="font-family: Verdana, sans-serif;">Three studies showing large DNA deletions and reshuffling heighten safety concerns about heritable genome editing.</span><br />
<br />
<span style="font-family: Verdana, sans-serif;"><b><a href="https://keck.usc.edu/new-dna-sequencing-technique-may-help-unravel-genetic-diversity-of-cancer-tumors/" target="_blank">New DNA Sequencing technique may help unravel genetic diversity of cancer tumors [Keck School of Medicine]</a></b> </span><br />
<span style="font-family: Verdana, sans-serif;">Using a microfluidic-droplet-based single cell sequencing method, USC researchers have simultaneously sequenced the genomes of close to 1,500 single cells, revealing genetic diversity previously hidden in a well-studied melanoma cell line.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">ÉTIOLOGIE - ENVIRONNEMENT</span></b></div>
<b><span style="font-family: Verdana, sans-serif;"><a href="https://media.bayer.com/baynews/baynews.nsf/ID/E5F9EDCBBBC030B8C125859100413DAE" target="_blank">Bayer announces agreements to resolve major legacy Monsanto litigation [Bayer]</a> </span></b><br />
<span style="font-family: Verdana, sans-serif;">Company will make a total payment of $10.1 billion to $10.9 billion (EUR 9.1 billion to EUR 9.8 billion) to resolve current and address potential future Roundup™ litigation.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">ÉTIOLOGIE - GÉNOME</span></b></div>
<span style="font-family: Verdana, sans-serif;"><b><a href="https://www.stjude.org/media-resources/news-releases/2020-medicine-science-news/inherited-mutation-found-among-brazilians-increases-cancer-risk.html" target="_blank">Inherited mutation found among Brazilians increases cancer risk [St. Jude Children’s Research Hospital]</a></b> </span><br />
<span style="font-family: Verdana, sans-serif;">Genomic research helps explain why some people with a common TP53 mutation widespread in Brazil get cancer while others do not.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">PRÉVENTION - ALIMENTATION</span></b></div>
<span style="font-family: Verdana, sans-serif;"><b><a href="https://chhs.gmu.edu/news/586696" target="_blank">Cancer Survivors Overestimate the Quality of their Diets, Finds First Study on the Topic [George Mason University]</a></b> </span><br />
<span style="font-family: Verdana, sans-serif;">Xue and colleagues analyzed data from the National Health and Nutrition Examination Survey (NHANES) from 2005-2014 on 2,361 cancer survivors and 23,114 participants who had not had cancer as a comparison group.</span><br />
<br />
<span style="font-family: Verdana, sans-serif;"><b><a href="https://medicalxpress.com/news/2020-06-results-fasting-mimicking-diet-cancer.html" target="_blank">First results of fasting mimicking diet to support cancer patients undergoing chemotherapy [Medical Xpress]</a></b> </span><br />
<span style="font-family: Verdana, sans-serif;">Does fasting help make chemotherapy more effective in breast cancer patients? Researchers led by Leiden University Medical Centre (LUMC) and Breast Cancer Research Group (BOOG) are a step closer to answering that question after completing the first randomized study. They describe their auspicious results in the scientific journal Nature Communications. </span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">DÉP., DIAG. & PRONO. - COL DE L’UTÉRUS</span></b></div>
<span style="font-family: Verdana, sans-serif;"><b><a href="https://www.nih.gov/news-events/news-releases/ai-dual-stain-approach-improved-accuracy-efficiency-cervical-cancer-screening-nih-study" target="_blank">AI dual-stain approach improved accuracy, efficiency of cervical cancer screening in NIH study [NIH]</a></b> </span><br />
<span style="font-family: Verdana, sans-serif;">The new approach uses artificial intelligence (AI) to automate dual-stain evaluation and has clear implications for clinical care. Findings from the study were published June 25, 2020, in the Journal of the National Cancer Institute.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">DÉP., DIAG. & PRONO. - BIOPSIES LIQUIDES</span></b></div>
<span style="font-family: Verdana, sans-serif;"><b><a href="https://www.genomeweb.com/liquid-biopsy/inivata-demonstrates-potential-ctdna-assay-cancer-recurrence-mrd-applications" target="_blank">Inivata Demonstrates Potential of ctDNA Assay for Cancer Recurrence, MRD Applications [Genome Web]</a></b> </span><br />
<span style="font-family: Verdana, sans-serif;">In one study, the UK-based firm found that RaDaR detected circulating tumor DNA (ctDNA) in lung cancer patients up to a year before standard clinical progression occurred in most of the cases.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">DÉP., DIAG. & PRONO. - POUMON</span></b></div>
<span style="font-family: Verdana, sans-serif;"><b><a href="https://www.roche.com/media/releases/med-cor-2020-06-26.htm">Roche improves speed and accuracy of non-small cell lung cancer diagnosis with launch of automated digital pathology algorithm [Roche]</a></b> </span><br />
<span style="font-family: Verdana, sans-serif;">uPath PD-L1 (SP263) image analysis uses automated pre-computing and one-click scoring to enable quicker and accurate detection and measurement of tumour cell staining positivity.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">TRAITEMENTS - PRÉ-CLINIQUE</span></b></div>
<span style="font-family: Verdana, sans-serif;"><b><a href="https://www.icr.ac.uk/news-archive/drug-used-in-breast-and-ovarian-cancer-could-lead-to-safer-more-effective-treatment-for-neuroblastoma" target="_blank">Drug used in breast and ovarian cancer could lead to safer, more effective treatment for neuroblastoma [Institute of Cancer Research]</a></b> </span><br />
<span style="font-family: Verdana, sans-serif;">“We have shown that PARP inhibitors kill neuroblastoma cells with MYCN in the laboratory. The next step is to see whether they are beneficial in children with neuroblastoma, probably in combination with chemotherapy or radiotherapy. This would be done in a clinical trial.”</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">IMMUNOTHÉRAPIES - BIOTECH</span></b></div>
<span style="font-family: Verdana, sans-serif;"><b><a href="https://endpts.com/out-of-jobs-a-pair-of-early-cell-therapy-executives-went-to-seoul-came-back-with-a-new-company-70m-and-a-plan-to-leapfrog-natural-killer-competitors/" target="_blank">Out of jobs, a pair of early cell therapy executives went to Seoul, came back with a new company, $70M and a plan to leapfrog natural killer competitors [EndPoints]</a></b> </span><br />
<span style="font-family: Verdana, sans-serif;">They’ll start with a therapy that combines NKs with an approved antibody therapy like rituximab to improve the antibody’s effectiveness. Behind that, they’re working on CAR-NK therapy and, longer term, gene-edited CAR-NK cells.</span><br />
<br />
<span style="font-family: Verdana, sans-serif;"><b><a href="https://endpts.com/yale-spinout-re-engineers-an-immunotherapy-gsk-others-once-abandoned/" target="_blank">Yale spinout re-engineers an immunotherapy GSK, others once abandoned [EndPoints]</a></b> </span><br />
<span style="font-family: Verdana, sans-serif;">If it holds up, the new protein, called DR-18, could be given with other immunotherapies such as PD-1 inhibitors or CAR-T to enhance their effectiveness. </span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">IMMUNOTHÉRAPIES - AMM </span></b></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><b><a href="https://endpts.com/fda-oks-mercks-heavyweight-keytruda-for-cancer-niche-triggering-title-fight-with-the-street-brawlers-at-regeneron/">FDA OKs Merck’s heavyweight Keytruda for cancer niche — triggering title fight with the street brawlers at Regeneron [EndPoints]</a></b> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;">Regeneron and their partners at Sanofi no longer enjoy a monopoly in that particular field. Merck grabbed an OK for their top-selling PD-1 Keytruda in the same group of patients. But don’t expect Regeneron — still struggling to boost sales — to let go of their best-in-class claims.</span></div>
<div style="text-align: left;">
<br /></div>
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">IMMUNOTHÉRAPIES - PRÉ-CLINIQUE</span></b></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><b><a href="https://endpts.com/over-a-decade-ago-a-disastrous-trial-killed-research-on-a-potential-immunotherapy-can-a-regeneron-bispecific-revive-it/" target="_blank">Over a decade ago, a disastrous trial killed research on a potential immunotherapy. Can a Regeneron bispecific revive it? [EndPoints]</a></b> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;">These bispecifics work by binding to both a protein on a tumor and a protein on a T cell (as opposed to a conventional antibody that only binds to one protein). </span></div>
<div style="text-align: left;">
<br /></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><b><a href="https://www.fiercebiotech.com/research/regeneron-identifies-new-combo-approach-may-boost-i-o-drug-s-cancer-response" target="_blank">Regeneron identifies new combos to boost I-O drug Libtayo's cancer response [Fierce Biotech]</a></b> </span></div>
<span style="font-family: Verdana, sans-serif;">In a new study published in Science Translational Medicine, Regeneron showed that adding bispecific antibodies targeting a T cell protein called CD28 to its Sanofi-partnered PD-1 inhibitor Libtayo led to enhanced anti-tumor activity in multiple animal models as well as long-term T-cell memory against the tumors.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">PHARMA - PARTENARIATS</span></b></div>
<span style="font-family: Verdana, sans-serif;"><b><a href="https://endpts.com/takeda-joins-microbiome-focused-biotech-partners-52-6m-raise-as-it-pursues-more-in-house-cancer-work/">Takeda joins microbiome-focused biotech partner's $52.6M raise as it pursues more in-house cancer work [EndPoints]</a></b> </span><br />
<span style="font-family: Verdana, sans-serif;">While protected in the GI tract, these microbiome-derived peptide antigens are identifiable by their epitopes to memory T cells such that once they are spotted in the blood, they activate a rapid immune attack, according to the CEO.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">PHARMA - BIOTECH</span></b></div>
<span style="font-family: Verdana, sans-serif;"><b><a href="https://xconomy.com/boston/2020/06/25/relay-lays-200m-ipo-plan-to-fund-tests-of-protein-motion-cancer-drugs/" target="_blank">Relay Lays $200M IPO Plan to Fund Tests of Protein Motion Cancer Drugs [Xconomy]</a></b> </span><br />
<span style="font-family: Verdana, sans-serif;">Sophisticated computational tools have guided Relay Therapeutics in its efforts to develop new drugs based on analysis of the movement and shape of disease-causing proteins.</span><br />
<br />
<span style="font-family: Verdana, sans-serif;"><b><a href="https://www.fiercebiotech.com/biotech/relay-therapeutics-tees-up-200m-ipo-to-push-a-trio-oncology-meds" target="_blank">Relay Therapeutics tees up $200M IPO to push a trio of oncology meds [Fierce Pharma]</a></b> </span><br />
<span style="font-family: Verdana, sans-serif;">The proceeds will move Relay’s leading programs, a SHP2 inhibitor dubbed RLY-1971 and an FGFR2 inhibitor called RLY-4008, through phase 1 and into phase 2/3 confirmatory studies.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">TRAITEMENTS - ÉCONOMIE</span></b></div>
<b><span style="font-family: Verdana, sans-serif;"><a href="https://www.nice.org.uk/news/article/cancer-patients-to-benefit-from-new-histology-independent-treatment" target="_blank">Cancer patients to benefit from new histology independent treatment [NICE] </a> </span></b><br />
<span style="font-family: Verdana, sans-serif;">Entrectinib (Rozlytrek, Roche), a revolutionary treatment for a range of cancers, is the second histology independent drug to be recommended by NICE for use on the Cancer Drugs Fund (CDF).</span><br />
<br />
<span style="font-family: Verdana, sans-serif;"><b><a href="https://www.icr.ac.uk/news-archive/men-in-england-and-wales-miss-out-on-abiraterone-as-first-line-treatment-for-advanced-prostate-cancer" target="_blank">Men in England and Wales miss out on abiraterone as first-line treatment for advanced prostate cancer [Institute of Cancer Research]</a></b> </span><br />
<span style="font-family: Verdana, sans-serif;">The Institute of Cancer Research, London, has expressed disappointment at the decision by NICE not to recommend abiraterone as a first-line treatment on the NHS for newly diagnosed, advanced prostate cancer.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">LUTTE CONTRE LES CANCERS - OBSERVATION</span></b></div>
<b><span style="font-family: Verdana, sans-serif;"><a href="https://news.cision.com/karolinska-institutet/r/steep-rise-in-skin-cancer-since-1960s,c3140729" target="_blank">Steep rise in skin cancer since 1960s [Karolinska Institutet]</a> </span></b><br />
<span style="font-family: Verdana, sans-serif;">The researchers suspect that the increase is due to a change in holiday customs with more active sunbathing and overseas trips to southern climes.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">LUTTE CONTRE LES CANCERS - COVID19</span></b></div>
<span style="font-family: Verdana, sans-serif;"><b><a href="https://www.esmo.org/oncology-news/pharmacokinetic-and-pharmacodynamic-interactions-between-anticancer-and-antiviral-drugs" target="_blank">Pharmacokinetic and Pharmacodynamic Interactions Between Anticancer and Antiviral Drugs [ESMO]</a></b> </span><br />
<span style="font-family: Verdana, sans-serif;">They emphasised that safety data are lacking, and it might not be safe to treat symptomatic COVID-19 patients with immunosuppressive anticancer drugs which increase infections.</span>OVEhttp://www.blogger.com/profile/16701670533772026788noreply@blogger.comtag:blogger.com,1999:blog-6449150757505425806.post-46213145791735305382020-06-25T10:12:00.001+02:002020-06-25T10:12:51.959+02:00Onco Actu du 25 juin 2020<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">ÉTIOLOGIE - ENVIRONNEMENT</span></b></div>
<span style="font-family: Verdana, sans-serif;"><b><a href="https://www.reuters.com/article/us-bayer-litigation-settlement-analysis/bayer-bets-on-science-in-bid-to-prevent-future-roundup-lawsuits-legal-experts-idUSKBN23W0GX" target="_blank">Bayer bets on science in bid to prevent future Roundup lawsuits: legal experts [Reuters]</a></b> </span><br />
<span style="font-family: Verdana, sans-serif;">The company will pay $1.25 billion to support the panel’s research, an amount that does not include any payouts to settle future lawsuits.</span><br />
<br />
<span style="font-family: Verdana, sans-serif;"><b><a href="https://www.nytimes.com/2020/06/24/business/roundup-settlement-lawsuits.html" target="_blank">Roundup Maker to Pay $10 Billion to Settle Cancer Suits [NY Times]</a></b> </span><br />
<span style="font-family: Verdana, sans-serif;">Bayer faced tens of thousands of claims linking the weedkiller to cases of non-Hodgkin’s lymphoma. Some of the money is set aside for future cases.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">DÉP., DIAG. & PRONO.</span></b></div>
<span style="font-family: Verdana, sans-serif;"><b><a href="https://www.esmo.org/oncology-news/picos-score-may-help-in-identification-of-patients-with-brain-metastasis-at-high-risk-for-vtes" target="_blank">PICOS Score May Help in Identification of Patients with Brain Metastasis at High Risk for VTEs [ESMO]</a></b> </span><br />
<span style="font-family: Verdana, sans-serif;">Thrombogenicity of primary tumour, immobilisation, chemotherapy, obesity and steroid use are independently associated with venous thromboembolic events.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">DÉP., DIAG. & PRONO. - SEIN</span></b></div>
<span style="font-family: Verdana, sans-serif;"><b><a href="https://medicalxpress.com/news/2020-06-digital-breast-cancer-technology-outcomes.html" target="_blank">Digital breast cancer detection technology does not improve outcomes [Medical XPress]</a></b> </span><br />
<span style="font-family: Verdana, sans-serif;">A new study in JNCI: Journal of the National Cancer Institute finds that breast cancer screening using digital mammography technology is not associated with improved health outcomes when compared to older film detection technology.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">DÉP., DIAG. & PRONO. - BIOPSIES LIQUIDES</span></b></div>
<span style="font-family: Verdana, sans-serif;"><b><a href="https://www.nih.gov/news-events/nih-research-matters/signature-virus-exposure-may-help-detect-liver-cancer" target="_blank">Signature of virus exposure may help detect liver cancer [NIH]</a></b> </span><br />
<span style="font-family: Verdana, sans-serif;">The team used a blood test called VirScan to identify antibodies to more than 1,000 viral strains in people at high risk of HCC. The immune system makes such antibodies when it’s been exposed to a virus. Results were published on June 9, 2020, in Cell.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">TRAITEMENTS - PRÉ-CLINIQUE</span></b></div>
<span style="font-family: Verdana, sans-serif;"><b><a href="https://aktuelles.uni-frankfurt.de/englisch/mystery-about-the-cancer-drug-nelarabine-solved-after-decades/" target="_blank">Mystery about the cancer drug nelarabine solved after decades [Goethe University]</a></b> </span><br />
<span style="font-family: Verdana, sans-serif;">“In studies of various ALL cell lines and leukaemia cells from ALL patients, we have been able to demonstrate that the enzyme SAMHD1 splits the phosphate groups off so that the medicine loses its effect.” Because B-ALL cells contain more SAMHD1 than T-ALL cells, nelarabine is less effective with B-ALL.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">TRAITEMENTS - ESSAIS</span></b></div>
<span style="font-family: Verdana, sans-serif;"><b><a href="https://news.vumc.org/2020/06/24/study-shows-better-option-for-treatment-of-inoperable-anal-cancer/" target="_blank">Study shows better option for treatment of inoperable anal cancer [VUMC]</a></b> </span><br />
<span style="font-family: Verdana, sans-serif;">The results from an international trial, published by the Journal of Clinical Oncology,suggest that carboplatin-paclitaxel become the standard of care for anal cancer, a rare disease that accounts for less than 3% of all gastrointestinal malignancies. The InterAAct trial compared carboplatin-paclitaxel with cisplatin plus 5-flourouracil (5FU).</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">IMMUNOTHÉRAPIES - BIOTECH</span></b></div>
<span style="font-family: Verdana, sans-serif;"><b><a href="https://www.fiercebiotech.com/biotech/simcha-debuts-25m-to-advance-custom-built-il-18-for-cancer" target="_blank">Simcha debuts with $25M to advance custom-built IL-18 for cancer [Fierce Biotech]</a></b> </span><br />
<span style="font-family: Verdana, sans-serif;">Its lead program is a custom-built IL-18 that surmounts hurdles faced by the native protein. Other companies, like GlaxoSmithKline, had tried to develop IL-18 before, but ran into an unexpected problem.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">IMMUNOTHÉRAPIES - AMM</span></b></div>
<b><span style="font-family: Verdana, sans-serif;"><a href="https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-cutaneous-squamous-cell-carcinoma" target="_blank">FDA approves pembrolizumab for cutaneous squamous cell carcinoma [FDA]</a> </span></b><br />
<span style="font-family: Verdana, sans-serif;">Efficacy was investigated in KEYNOTE-629 (NCT03284424), a multicenter, multi-cohort, non-randomized, open-label trial. The trial excluded patients who had previously received therapy with an anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody and those with autoimmune disease or a medical condition that required immunosuppression.</span><br />
<br />
<span style="font-family: Verdana, sans-serif;"><b><a href="https://www.mrknewsroom.com/newsroom/news-releases/news-details/2020/FDA-Approves-Mercks-KEYTRUDA-pembrolizumab-for-the-Treatment-of-Patients-with-Recurrent-or-Metastatic-Cutaneous-Squamous-Cell-Carcinoma-cSCC-that-is-Not-Curable-by-Surgery-or-Radiation/default.aspx" target="_blank">FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (cSCC) that is Not Curable by Surgery or Radiation [Merck]</a></b> </span><br />
<span style="font-family: Verdana, sans-serif;">This approval is based on data from the Phase 2 KEYNOTE-629 trial, in which KEYTRUDA demonstrated meaningful efficacy and durability of response, with an objective response rate (ORR) of 34% (95% CI, 25-44), including a complete response rate of 4% and a partial response rate of 31%.</span><br />
<br />
<span style="font-family: Verdana, sans-serif;"><b><a href="https://www.fiercepharma.com/pharma/merck-treads-sanofi-regeneron-s-turf-keytruda-s-latest-skin-cancer-ok" target="_blank">Merck treads on Sanofi, Regeneron's turf with Keytruda's latest skin cancer OK [Fierce Pharma]</a></b> </span><br />
<span style="font-family: Verdana, sans-serif;">At the time of the trial check-in, the median duration of response hadn’t been reached, and some patients were still seeing benefit from Keytruda past the 13-month mark.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">IMMUNOTHÉRAPIES - PRÉ-CLINIQUE</span></b></div>
<span style="font-family: Verdana, sans-serif;"><b><a href="https://www.uc.edu/news/articles/2020/06/n20925513.html" target="_blank">Immunotherapy for breast cancer [University of Cincinnati]</a></b> </span><br />
<span style="font-family: Verdana, sans-serif;">In this study, researchers found that targeting a protein called FIP200 could “overwrite” the nonresponsive nature of breast cancers to certain immunotherapies, called immune checkpoint inhibitors.</span><br />
<br />
<span style="font-family: Verdana, sans-serif;"><b><a href="https://news.yale.edu/2020/06/24/blocking-jamming-signal-can-unleash-immune-system-fight-tumors" target="_blank">Blocking a ‘jamming signal’ can unleash immune system to fight tumors [Yale]</a></b> </span><br />
<span style="font-family: Verdana, sans-serif;">Yale researchers have discovered a “jamming signal” that blocks a powerful immune system stimulant called interleukin-18 (IL-18) from reaching tumors, including in cancers that are resistant to conventional immunotherapy treatments, they report June 24 in the journal Nature.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">PHARMA</span></b></div>
<span style="font-family: Verdana, sans-serif;"><b><a href="https://endpts.com/fda-lifts-partial-hold-on-cancer-drug-after-innate-resolves-manufacturing-issue/" target="_blank">FDA lifts partial hold on cancer drug after Innate resolves manufacturing issue [EndPoints]</a></b> </span><br />
<span style="font-family: Verdana, sans-serif;">The hold, which was issued in January, came after the French biotech stopped treating new patients following discussions with regulators in Europe. Its manufacturing subcontractor, Rentschler Fill Solutions, had abruptly filed for bankruptcy and withdrawn a certificate of conformity on the lacutamab batches they produced.</span><br />
<br />
<span style="font-family: Verdana, sans-serif;"><b><a href="https://www.innate-pharma.com/en/news-events/press-releases/us-food-and-drug-administration-lifts-partial-clinical-hold-lacutamab-tellomak-trial-advanced-t-cell-lymphomas" target="_blank">U.S. Food and Drug Administration lifts partial clinical hold on lacutamab TELLOMAK trial in advanced T-cell lymphomas [Innate]</a></b> </span><br />
<span style="font-family: Verdana, sans-serif;">The FDA decision is based on a quality assessment of a new Good Manufacturing Practice (GMP)-certified batch that has been successfully manufactured for the lacutamab clinical development program, including the TELLOMAK trial.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">FDA, EMA, ...</span></b></div>
<span style="font-family: Verdana, sans-serif;"><b><a href="https://www.scienceboard.net/index.aspx?sec=sup&sub=Drug&pag=dis&ItemID=934" target="_blank">FDA debuts website for patient-reported cancer outcomes [Science Board]</a></b> </span><br />
<span style="font-family: Verdana, sans-serif;">An initiative of the FDA's Oncology Center of Excellence, Project Patient Voice will serve as a source of publicly available information describing patient-reported symptoms from cancer trials for commercially available treatments. </span><br />
<br />
<span style="font-family: Verdana, sans-serif;"><b><a href="https://www.fiercepharma.com/marketing/az-first-drugmaker-fda-pilot-program-to-collect-patient-reported-symptoms-cancer-clinical" target="_blank">AstraZeneca first to join FDA's push for patient-reported symptoms in cancer trials [Fierce Pharma]</a></b> </span><br />
<span style="font-family: Verdana, sans-serif;">AstraZeneca is the first, and so far only, drugmaker in the program, and it's starting with expanded patient details from its late-stage AURA3 trial that compared Tagrisso to platinum-based chemotherapy.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">AACR</span></b></div>
<span style="font-family: Verdana, sans-serif;"><b><a href="https://www.aacr.org/professionals/blog/aacr-virtual-annual-meeting-ii-clinical-trials-plenary-session-highlights-immunotherapeutic-combinations-and-a-liquid-biopsy-based-strategy-for-predicting-progression-free-survival/" target="_blank">AACR Virtual Annual Meeting II: Clinical Trials Plenary Session Highlights Immunotherapeutic Combinations and a Liquid Biopsy-based Strategy for Predicting Progression-free Survival [AACR]</a></b> </span><br />
<span style="font-family: Verdana, sans-serif;">The second day of the AACR Virtual Annual Meeting II began with a clinical trials plenary session.</span><br />
<br />
<div style="text-align: center;">
<span style="font-family: Verdana, sans-serif;"><b>ASCO</b> </span></div>
<span style="font-family: Verdana, sans-serif;"><b><a href="https://www.cancer.gov/news-events/cancer-currents-blog/2020/avelumab-bladder-cancer-maintenance-therapy" target="_blank">Study Clarifies Timing of Immunotherapy for Advanced Bladder Cancer [NCI]</a></b> </span><br />
<span style="font-family: Verdana, sans-serif;">Patients who received avelumab as maintenance therapy had “the longest overall survival ever documented” in a clinical trial for patients with metastatic bladder cancer, said Elizabeth Plimack, M.D., head of bladder cancer research at Fox Chase Cancer Center, who was not involved with the study, speaking at the ASCO meeting.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">LUTTE CONTRE LES CANCERS - COVID19</span></b></div>
<span style="font-family: Verdana, sans-serif;"><b><a href="https://www.mskcc.org/blog/should-you-delay-cancer-treatment-because-covid-19-study-says-most-treatments-don-t-worsen-coronavirus-infection" target="_blank">Should You Delay Cancer Treatment Because of COVID-19? Study Says Most Treatments Don’t Worsen Coronavirus Infection [Memorial Sloan Kettering Cancer Center]</a></b> </span><br />
<span style="font-family: Verdana, sans-serif;">A review of 423 patients treated at MSK finds that most people with cancer don’t fare any worse if they get COVID-19 than other people who are hospitalized for that infection.<b id="docs-internal-guid-1994d594-7fff-6c37-80a5-7ba87a342986" style="font-weight: normal;"><br /></b></span>OVEhttp://www.blogger.com/profile/16701670533772026788noreply@blogger.comtag:blogger.com,1999:blog-6449150757505425806.post-12125159843785476352020-06-24T10:40:00.001+02:002020-06-24T10:40:17.624+02:00Onco Actu du 24 juin 2020<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">BIOLOGIE</span></b></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://www.bartscancer.london/general-news/2020/06/unravelling-the-circuitry-that-controls-cancer-growth-and-spread/" target="_blank">Unravelling the circuitry that controls cancer growth and spread [Barts Cancer Institute]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">The study, published today in Science Signaling, set out to uncover how a protein called MET drives cancer progression.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">BIOLOGIE - TECHNOS, MODÈLES</span></b></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://www.stjude.org/media-resources/news-releases/2020-medicine-science-news/st-jude-creates-resource-for-pediatric-brain-tumor-research.html" target="_blank">St. Jude creates resource for pediatric brain tumor research [St. Jude Children’s Research Hospital]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">Researchers worldwide can access orthotopic patient-derived xenograft models to speed discovery and test novel therapies for childhood brain tumors.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">ÉTIOLOGIE - GÉNOME</span></b></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://www.mcgill.ca/newsroom/channels/news/skin-cancer-men-are-genetically-more-prone-322914" target="_blank">Skin cancer: men are genetically more prone [McGill]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">The research led by Professor Ian Watson of McGill’s Goodman Cancer Research Centre (GCRC), published in the journal Nature Cancer, identified three genes on the X chromosome with significant mutations.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">ÉTIOLOGIE - NDMA</span></b></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://www.ema.europa.eu/en/news/european-regulators-make-recommendations-drawing-lessons-learnt-presence-nitrosamines-sartan" target="_blank">European regulators make recommendations drawing on lessons learnt from presence of nitrosamines in sartan medicines [EMA]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">The recommendations aim to clarify the roles and responsibilities of companies involved in the manufacture of medicines and to amend guidance on controlling impurities and good manufacturing practice.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">TRAITEMENTS - ESSAIS</span></b></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://www.icr.ac.uk/news-archive/breast-cancer-drug-capivasertib-enters-major-trial" target="_blank">Breast cancer drug capivasertib enters major trial [Institute of Cancer Research]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">The CAPItello-291 trial, which will enrol around 830 patients across 20 countries, will examine the effects of the drug in pre-menopausal or post-menopausal women, and men, with an advanced form of oestrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">IMMUNOTHÉRAPIES - FUSIONS & ACQUISITIONS</span></b></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://endpts.com/daniel-oday-snatches-another-i-o-company-buying-half-of-a-pioneers-biotech/" target="_blank">Daniel O’Day snatches another I/O company, buying half of a pioneering cancer drug discoverer's biotech [EndPoints]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">Gilead will pay South San Francisco-based Pionyr $275 million for 49.9% ownership in the company, which is focused on targeting the innate immune cells that help tumors hide.</span><br />
<br />
<span style="font-family: Verdana, sans-serif;"><a href="https://xconomy.com/san-francisco/2020/06/23/gilead-grabs-option-to-acquire-pionyr-its-clinic-bound-immunotherapies/" target="_blank">Gilead Grabs Option to Acquire Pionyr & Its Clinic-Bound Immunotherapies [Xconomy]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">In cancer, it aims to change the makeup of the cell populations at the site of a tumor to favor myeloid immune cells that play a role in prompting an immune reaction over those that tamp it down.</span><br />
<br />
<span style="font-family: Verdana, sans-serif;"><a href="https://www.biopharmadive.com/news/gilead-pionyr-cancer-immunotherapy-deal/580364/" target="_blank">Gilead, in latest cancer bet, puts $275M into immunotherapy startup Pionyr [Biopharma Dive]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">Pionyr's cancer immunotherapy drugs are meant to turn immune cells within tumors against the disease itself, a technique it calls "myeloid tuning.</span><br />
<br />
<span style="font-family: Verdana, sans-serif;"><a href="https://www.fiercebiotech.com/biotech/gilead-pens-buyout-option-deal-for-pionry-biotech-a-1-5b-deal" target="_blank">Gilead pens $1.5B buyout option deal for Pionyr [Fierce Biotech]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">This tech can in essence help predict checkpoint inhibitor responsiveness, with two of its staffers having already worked on two such drugs: Yervoy and Keytruda.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES, … </span></b></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://www.dkfz.de/en/presse/pressemitteilungen/2020/dkfz-pm-20-40-CAR-T-cell-therapy-potential-for-considerable-savings.php" target="_blank">CAR T cell therapy: potential for considerable savings [DKFZ]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">Under these conditions, DKFZ could produce a CAR T cell product to treat a patient for less than EUR 60,000. "That would be only about a fifth of the price that the companies charge. And we can cut these costs even further by a considerable amount."</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">PHARMA</span></b></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://endpts.com/sanofi-wants-to-earn-the-rep-for-being-the-hare-in-drug-rd-but-that-darn-tortoise-keeps-sticking-its-head-out/" target="_blank">Sanofi wants to earn the rep for being the hare in drug R&D. But that darn tortoise keeps sticking its head out [EndPoints]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">Oncology, though, will remain a central focus, with plans to add 1 molecule a year through the deal channel and several more from in-house sources, for around 4-5 a year to feed a continually developing pipeline.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">PHARMA - BIOTECH</span></b></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://endpts.com/seven-years-after-licensing-btk-inhibitor-from-biogen-beleaguered-pennystock-biotech-partner-concedes-defeat/" target="_blank">Seven years after licensing BTK inhibitor from Biogen, beleaguered pennystock biotech partner concedes defeat [EndPoints]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">The trial had enrolled adult patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and other B-cell malignancies. The safety profile was “excellent”; it just didn’t seem to have much of an effect.</span><br />
<br />
<span style="font-family: Verdana, sans-serif;"><a href="https://www.fiercepharma.com/marketing/karyopharm-snags-new-xpovio-blood-cancer-nod-will-sales-improve" target="_blank">Karyopharm snags new Xpovio blood cancer nod. Will sales improve? [Fierce Pharma]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">Aiming to turn the conditional nod into a full one, Karyopharm will run a confirmatory phase 2/3 study dubbed XPORT-DLBCL-030. The study will combine Xpovio with the so-called R-GDP regimen that includes Roche’s Rituxan, chemotherapy gemcitabine, steroid dexamethasone and platinum chemo.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">AACR</span></b></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://www.aacr.org/professionals/blog/aacr-virtual-annual-meeting-ii-opening-plenary-captures-the-breadth-of-cutting-edge-cancer-research/" target="_blank">AACR Virtual Annual Meeting II: Opening Plenary Captures the Breadth of Cutting-edge Cancer Research [AACR]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">Presentations in the Opening Plenary Session showcased wide-ranging topics from innovative research disciplines, including the role of long noncoding RNAs in cancer, the utility of epigenetics in early detection and classification of cancer, the role of aging and the tumor microenvironment in shaping responses to cancer therapies, recent developments in cancer precision medicine aided by artificial intelligence (AI), and the utility of CRISPR-mediated gene-editing approaches to reprogram T cells for the treatment of cancer. </span><br />
<br />
<span style="font-family: Verdana, sans-serif;"><a href="https://www.aacr.org/about-the-aacr/newsroom/news-releases/use-of-lipophilic-statins-is-associated-with-lower-mortality-from-ovarian-cancer/" target="_blank">Use of Lipophilic Statins is Associated with Lower Mortality from Ovarian Cancer [AACR]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">The researchers linked data from the Finnish national cancer registry to prescription claims on 10,062 women diagnosed with ovarian cancer between 1995 and 2015 to examine the association between pre- and post-diagnostic statin use and ovarian cancer mortality. </span><br />
<br />
<span style="font-family: Verdana, sans-serif;"><a href="https://www.aacr.org/about-the-aacr/newsroom/news-releases/young-adults-with-cancer-may-harbor-germline-mutations/" target="_blank">Young Adults With Cancer May Harbor Germline Mutations [AACR]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">Stadler and colleagues studied germline mutations in 1,201 young adult patients who received a cancer diagnosis between 2015 and 2019 at MSK. </span><br />
<br />
<span style="font-family: Verdana, sans-serif;"><a href="https://www.aacr.org/about-the-aacr/newsroom/news-releases/real-world-data-shows-immunotherapy-after-melanoma-surgery-yields-survival-benefit/" target="_blank">Real-world Data Shows Immunotherapy After Melanoma Surgery Yields Survival Benefit [AACR]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">The database is the largest clinical cancer registry in the world, covering 72 percent of new cancer diagnoses in the United States, Moyers said. The researchers queried treatment data from cases diagnosed in 2015 and 2016, and survival data from cases diagnosed in 2015.</span><br />
<br />
<span style="font-family: Verdana, sans-serif;"><a href="https://www.aacr.org/about-the-aacr/newsroom/news-releases/personalized-cancer-vaccine-plus-atezolizumab-shows-clinical-activity-in-patients-with-advanced-solid-tumors/" target="_blank">Personalized Cancer Vaccine Plus Atezolizumab Shows Clinical Activity in Patients With Advanced Solid Tumors [AACR]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">To produce the vaccine, tumor and blood samples are sequenced and tumor-specific neoantigens are identified. Following the selection of up to 20 neoantigens, the corresponding mRNA is generated, making the backbone of the vaccine, which is then encapsulated in a liposomal formulation to enable intravenous administration.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">LUTTE CONTRE LES CANCERS - COVID19</span></b></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://scienceblog.cancerresearchuk.org/2020/06/24/opinion-uk-cancer-research-could-be-set-back-years-by-covid-19-we-must-act-now" target="_blank">Opinion: ‘UK cancer research could be set back years by COVID-19. We must act now’ [Cancer Research UK]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">Today, we announced that because of COVID-19 and the devastating impact it’s had on our income, we could be forced to cut £150 million per year from our research funding.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">LUTTE CONTRE LES CANCERS - CONTROVERSES</span></b></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://www.nytimes.com/2020/06/23/health/baby-powder-cancer.html" target="_blank">Women With Cancer Awarded Billions in Baby Powder Suit [NY Times]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">An appellate court in Missouri upheld more than $2 billion in damages against Johnson & Johnson, saying the company knew there was asbestos in its baby powder.</span>OVEhttp://www.blogger.com/profile/16701670533772026788noreply@blogger.comtag:blogger.com,1999:blog-6449150757505425806.post-80286904949944198482020-06-23T11:30:00.000+02:002020-06-23T11:30:18.296+02:00Onco Actu du 23 juin 2020<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">ÉTIOLOGIE - ENVIRONNEMENT</span></b></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://www.reuters.com/article/cus-bayer-glyphosate-lawsuit/u-s-court-blocks-california-cancer-label-on-bayers-roundup-weed-killer-idUSKBN23T38Y" target="_blank">U.S. court blocks California cancer label on Bayer's Roundup weed killer [Reuters]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">In his ruling, U.S. District Judge William Shubb called California’s cancer warning misleading and said the state’s label is not backed up by regulatory findings.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">DÉP., DIAG. & PRONO. - BIOPSIES LIQUIDES</span></b></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://www.dana-farber.org/newsroom/news-releases/2020/biomarker-test-highly-accurate-in-detecting-early-kidney-cancer/" target="_blank">Biomarker Test Highly Accurate in Detecting Early Kidney Cancer [Dana-Farber Cancer Institute]</a> </span><br />
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;">The technical name for the testing method is cfMeDIP-seq, which stands for cell-free methylated DNA immunoprecipitation and high-throughput sequencing.</span></div>
<div style="text-align: center;">
<br /></div>
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">DÉP., DIAG. & PRONO. - INDUSTRIELS</span></b></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><a href="https://xconomy.com/san-francisco/2020/06/22/invitae-makes-a-precision-oncology-push-with-886m-deal-for-archerdx/" target="_blank">Invitae Makes a Precision Oncology Push With $886M Deal for ArcherDx [Xconomy]</a> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;">Boulder, CO-based ArcherDx develops lab tests intended to guide cancer treatment decisions. The Stratafide product is a lab test and companion diagnostic that analyzes DNA, RNA, and circulating tumor DNA from either a blood or tissue sample.</span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><br /></span></div>
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">TRAITEMENTS - PRÉ-CLINIQUE</span></b></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://www.genomeweb.com/sequencing/single-cell-analysis-ovarian-cancer-points-potential-treatment-avenue" target="_blank">Single-Cell Analysis of Ovarian Cancer Points to Potential Treatment Avenue [Genome Web]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">As they reported in Nature Medicine on Monday, the researchers further found that an inhibitor targeting the JAK/STAT pathway, which is expressed in both malignant and cancer-associated fibroblast cells (CAFs), had antitumor activity in cell cultures and patient-derived xenografts.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">TRAITEMENTS - ESSAIS</span></b></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://www.icr.ac.uk/news-archive/new-class-of-precision-medicine-strips-cancer-of-its-dna-defences" target="_blank">New class of precision medicine strips cancer of its DNA defences [Institute of Cancer Research]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">A team at The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust, led a trial of the benefit of an ATR inhibitor called berzosertib either on its own or with chemotherapy in 40 patients with very advanced tumours, treated in hospitals around the world.</span><br />
<br />
<span style="font-family: Verdana, sans-serif;"><a href="https://www.icr.ac.uk/news-archive/new-class-of-precision-medicine-strips-cancer-of-its-dna-defences" target="_blank">Cancer drug: New treatment halts tumour growth [BBC News]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">“The unusually strong effects of berzosertib, especially in combination with conventional chemotherapy, give reasons to be optimistic regarding the outcomes of follow-up studies."</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">IMMUNOTHÉRAPIES - FDA, EMA, ...</span></b></div>
<span style="font-family: Verdana, sans-serif;"><a href="http://www.pharmatimes.com/news/ema_to_consider_expanding_use_of_merckpfizers_bavencio_1342613" target="_blank">EMA to consider expanding use of Merck/Pfizer's Bavencio [Pharma Times]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">The European Medicines Agency has validated for review Merck and Pfizer's application to market Bavencio (avelumab) for first-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC).</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">IMMUNOTHÉRAPIES - AMM</span></b></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://www.mrknewsroom.com/newsroom/news-releases/news-details/2020/Mercks-KEYTRUDA-pembrolizumab-Approved-in-China-for-Second-Line-Treatment-of-Patients-with-Locally-Advanced-or-Metastatic-Esophageal-Squamous-Cell-Carcinoma-Whose-Tumors-Express-PD-L1-CPS-10/default.aspx" target="_blank">Merck’s KEYTRUDA® (pembrolizumab) Approved in China for Second-Line Treatment of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma Whose Tumors Express PD-L1 (CPS ≥10) [Merck]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">KEYTRUDA Is Now Approved Across Five indications for Three Different Types of Cancer in China and Is First Anti-PD-1 Therapy Approved for Esophageal Cancer.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">IMMUNOTHÉRAPIES - PRÉ-CLINIQUE </span></b></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://health.ucsd.edu/news/releases/Pages/2020-06-22-immune-cells-infiltrating-tumors-may-play-bigger-cancer-role-than-previously-thought.aspx" target="_blank">Immune Cells Infiltrating Tumors May Play Bigger Cancer Role Than Previously Thought [UCSD]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">The study, published in PLoS Biology, is the first to uncover the role a molecule called IRE1α plays in determining whether macrophages promote inflammation in the tissues surrounding cancer cells — a region known as the tumor microenvironment — and throw off the ability of other immune cells to fight cancer. </span><br />
<br />
<span style="font-family: Verdana, sans-serif;"><a href="https://www.tgen.org/news/2020/june/22/tgen-city-of-hope-identify-response-to-immunotherapy/" target="_blank">Study led by TGen and City of Hope shows new way of identifying tumor response to immunotherapy [TGen]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">The findings highlight, for the first time, an important predator-prey relationship between circulating immune cell dynamics and a tumor’s response to immunotherapy. </span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">PHARMA</span></b></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://www.fiercepharma.com/marketing/jazz-nabs-first-solid-tumor-nod-pharmamar-for-zepzelca-to-treat-small-cell-lung-cancer" target="_blank">Jazz preps first solid tumor launch with Zepzelca's small cell lung cancer nod [Fierce Pharma]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">The Zepzelca launch is physician-focused to make sure doctors are aware that the drug exists, Jazz Chairman and CEO Bruce Cozadd said. About 30,000 people in the U.S. are diagnosed with small cell lung cancer every year, and about 17,000 of them go on to second-line treatment.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">TRAITEMENTS - AMM</span></b></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selinexor-relapsedrefractory-diffuse-large-b-cell-lymphoma" target="_blank">FDA approves selinexor for relapsed/refractory diffuse large B-cell lymphoma [FDA]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">Approval was based on SADAL (KCP-330-009; NCT02227251), a multicenter, single-arm, open-label trial in patients with DLBCL after 2 to 5 systemic regimens. </span><br />
<br />
<span style="font-family: Verdana, sans-serif;"><a href="https://investors.karyopharm.com/news-releases/news-release-details/karyopharm-announces-fda-approval-xpovior-selinexor-treatment" target="_blank">Karyopharm Announces FDA Approval of XPOVIO® (selinexor) for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) [Karyopharm]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">XPOVIO is the First and Only FDA-Approved Drug for Use in Both Multiple Myeloma and DLBCL.</span><br />
<br />
<span style="font-family: Verdana, sans-serif;"><a href="https://www.esmo.org/oncology-news/fda-granted-accelerated-approval-to-tazemetostat-for-follicular-lymphoma" target="_blank">FDA Granted Accelerated Approval to Tazemetostat for Follicular Lymphoma [ESMO]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">FDA also approved the cobas EZH2 Mutation Test as a companion diagnostic for tazemetostat.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">TRAITEMENTS - ÉCONOMIE</span></b></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://endpts.com/pivotal-trial-costs-are-modest-per-new-estimate-what-does-that-mean-for-the-overall-drug-pricing-debate/" target="_blank">What's the hard cost of a pivotal drug trial? A lot less than you might expect [EndPoints]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">After plugging details about 101 new drugs approved between 2015 and 2017 into a clinical trial cost estimator created by IQVIA, the authors concluded that the estimated median pivotal trial cost was $48 million, with an interquartile range of $20 million to $102 million.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">AACR</span></b></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://www.aacr.org/professionals/blog/aacr-virtual-annual-meeting-ii-opening-ceremony-sets-focus-on-science-policy/" target="_blank">AACR Virtual Annual Meeting II: Opening Ceremony Sets Focus on Science, Policy [AACR]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">The Opening Ceremony of the American Association for Cancer Research (AACR) Virtual Annual Meeting II provided a stark reminder that while the entire world takes aim at the COVID-19 pandemic, cancer remains a relentless foe, requiring a resolute focus of its own. </span><br />
<br />
<span style="font-family: Verdana, sans-serif;"><a href="https://endpts.com/roches-anti-tigit-drug-shows-zero-response-as-monotherapy-but-data-back-effect-for-lung-cancer-subset/" target="_blank">Roche’s anti-TIGIT drug shows zero response as monotherapy — but data back effect for lung cancer subset [EndPoints]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">Among the 24 patients signed up for the Phase Ia study using escalating doses of tiragolumab, none demonstrated an objective response to the monotherapy, according to the abstract posted by AACR.</span><br />
<br />
<span style="font-family: Verdana, sans-serif;"><a href="https://www.evaluate.com/vantage/articles/events/conferences/aacr-2020-biontech-and-roche-try-resuscitate-cancer-vaccines" target="_blank">AACR 2020 – Biontech and Roche try to resuscitate cancer vaccines [EndPoints]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">A first-in-human study of the companies’ neoantigen mRNA cancer vaccine fails to rewrite these agents’ poor history.</span><br />
<br />
<span style="font-family: Verdana, sans-serif;"><a href="https://www.mskcc.org/news-releases/aacr-virtual-annual-meeting-2020-ii-msk-research-shows-young-adults-early-onset-cancer-are-high-risk-harboring-inherited-genetic-mutations" target="_blank">AACR Virtual Annual Meeting 2020 II: MSK Research Shows that Young Adults with Early-Onset Cancer Are at High Risk of Harboring Inherited Genetic Mutations [Memorial Sloan Kettering Cancer Center]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">Among patients with early-onset cancers, the highest rates of genetic mutations were found in those with cancer in the pancreas, breast, or kidney, with mutations in the BRCA1, BRCA2, ATM, CHEK2, and the Lynch syndrome-associated genes being the most frequent.</span><br />
<br />
<span style="font-family: Verdana, sans-serif;"><a href="https://www.tgen.org/news/2020/june/22/tgen-ashion-honorhealth-patriot-organoid-analysis/" target="_blank">TGen’s Ashion Analytics® and HonorHealth show how ‘organoids’ can help pinpoint the right therapies for cancer patients [TGen]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">PATRIOT, which stands for PAThway based RNA and DNA Integration with tumor Organoid Testing for clinical therapeutics, will be showcased in a study presentation June 22-24 at the second 2020 virtual annual meeting of the American Association for Cancer Research (AACR).</span><br />
<br />
<span style="font-family: Verdana, sans-serif;"><a href="https://grail.com/press-releases/grail-to-present-new-data-supporting-its-multi-cancer-early-detection-test-at-the-american-association-for-cancer-research-aacr-annual-meeting-ii/" target="_blank">GRAIL to Present New Data Supporting its Multi-Cancer Early Detection Test at the American Association for Cancer Research (AACR) Annual Meeting II [GRAIL]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">GRAIL’s multi-cancer early detection test is supported by evidence from its population-scale clinical study program, which is believed to be the largest ever conducted in genomic medicine.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">LUTTE CONTRE LES CANCERS - COVID19</span></b></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://scienceblog.cancerresearchuk.org/2020/06/22/getting-cancer-services-back-on-track-during-the-covid-19-pandemic/" target="_blank">Getting cancer services back on track during the COVID-19 pandemic [Cancer Research UK]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">Here’s what we think needs to happen to make sure patients get the care they need, when they need it.</span><br />
OVEhttp://www.blogger.com/profile/16701670533772026788noreply@blogger.comtag:blogger.com,1999:blog-6449150757505425806.post-17400752931657150412020-06-22T11:00:00.000+02:002020-06-22T11:00:12.885+02:00Onco Actu du 22 juin 2020<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">BIOLOGIE</span></b></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://scienceblog.cancerresearchuk.org/2020/06/19/searching-for-novel-connections-in-cancer-metabolism/" target="_blank">Searching for novel connections in cancer metabolism [Cancer Research UK]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">To assess the metabolic changes that occur in cancer cells, the team acquired an ingenious piece of equipment known as the Intelligent Knife (or iKnife).</span><br />
<br />
<div style="text-align: center;">
<span style="font-family: Verdana, sans-serif;"><b>ÉTIOLOGIE - GÉNOME</b></span></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://www.genomeweb.com/sequencing/incidental-findings-most-frequent-cancer-risk-genes-emerge-iii-data-show" target="_blank">Incidental Findings Most Frequent in Cancer Risk Genes, EMERGE III Data Show [Genome Web]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">The team found that more than 2.5 percent of participants, who were enrolled at 10 sites in the US, carried pathogenic or likely pathogenic variants in one or more of the 59 genes flagged for reporting by the American College of Medical Genetics and Genomics (ACMG), while a further 0.48 percent carried clinically actionable changes in the other genes and SNPs considered.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">PRÉVENTION - ACTIVITÉ PHYSIQUE</span></b></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://www.mdanderson.org/newsroom/study-shows-sedentary-behavior-independently-predicts-cancer-mortality.h00-159382734.html" target="_blank">Study shows sedentary behavior independently predicts cancer mortality [MD Anderson Cancer Center]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">Replacing sitting time with 30 minutes of activity associated with lower risk of cancer death.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">DÉP., DIAG. & PRONO. - BIOPSIES LIQUIDES</span></b></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://www.nature.com/articles/d41586-020-01763-1" target="_blank">Could tracking RNA in body fluids reveal disease? [Nature]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">Tests that detect extracellular RNA to spot cancer, heart disease and other conditions are in development.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">DÉP., DIAG. & PRONO. - IMAGERIE</span></b></div>
<span style="font-family: Verdana, sans-serif;"> <a href="https://news.yale.edu/2020/06/18/will-chemo-cause-heart-failure-new-test-may-have-answers" target="_blank">Will chemo cause heart failure? A new test may have answers [Yale]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">A study based on an animal model experiment to test the procedure appears in the journal JACC CardioOncology. The new method uses coronary CT angiography (CTA) to measure the diameter of epicardial coronary vessels, which help direct blood flow to the heart muscle.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">TRAITEMENTS - PRÉ-CLINIQUE</span></b></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://www.nature.com/articles/d41586-020-01838-z" target="_blank">How cells’ ‘lava lamp’ effect could make cancer drugs more powerful [Nature]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">In a study published today in Science, Young and his colleagues at the Whitehead Institute in Cambridge, Massachusetts, show that cancer-drug compounds become concentrated in precise spots in cells — because of a phenomenon called phase separation by which all cells partition their contents.</span><br />
<br />
<span style="font-family: Verdana, sans-serif;"><a href="https://www.bumc.bu.edu/busm/2020/06/19/researchers-attempt-new-treatment-approach-for-blood-cancer/" target="_blank">Researchers Attempt New Treatment Approach for Blood Cancer [Boston University]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">In an effort to improve the survival of patients with myeloproliferative neoplasms, a type of leukemia, researchers inhibited a specific protein (alpha5beta1 integrin) to decrease the number of large bone marrow cells (megakaryocytes) in an experimental model. </span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">IMMUNOTHÉRAPIES - BIOTECH</span></b></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://xconomy.com/raleigh-durham/2020/06/19/shattuck-labs-nabs-118m-for-cancer-drugs-like-keytruda-but-better/" target="_blank">Shattuck Labs Nabs $118M for Cancer Drugs Like Keytruda, But Better [Xconomy]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">Shattuck’s drugs are fusion proteins. Schreiber says his company designs its drugs using proprietary technology called Agonist Redirected Checkpoint (ARC). The drugs it produces have six costimulatory domains, which are the parts of the drug that activate an immune response.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">PHARMA</span></b></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://endpts.com/one-of-roches-spotlight-phiii-cancer-drug-hopefuls-stumbles-in-a-key-trial-with-hit-and-miss-results/" target="_blank">One of Roche’s spotlight PhIII cancer drug hopefuls stumbles in a key trial, with hit-and-miss results [EndPoints]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">Ipatasertib is designed to block the PI3K/AKT pathway, coming out of a partnership that Genentech struck with Array before Pfizer bought them out. </span><br />
<br />
<span style="font-family: Verdana, sans-serif;"><a href="https://www.roche.com/media/releases/med-cor-2020-06-19.htm" target="_blank">Roche’s IPATential150 study evaluating ipatasertib in combination with abiraterone and prednisone/prednisolone met one of its co-primary endpoints [Roche]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">The results of the IPATential150 study will be presented at an upcoming medical meeting. While initial data are encouraging, overall survival benefit and additional secondary endpoints are not yet mature.</span><br />
<br />
<span style="font-family: Verdana, sans-serif;"><a href="https://www.fiercebiotech.com/biotech/roche-phase-3-hits-goal-subgroup-prostate-cancer-patients" target="_blank">Roche phase 3 hits goal in subgroup of prostate cancer patients [Fierce Biotech]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">Roche is yet to share full data from the trial, but the top-line findings suggest ipatasertib may have a future. There is a mechanistic explanation for why ipatasertib would perform better in patients with PTEN-loss tumors. </span><br />
<br />
<span style="font-family: Verdana, sans-serif;"><a href="https://www.reuters.com/article/us-roche-trial/roche-prostate-cancer-hopeful-has-mixed-results-in-late-stage-trial-idUSKBN23Q0QI" target="_blank">Roche prostate cancer hopeful has mixed results in late-stage trial [Reuters]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">For the overall group of patients in its Phase III IPATential150 study, Roche said ipatasertib did not meet its goal of boosting radiographic progression-free survival (rPFS), a key goal in mCRPC.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">TRAITEMENTS - FDA, EMA,...</span></b></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://www.gsk.com/en-gb/media/press-releases/gsk-announces-fda-advisory-committee-meeting-to-review-belantamab-mafodotin-for-the-treatment-of-patients-with-relapsedrefractory-multiple-myeloma/" target="_blank">GSK announces FDA Advisory Committee meeting to review belantamab mafodotin for the treatment of patients with relapsed/refractory multiple myeloma [GSK]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">Six-month primary results from the study were published in The Lancet Oncology and follow-up data were presented at the 2020 American Society of Clinical Oncology annual meeting.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">TRAITEMENTS - AMM</span></b></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://www.fda.gov/drugs/fda-granted-accelerated-approval-tazemetostat-follicular-lymphoma" target="_blank">FDA granted accelerated approval to tazemetostat for follicular lymphoma [FDA]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).</span><br />
<br />
<span style="font-family: Verdana, sans-serif;"><a href="https://endpts.com/epizyme-hits-the-ground-running-with-second-and-crucial-ok-for-tazverik-in-follicular-lymphoma/" target="_blank">Epizyme hits the ground running with second — and crucial — OK for Tazverik, in follicular lymphoma [EndPoints]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">The OK was anchored on overall response rate and duration of response in a Phase II, which encompassed both mutated and wild-type EZH2.</span><br />
<br />
<span style="font-family: Verdana, sans-serif;"><a href="https://www.esmo.org/oncology-news/fda-grants-accelerated-approval-to-lurbinectedin-for-metastatic-sclc" target="_blank">FDA Grants Accelerated Approval to Lurbinectedin for Metastatic SCLC [ESMO]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">Efficacy was demonstrated in the PM1183-B-005-14 study.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">AACR</span></b></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://www.icr.ac.uk/news-archive/aacr-virtual-annual-meeting-2020-personalised-cancer-vaccine-shows-promise-in-early-trial" target="_blank">AACR Virtual Annual Meeting 2020: Personalised cancer vaccine shows promise in early trial [Institute of Cancer Research]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">The vaccine comprises of genetic material called messenger RNA that corresponds to the genetic make-up of the neoantigens specific to each person’s tumour.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">LUTTE CONTRE LES CANCERS - COVID19</span></b></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://cancerletter.com/articles/20200619_1/" target="_blank">Sharpless: COVID-19 expected to increase mortality by at least 10,000 deaths from breast and colorectal cancers over 10 years [The Cancer Letter]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">This analysis, frankly, is pretty conservative. We do not consider cancers other than those of breast and colon, but there is every reason to believe the pandemic will affect other types of cancer, too.</span><br />
<br />
<span style="font-family: Verdana, sans-serif;"><a href="https://www.statnews.com/2020/06/19/ignoring-cancer-care-covid-19-nci-sharpless/" target="_blank">Ignoring cancer care now may trade one public health crisis — Covid-19 — for another, NCI chief warns [STAT]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">NCI estimates a drop of 75% in mammograms since March, which may be conservative, Sharpless said, compared to the 95% cited by Epic, the electronic health records vendor.</span><br />
<br />
<span style="font-family: Verdana, sans-serif;"><a href="https://cancerletter.com/articles/20200619_2/" target="_blank">ACS faces precipitous drop in fundraising [The Cancer Letter]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">According to information widely shared with the staff, ACS, the largest nonprofit focused on all cancers, is hoping to raise $512 million this year. This target represents the best-case scenario for the charity, which is believed to have raised around $700 million last year.</span>OVEhttp://www.blogger.com/profile/16701670533772026788noreply@blogger.comtag:blogger.com,1999:blog-6449150757505425806.post-52397173752271151412020-06-19T11:35:00.000+02:002020-06-19T11:35:45.630+02:00Onco Actu du 19 juin 2020<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">PRÉVENTION - ACTIVITÉ PHYSIQUE</span></b></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://www.mdanderson.org/newsroom/study-shows-sedentary-behavior-independently-predicts-cancer-mortality.h00-159382734.html" target="_blank">Study shows sedentary behavior independently predicts cancer mortality [MD Anderson Cancer Center]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">Replacing sitting time with 30 minutes of activity associated with lower risk of cancer death.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">DÉP., DIAG. & PRONO. - BIOPSIES LIQUIDES</span></b></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://theconversation.com/cancer-treatment-personalised-blood-tests-can-better-detect-dna-from-tumours-in-the-body-new-research-140777" target="_blank">Cancer treatment: personalised blood tests can better detect DNA from tumours in the body – new research [The Conversation]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">In our recent study, published in Science Translational Medicine, we show that circulating tumour DNA can be detected with very high sensitivity in the blood when we compare it to a profile of the tumour’s genome.</span><br />
<br />
<span style="font-family: Verdana, sans-serif;"><a href="https://scienceblog.cancerresearchuk.org/2020/06/18/picking-out-the-sound-of-tumours/" target="_blank">Picking out the sound of tumours [Cancer Research UK]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">In future studies, the team and their collaborators plan to use this technique to measure ctDNA levels in people who are at high risk of developing cancer and hope that the information they will generate can be used to help refine future tests for cancer early detection.</span><br />
<br />
<div style="text-align: center;">
<span style="font-family: Verdana, sans-serif;"><b>TRAITEMENTS - PRÉ-CLINIQUE</b></span></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://www.icr.ac.uk/news-archive/cancer-s-reliance-on-fat-could-be-targeted-with-new-drugs-and-diet-treatment" target="_blank">Cancer’s reliance on fat could be targeted with new ‘drugs and diet’ treatment [Institute of Cancer Research]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">Researchers found that targeting cancer’s ability to process fat using a new class of drugs could halt tumour growth in mice, but only when combined with a diet free of fats.</span><br />
<br />
<span style="font-family: Verdana, sans-serif;"><a href="http://wi.mit.edu/news/archive/2020/discovery-how-cancer-drugs-find-their-targets-could-lead-new-toolset-drug" target="_blank">Discovery Of How Cancer Drugs Find Their Targets Could Lead To A New Toolset For Drug Development [Whitehead Institute]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">The new insights in condensate behavior also provided some answers to another question in cancer research: why people become immune to the breast cancer drug tamoxifen.</span><br />
<br />
<span style="font-family: Verdana, sans-serif;"><a href="https://www.genomeweb.com/cancer/crispr-technique-targeting-tumor-cells-aims-improve-chemo-efficacy" target="_blank">CRISPR Technique Targeting Tumor Cells Aims to Improve Chemo Efficacy [Genome Web]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">In their study, the researchers also concluded that this technique could eventually be used in many different types of cancer where NRF2 keeps cells resistant to chemotherapy.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">IMMUNOTHÉRAPIES - AMM</span></b></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><a href="https://www.esmo.org/oncology-news/fda-approves-pembrolizumab-for-adults-and-children-with-tmb-h-solid-tumours" target="_blank">FDA Approves Pembrolizumab for Adults and Children with TMB-H Solid Tumours [ESMO]</a> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;">FDA also approved a companion diagnostic for pembrolizumab.</span></div>
<div style="text-align: left;">
<br /></div>
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">IMMUNOTHÉRAPIES - ESSAIS</span></b></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><a href="https://endpts.com/tecentriq-passes-neoadjuvant-breast-cancer-trial-as-roche-looks-for-early-start-on-the-next-big-checkpoint-opportunity/" target="_blank">Tecentriq passes neoadjuvant breast cancer trial as Roche looks for early start on the next big checkpoint opportunity [EndPoints]</a> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;">Known as IMpassion031, the Phase III study enrolled early-stage triple-negative breast cancer patients who were scheduled for surgery and gave them either Roche’s PD-L1 therapy Tecentriq plus the chemotherapy Abraxane or simply chemotherapy alone.</span></div>
<div style="text-align: left;">
<br /></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><a href="https://www.roche.com/media/releases/med-cor-2020-06-18.htm" target="_blank">Roche’s Tecentriq in combination with chemotherapy (including Abraxane) meets primary endpoint of improved pathological complete response, regardless of PD-L1 status, as initial treatment for people with early triple-negative breast cancer [Roche]</a> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;">Results of the IMpassion031 study will be presented at an upcoming medical meeting and will be discussed with global health authorities including the US Food and Drug Administration (FDA) and European Medicines Agency (EMA).</span></div>
<div style="text-align: left;">
<br /></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><a href="https://www.fiercepharma.com/marketing/roche-redeems-itself-new-tecentriq-win-early-triple-negative-breast-cancer" target="_blank">Roche redeems itself with new Tecentriq win in early triple-negative breast cancer [Fierce Pharma]</a> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;">The result was achieved in patients with early invasive TNBC regardless of PD-L1 expression, whereas Tecentriq’s current TNBC approval is for PD-L1-positive, metastatic disease.</span></div>
<div style="text-align: left;">
<br /></div>
<div style="text-align: center;">
<span style="font-family: Verdana, sans-serif;"><b>TRAITEMENTS - ÉCONOMIE</b></span></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://www.biopharmadive.com/news/drug-price-value-based-trump-medicaid-rule/580099/" target="_blank">With new proposal, Trump administration tries to encourage 'value-based' drug deals [Biopharma Dive]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">The proposed changes, laid out in a proposed rule issued by the Centers for Medicare and Medicaid Services, would lower some of the regulatory requirements that drugmakers have complained limit their ability to enter into outcomes-based agreements.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">LUTTE CONTRE LES CANCERS - COVID19</span></b></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://science.sciencemag.org/content/368/6497/1290" target="_blank">COVID-19 and cancer [Science]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">Many scientists and clinicians are pivoting their cancer research activities to study the impact of SARS-CoV-2 on cancer. The scientific community must ensure that this pause is only temporary, because trials are the only way to make progress in developing new therapies for cancer. </span><br />
<br />
<span style="font-family: Verdana, sans-serif;"><a href="https://www.washingtonpost.com/health/2020/06/18/nations-cancer-chief-warns-delays-cancer-care-are-likely-result-thousands-extra-deaths-coming-years" target="_blank">Nation’s cancer chief warns delays in cancer care are likely to result in thousands of extra deaths in coming years [Washington Post]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">Because of the pandemic, some cancers will be found later when they are harder to cure, he says.</span>OVEhttp://www.blogger.com/profile/16701670533772026788noreply@blogger.comtag:blogger.com,1999:blog-6449150757505425806.post-53713848716862287912020-06-18T12:02:00.000+02:002020-06-18T12:02:53.527+02:00Onco Actu du 18 juin 2020<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">DÉP., DIAG. & PRONO. - BIOPSIES LIQUIDES</span></b></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><a href="https://www.med.ubc.ca/news/new-test-paves-the-way-for-tailored-treatment-of-deadliest-form-of-ovarian-cancer/" target="_blank">New test paves the way for tailored treatment of deadliest form of ovarian cancer [University of British Columbia]</a> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;">The new test, known as PrOTYPE (Predictor of high-grade serous Ovarian carcinoma molecular subTYPE), is specifically designed to analyze and classify high-grade serous ovarian cancer, the most common and lethal form of ovarian cancer.</span></div>
<div style="text-align: left;">
<br /></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><a href="https://www.cancerresearchuk.org/about-us/cancer-news/press-release/2020-06-17-new-blood-test-to-monitor-cancer-up-to-ten-times-more-sensitive-than-current-methods" target="_blank">New blood test to monitor cancer up to ten times more sensitive than current methods [Cancer Research UK]</a> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;">The technique uses personalised genetic testing of a patient’s tumour to search blood samples for hundreds of different genetic mutations in circulating tumour DNA (ctDNA); DNA released by cancer cells into the bloodstream.</span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><br class="Apple-interchange-newline" /></span></div>
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">DÉP., DIAG. & PRONO. - PROSTATE</span></b></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><a href="https://newsroom.uw.edu/news/psa-screening-affords-men-long-term-benefits-study-finds" target="_blank">PSA screening affords men long-term benefits, study finds [UW Medicine]</a> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;">The benefits of the prostate-specific antigen (PSA) test to screen men for prostate cancer may be greater than the harm, according to a study published today in the New England Journal of Medicine. <br class="Apple-interchange-newline" /> </span></div>
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">TRAITEMENTS</span></b></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><a href="https://www.acc.org/latest-in-cardiology/articles/2020/06/16/14/41/study-highlights-need-to-improve-cardioprotective-therapies-in-cardio-oncology" target="_blank">Study Highlights Need to Improve Cardioprotective Therapies in Cardio-Oncology [ACC]</a> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;">Cardioprotective therapies, especially statins and antiplatelet agents, may be underutilized in patients with a prior or current history of cancer compared with patients without cancer and comparable cardiovascular risk factors, according to a study published June 16 in JACC: CardioOncology. </span></div>
<div style="text-align: left;">
<br /></div>
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">IMMUNOTHÉRAPIES - BIOMARQUEURS</span></b></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><a href="https://www.mdanderson.org/newsroom/combination-biomarker-predicts-response-to-immune-checkpoint-therapy-in-patients-with-advanced-bladder-cancer.h00-159382734.html" target="_blank">Combination biomarker predicts response to immune checkpoint therapy in patients with advanced bladder cancer [MD Anderson Cancer Center]</a> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;">ARID1A mutations and CXCL13 expression in baseline tumor tissues associated with improved survival, may improve patient selection.</span></div>
<div style="text-align: left;">
<br /></div>
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">IMMUNOTHÉRAPIES - AMM</span></b></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors" target="_blank">FDA approves pembrolizumab for adults and children with TMB-H solid tumors [FDA]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">Efficacy was investigated in a prospectively-planned retrospective analysis of 10 cohorts of patients with various previously treated unresectable or metastatic TMB-H solid tumors enrolled in a multicenter, non-randomized, open-label trial, KEYNOTE-158 (NCT02628067). </span><br />
<br />
<span style="font-family: Verdana, sans-serif;"><a href="https://www.mrknewsroom.com/newsroom/news-releases/news-details/2020/FDA-Approves-Second-Biomarker-Based-Indication-for-Mercks-KEYTRUDA-pembrolizumab-Regardless-of-Tumor-Type/default.aspx" target="_blank">FDA Approves Second Biomarker-Based Indication for Merck’s KEYTRUDA® (pembrolizumab), Regardless of Tumor Type [Merck]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">KEYTRUDA Is the First Checkpoint Inhibitor Approved for These Patients with TMB-H Solid Tumors.</span><br />
<br />
<span style="font-family: Verdana, sans-serif;"><a href="https://www.foundationmedicine.com/press-releases/2bac198e-d31b-4e95-bfbf-28a55093b8e8" target="_blank">FoundationOne®CDx Receives FDA Approval as the First Companion Diagnostic to Identify Advanced Cancer Patients with Solid Tumors that are Tumor Mutational Burden-High (TMB-H) and Appropriate for Immunotherapy Treatment with KEYTRUDA® (pembrolizumab) [Foundation Medicine]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">FoundationOne CDx is the first and only FDA-approved companion diagnostic to measure TMB and help identify patients who may be appropriate for treatment with KEYTRUDA, regardless of solid tumor type.</span><br />
<br />
<span style="font-family: Verdana, sans-serif;"><a href="https://www.biopharmadive.com/news/merck-keytruda-approval-tumor-mutational-burden/579977/" target="_blank">With latest Keytruda approval, Merck beats Bristol Myers to a new immunotherapy target [Biopharma Dive]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">The decision marks the second so-called tissue agnostic approval for Keytruda, which made history in 2017 when the Food and Drug Administration cleared it for patients whose tumors have one of two genetic problems — microsatellite instability-high or mismatch repair deficiency. </span><br />
<br />
<span style="font-family: Verdana, sans-serif;"><a href="https://www.fiercepharma.com/marketing/merck-s-keytruda-nabs-2nd-biomarker-driven-fda-nod-regardless-tumor-type" target="_blank">Merck's Keytruda nabs 2nd biomarker-driven FDA nod, regardless of tumor type [Fierce Pharma]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">Among the 30 patients who responded, half had ongoing responses of two years or longer. The median duration of response had not been reached after a median follow-up of 11.1 months.</span><br />
<br />
<span style="font-family: Verdana, sans-serif;"><a href="https://endpts.com/merck-eats-the-lunch-bristol-myers-never-served-winning-tmb-based-ok-for-keytruda/" target="_blank">Merck eats the lunch Bristol Myers never served, winning TMB-based OK for Keytruda [EndPoints]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">The OK for unresectable or metastatic TMB-high solid tumors — defined as 10 mutations per megabase or more — is the second biomarker-based indication for Keytruda that covers tumors that fit the bill regardless of where in the body they originate.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES, …</span></b></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><a href="https://www.carrerasresearch.org/en/call-for-caution-for-using-a-car-t-immunotherapy-against-acute-myeloid-leukemia_153966" target="_blank">Call for caution for using a CAR-T immunotherapy against Acute Myeloid Leukemia [Josep Carreras Research Institute]</a> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;">Researchers from the Josep Carreras Research Institute prove that the preclinical implementation of Acute Myeloid Leukaemia immunotherapy, based on CD123-redirected CAR T-cells, affects hematopoiesis, blood cells production, and reconstitution.</span></div>
<div style="text-align: left;">
<br /></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><a href="https://www.mskcc.org/blog/new-target-car-cells-senescence-related-diseases" target="_blank">A New Target for CAR T Cells: Senescence-Related Diseases [Memorial Sloan Kettering]</a> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;">Scientists at Memorial Sloan Kettering have genetically engineered immune cells to find and kill cells that contribute to diseases caused by senescence, a tissue-damaging inflammatory process. Studies in mice show that these engineered cells can kill their targets without causing undue toxicity.</span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><br class="Apple-interchange-newline" /></span></div>
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">AACR</span></b></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><a href="https://media.bayer.com/baynews/baynews.nsf/id/Bayer-highlight-latest-research-advancing-Oncology-portfolio-AACR20-Virtual-Annual-Meeting-II" target="_blank">Bayer to highlight latest research on its advancing Oncology portfolio at the AACR20 Virtual Annual Meeting II [Bayer]</a> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;">Focus on Targeted Thorium Conjugate (TTC) platform, the company’s proprietary targeted alpha therapies program / Synergistic effects of investigational PSMA-TTC in combination with androgen receptor inhibitor darolutamide in preclinical prostate cancer.</span></div>
OVEhttp://www.blogger.com/profile/16701670533772026788noreply@blogger.comtag:blogger.com,1999:blog-6449150757505425806.post-50637750270857485152020-06-17T11:12:00.000+02:002020-06-17T11:12:05.887+02:00Onco Actu du 17 juin 2020<div style="text-align: center;">
<span style="font-family: Verdana, sans-serif;"><b>BIOLOGIE</b></span></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://www.hopkinsmedicine.org/news/newsroom/news-releases/loss-of-lipid-regulating-gene-fuels-prostate-cancer-spread" target="_blank">Loss of Lipid-Regulating Gene Fuels Prostate Cancer Spread [Johns Hopkins]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">The researchers say the loss of CAVIN1 in tumor cells could potentially be used as a biomarker, alerting clinicians to a risk of metastasis. </span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">DÉPISTAGE</span></b></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><a href="https://www.dana-farber.org/newsroom/news-releases/2020/new-technique-may-quickly-and-accurately-predict-effective-therapies-in-solid-tumors/" target="_blank"> New technique may quickly and accurately predict effective therapies in solid tumors [Dana-Farber Cancer Institute]</a> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;">The technique, known as high-throughput dynamic BH3 profiling (HT-DBP) is a scaled-up version of a test created by Dana-Farber researchers that gauges how close tumor cells are to death after treatment with cancer drugs.</span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><br class="Apple-interchange-newline" /></span></div>
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">DÉPISTAGE - PROSTATE</span></b></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><a href="https://www.exactsciences.com/newsroom/odx-gps-result-shows-value-for-unfavorable-intermediate-risk-prostate-cancer-patients" target="_blank">Oncotype Dx Genomic Prostate Score® Result Shows For The First Time The Value Of The Test To Guide Treatment Plans For Unfavorable Intermediate-risk Prostate Cancer Patients [Exact Sciences]</a> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;">Published in Urology, the new results demonstrate the GPS test is a strong independent predictor of critical outcomes in UFI-risk prostate cancer patients.</span></div>
<div style="text-align: left;">
<br /></div>
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">TRAITEMENTS - PRÉ-CLINIQUE</span></b></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><a href="https://www.cityofhope.org/news/powerful-small-molecules-may-be-able-to-kill-cancers" target="_blank">Two new, powerful small molecules may be able to kill cancers that other therapies can't [City of Hope]</a> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;">Using human cell and mouse models, City of Hope scientists demonstrate that the cancer inhibitors they’re developing could destroy acute myeloid leukemia and tumors from brain, pancreatic and breast cancers.</span></div>
<span style="font-family: Verdana, sans-serif;"><br /></span>
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">PHARMA</span></b></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><a href="https://investor.lilly.com/news-releases/news-release-details/verzenior-abemaciclib-significantly-reduced-risk-cancer" target="_blank">Verzenio® (abemaciclib) Significantly Reduced the Risk of Cancer Returning in People with High Risk HR+, HER2- Early Breast Cancer [Lilly]</a> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;">Lilly plans to present these data at a medical meeting later this year.</span></div>
<div style="text-align: left;">
<br /></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><a href="https://www.reuters.com/article/us-lilly-breast-cancer/lillys-breast-cancer-drug-succeeds-in-study-shares-rise-11-idUSKBN23N1XU" target="_blank">Lilly's breast cancer drug succeeds in study, shares rise 11% [Reuters]</a> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;">The late-stage trial data on Verzenio delivering a reduced risk of breast cancer recurrence or death comes earlier than expected and sets up the drug to have an expanded approval by roughly the middle of next year.</span></div>
<div style="text-align: left;">
<br /></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><a href="https://endpts.com/adding-billions-in-value-eli-lilly-succeeds-where-pfizer-failed-halting-breast-cancer-recurrence/" target="_blank">Adding billions in value, Eli Lilly succeeds where Pfizer failed, halting breast cancer recurrence [EndPoints]</a> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;">Lilly’s stock was up 13% on the news, from $141.49 to $160.45. That represents over $17 billion in added market cap value.</span></div>
<div style="text-align: left;">
<br /></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><a href="https://www.biopharmadive.com/news/eli-lilly-verzenio-early-breast-cancer/579907/" target="_blank">Lilly claims success in early breast cancer study, leaping past Pfizer [Biopharma Dive]</a> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;">The results come two weeks after a rival Pfizer drug, Ibrance, failed in a similar trial, albeit in a different study population.</span></div>
<div style="text-align: left;">
<br /></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><a href="https://www.fiercepharma.com/marketing/lilly-s-verzenio-hits-goal-for-early-breast-cancer-use-where-pfizer-s-ibrance-faltered" target="_blank">Lilly’s Verzenio shows up Ibrance, hitting its goal in early breast cancer after Pfizer's drug faltered [Fierce Pharma]</a> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;">The win, which Evercore ISI analyst Umer Raffat called a “surprise” in a Tuesday note, marks the first for a CDK4/6 inhibitor in the so-called adjuvant setting, in which the intention with treatment is to prevent invasive disease from returning.</span></div>
<div style="text-align: left;">
<br /></div>
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">PHARMA - PARTENARIATS</span></b></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><a href="https://endpts.com/billions-on-the-table-gsks-hal-barron-antes-120m-cash-to-partner-with-a-specialist-in-synthetic-lethality/" target="_blank">Billions on the table, GSK’s Hal Barron antes $120M cash to partner with a specialist in synthetic lethality [EndPoints]</a> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;">The MAT2A program is designed for patients with tumors having MTAP gene deletion. Their other synthetic lethality programs, according to their web site, “are for patients having tumors with genetic mutations in homologous recombination deficiency, including BRCA mutations, or base excision repair, and tumors having high microsatellite instability.”</span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><a href="https://www.gsk.com/en-gb/media/press-releases/ideaya-and-gsk-announce-a-broad-partnership-in-synthetic-lethality-an-emerging-field-in-precision-medicine-oncology/" target="_blank">IDEAYA and GSK Announce a Broad Partnership in Synthetic Lethality, an Emerging Field in Precision Medicine Oncology [GSK]</a> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;">The strategic partnership includes IDEAYA’s Synthetic Lethality programs MAT2A, Pol Theta, and Werner Helicase programs, which are projected to reach clinical trials within the next three years.</span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><a href="https://xconomy.com/san-francisco/2020/06/16/gsk-expands-synthetic-lethality-scope-with-120m-ideaya-bio-alliance/" target="_blank">GSK Expands Synthetic Lethality Scope With $120M Ideaya Bio Alliance [Fierce Pharma]</a> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;">Ideaya CEO Yujiro Hata said the deal validated his company’s approach to synthetic lethality. He also revealed that the alliance could see the new partners work together in yet another hot, emerging area of cancer drug research—targeted protein degradation.</span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"> </span></div>
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">PHARMA - BIOTECH</span></b></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://www.fiercebiotech.com/biotech/ona-raises-eu30m-to-treat-metastases-by-blocking-fat-intake" target="_blank">Ona raises €30M to treat metastases by blocking fat intake [Fierce Biotech]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">The metastasis-initiating cells expressed high levels of CD36, leading the team to explore the effect of using neutralizing antibodies to block the receptor and thereby cut the cells off from the fatty acids that may fuel their journey between organs</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">TRAITEMENTS - FDA, EMA,...</span></b></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://www.ipsen.com/press-releases/7762/" target="_blank">Ipsen receives FDA Fast Track designation for liposomal irinotecan (ONIVYDE®) as a first-line combination treatment for metastatic pancreatic cancer [Ipsen]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">Final analysis of the Phase 1/2 clinical study to be presented as a late-breaking virtual presentation at the ESMO World Congress on Gastrointestinal Cancer (WCGI) on July 1, 2020.<br /></span><div style="text-align: center;">
<span style="font-family: Verdana, sans-serif;"><b> </b></span></div>
<div style="text-align: center;">
<span style="font-family: Verdana, sans-serif;"><b>TRAITEMENTS - AMM</b></span></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://endpts.com/jazz-pharmas-1b-bet-pays-off-with-accelerated-lung-cancer-approval/" target="_blank">Jazz Pharma’s $1B bet pays off with accelerated lung cancer approval [EndPoints]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">Seven months after the Irish biopharma licensed PharmaMar’s small cell lung cancer drug lurbinectedin, the FDA has granted it accelerated approval.</span><br />
<br />
<div style="text-align: center;">
<span style="font-family: Verdana, sans-serif;"><b>LUTTE CONTRE LES CANCERS - COVID19</b></span></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://medicalxpress.com/news/2020-06-registry-tracks-outcomes-thoracic-cancer.html" target="_blank">Registry tracks outcomes among thoracic cancer patients sickened by COVID-19 [Medical XPress]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">While the majority of those who died were hospitalized, only 9% were admitted to intensive care units, according to a study published in The Lancet Oncology. Most died from complications of COVID-19, not the progression of cancer.</span><br />
<br />
<span style="font-family: Verdana, sans-serif;"><a href="https://www.statnews.com/2020/06/16/cancer-patients-doctors-carry-on-clinical-trials-during-covid-19" target="_blank">‘We have a job to do’: Cancer patients and their doctors carry on with clinical trials during Covid-19 [STAT]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">In cancer, the number of new patients entering Phase 2 and 3 cancer trials in the U.S. plummeted by about 46% to 48% in the last two weeks of March.</span>OVEhttp://www.blogger.com/profile/16701670533772026788noreply@blogger.comtag:blogger.com,1999:blog-6449150757505425806.post-8852848234721047662020-06-16T10:32:00.003+02:002020-06-16T10:32:26.324+02:00Onco Actu du 16 juin 2020<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">BIOLOGIE - GÉNOME</span></b></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://www.stjude.org/media-resources/news-releases/2020-medicine-science-news/cicero-software-enables-detection-of-cancer-causing-gene-fusion.html" target="_blank">CICERO software enables detection of cancer-causing gene fusions [St. Jude Children’s Research Hospital]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">In developing CICERO, Zhang and her colleagues took advantage of a technology called RNA sequencing. Using this technique, they analyzed cancer cells to detect fusion events. CICERO distinguishes fusion events by comparing the cells’ RNA sequence, called the “transcriptome,” with the published reference version of the DNA sequence of the human genome.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">TRAITEMENTS - ESSAIS</span></b></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://www.dana-farber.org/newsroom/news-releases/2020/drug-with-new-approach-on-impeding-dna-repair-shows-promise-in-first-clinical-trial/" target="_blank">Drug with new approach on impeding DNA repair shows promise in first clinical trial [Dana-Farber Cancer Institute]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">The findings may set the stage for testing berzosertib – an inhibitor of the ATR protein – in a range of other cancers, investigators say.</span><br />
<div style="text-align: center;">
<br /></div>
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">IMMUNOTHÉRAPIES - PHARMA</span></b></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://www.fiercebiotech.com/biotech/eli-lilly-s-r-d-revolving-door-spins-again-as-leena-gandhi-heads-back-to-dana-farber" target="_blank">Eli Lilly's R&D revolving door spins again as Gandhi heads back to Dana-Farber [Fierce Biotech]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">Gandhi, a thoracic oncologist, was tapped in April 2018 to head up a team tasked with overseeing the advance of Lilly’s portfolio of immuno-oncology prospects.</span><br />
<div style="text-align: center;">
<br /></div>
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">IMMUNOTHÉRAPIES - BIOTECH</span></b></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://www.fiercebiotech.com/biotech/takeda-partnered-shattuck-nabs-a-mighty-118m-funding-round-for-i-o-autoimmune-work" target="_blank">Takeda-partnered Shattuck nabs mighty $118M funding round for immunotherapy, autoimmune work [Fierce Biotech]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">Shattuck has previously said it can create single molecules that not only block immune checkpoints like PD-1/PD-L1 to remove a brake on the immune system but also simultaneously encourage T cells to attack malignant cells. The result is “combination immunotherapy with a single product.”</span><br />
<span style="font-family: Verdana, sans-serif;"><br /></span><div style="text-align: center;">
<span style="font-family: Verdana, sans-serif;"><b>IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES, …</b></span></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://www.fiercepharma.com/manufacturing/gilead-sees-better-days-ahead-for-car-t-therapy-yescarta-after-eu-nod-for-amsterdam" target="_blank">Gilead sees better days ahead for CAR-T therapy Yescarta with Amsterdam manufacturing hub online [Fierce Pharma]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">After years in the works, Gilead's 117,000-square-foot CAR-T facility at SEGRO Park Amsterdam Airport is now fully operational after the European Medicines Agency (EMA) approved the plant's end-to-end manufacturing process late last week. </span><br />
<div style="text-align: center;">
<br /></div>
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">TRAITEMENTS - AMM</span></b></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://www.cancer.gov/news-events/cancer-currents-blog/2020/fda-selpercatinib-thyroid-lung-cancer-ret-alterations" target="_blank">Selpercatinib Approved for Thyroid and Lung Cancers with RET Gene Alterations [NCI]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">The drug’s approval was based on a study in which it shrank tumors in more than half of all patients with advanced RET-altered lung and thyroid cancers, in many cases for 6 months or longer.<br /> </span><br />
<span style="font-family: Verdana, sans-serif;"><a href="https://investor.jazzpharma.com/news-releases/news-release-details/jazz-pharmaceuticals-announces-us-fda-accelerated-approval" target="_blank">Jazz Pharmaceuticals Announces U.S. FDA Accelerated Approval of Zepzelca™ (lurbinectedin) for the Treatment of Metastatic Small Cell Lung Cancer [Jazz Pharmaceuticals]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">Zepzelca is approved under accelerated approval based on overall response rate and duration of response demonstrated in an open-label, monotherapy clinical trial.</span><br />
<br />
<span style="font-family: Verdana, sans-serif;"><a href="https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-announces-us-fda-accelerated-approval-of-zepzelca-lurbinectedin-for-the-treatment-of-metastatic-small-cell-lung-cancer-301077082.html" target="_blank">Jazz Pharma Gets Quick FDA OK for New Small Cell Lung Cancer Drug [Xconomy]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">Madrid-based PharmaMar, which developed lurbinectedin (Zepzelca), licensed its US commercialization rights to Jazz Pharmaceuticals last December.</span><br />
<div style="text-align: center;">
<br /></div>
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">TRAITEMENTS - ÉCONOMIE</span></b></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><a href="https://www.nice.org.uk/guidance/gid-ta10415/documents/final-appraisal-determination-document" target="_blank">Entrectinib for treating ROS1-positive advanced non-small-cell lung cancer [NICE]</a> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;">Entrectinib is recommended, within its marketing authorisation, as an option for treating ROS1-positive advanced non-small-cell lung cancer (NSCLC) in adults who have not had ROS1 inhibitors. It is recommended only if the company provides entrectinib according to the commercial arrangement.</span></div>
<div style="text-align: left;">
<br /></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><a href="https://pharmaphorum.com/news/nice-backs-funding-for-roches-lung-cancer-drug-after-price-cut/" target="_blank">NICE backs funding for Roche’s lung cancer drug after price cut [Pharmaforum]</a> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;">Rozlytrek is set for approval in the EU during the next few weeks after a positive opinion from the European Medicines Agency’s CHMP. It is estimated that this treatment will be made available to around 412 people in England. </span></div>
<div style="text-align: center;">
<br /></div>
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">AACR</span></b></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><a href="https://www.sanofigenzyme.com/en/about-us/newsroom/2020/2020-06-15-11-00-00" target="_blank">Sanofi's emerging oncology pipeline highlighted at the AACR Virtual Annual Meeting II [Sanofi]</a> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;">Preclinical data show anti-tumor activity in Sanofi's investigational compounds, including an oral selective estrogen receptor degrader (SERD) and an anti-CEACAM5 antibody-drug conjugate.</span></div>
<div style="text-align: left;">
<br /></div>
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">LUTTE CONTRE LES CANCERS - COVID-19</span></b></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://scienceblog.cancerresearchuk.org/2020/06/15/covid-19-keeping-patients-on-cancer-clinical-trials" target="_blank">COVID-19: Keeping patients on cancer clinical trials [Cancer Research UK]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">It’s clear that the impact of COVID-19 on cancer trials will be felt for many years to come. Data collection has been affected, which means that clinical trials that have been paused will take a while to get back on their feet.</span>OVEhttp://www.blogger.com/profile/16701670533772026788noreply@blogger.comtag:blogger.com,1999:blog-6449150757505425806.post-9590202368531179692020-06-15T11:35:00.003+02:002020-06-15T11:35:35.876+02:00Onco Actu du 15 juin 2020<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">BIOLOGIE</span></b></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://www.nature.com/articles/d41586-020-01672-3" target="_blank">Neutrophil ‘safety net’ causes cancer cells to metastasize and proliferate [Nature]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">Immune cells called neutrophils can support the spread of cancer. How neutrophils aid this process now comes into focus through insights into the function of structures called neutrophil extracellular traps.</span> <br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">PRÉVENTION - CHIMIOPRÉVENTION - ASPIRINE</span></b></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><a href="https://www.jyu.fi/en/current/archive/2020/06/aspirin-reduces-long-term-colorectal-cancer-risk-in-genetically-predisposed-individuals" target="_blank">Aspirin reduces long-term colorectal cancer risk in genetically predisposed individuals [University of Jyväskylä]</a> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;">The participants of the current study were identified carriers of Lynch Syndrome. The results were published in a distinguished medical journal The Lancet.</span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><br /></span></div>
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">PRÉVENTION - VACCINS </span></b></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://www.mrknewsroom.com/newsroom/news-releases/news-details/2020/FDA-Approves-Mercks-GARDASIL-9-for-the-Prevention-of-Certain-HPV-Related-Head-and-Neck-Cancers/default.aspx" target="_blank">FDA Approves Merck’s GARDASIL 9 for the Prevention of Certain HPV-Related Head and Neck Cancers [Merck]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant) Now Approved for the Prevention of HPV-Related Cervical, Vaginal, Vulvar, Anal, Oropharyngeal and Other Head and Neck Cancers.</span><br />
<br />
<span style="font-family: Verdana, sans-serif;"><a href="https://www.statnews.com/2020/06/12/fda-approves-gardasil-9-the-hpv-vaccine-to-prevent-head-and-neck-cancer/" target="_blank">FDA approves Gardasil 9, the HPV vaccine, to prevent head-and-neck cancer [STAT]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">The FDA is granting what’s known as an accelerated approval, meaning that the decision is contingent on the production of more data and is based on what’s known as a “surrogate endpoint” — an indication that a medicine works that is not foolproof. </span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">TRAITEMENTS</span></b></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><a href="https://www.cancer.gov/news-events/cancer-currents-blog/2020/olanzapine-reduces-nausea-advanced-cancer" target="_blank">Olanzapine Reduces Nausea and Vomiting Caused by Advanced Cancer [NCI]</a> </span></div>
<span style="font-family: Verdana, sans-serif;">Thirty people with incurable cancer and chronic nausea enrolled in the new study. None had received chemotherapy or radiation therapy in the 2 weeks prior to enrolling, or antipsychotic medications in the 30 days prior to enrolling. </span><br />
<span style="font-family: Verdana, sans-serif;"><br /></span>
<div style="text-align: center;">
<span style="font-family: Verdana, sans-serif;"><b>TRAITEMENTS - ESSAIS</b></span></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://www.royalmarsden.nhs.uk/royal-marsden-trial-leads-practice-changing-milestone-advanced-anal-cancer" target="_blank">Royal Marsden trial leads to practice changing milestone for advanced anal cancer [Royal Marsden]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">Published in the Journal of Clinical Oncology, researchers found that a chemotherapy combination of carboplatin and paclitaxel – which is primarily used to treat other cancers, including ovarian, womb and lung cancer - performed better overall with anal cancer patients living seven months longer compared to chemotherapy treatment with cisplatin and 5-fluorouracil.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">TRAITEMENTS - AMM</span></b></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><a href="https://www.esmo.org/oncology-news/fda-approves-ramucirumab-plus-erlotinib-for-first-line-metastatic-nsclc" target="_blank">FDA Approves Ramucirumab Plus Erlotinib for First-Line Metastatic NSCLC [ESMO]</a> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;">Evidence for efficacy is based on the results from the RELAY study.</span></div>
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES, …</span></b></div>
<span style="font-family: Verdana, sans-serif;"><a href="http://investors.gilead.com/news-releases/news-release-details/kite-receives-european-medicines-agency-approval-car-t-cell" target="_blank">Kite Receives European Medicines Agency Approval for CAR T Cell Therapy Manufacturing Facility in Europe [Gilead]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">Amsterdam Facility will Bring Kite’s Potentially Life-Saving Individualized Treatment Closer to People with Advanced Blood Cancers in the European Region.</span><br />
<div style="text-align: center;">
<br /></div>
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">PHARMA</span></b></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://xconomy.com/national/2020/06/12/glaxosmithkline-keeps-oncology-2-0-growth-plans-on-track/" target="_blank">GlaxoSmithKline Keeps Oncology 2.0 Growth Plans on Track [Xconomy]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">The oncology R&D head explained that GSK’s cancer drug development strategy falls into four major categories, the first and largest of which is immuno-oncology – including belantamab mafodotin, dostarlimab, the inducible T-cell co-stimulator (ICOS) agonist GSK3359609 and several earlier clinical-stage candidates against TIM-3, LAG-3, OX40, STING and TLR4.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">ASCO</span></b></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://www.genomeweb.com/cancer/new-data-support-role-agendia-blueprint-test-refining-breast-cancer-subtypes" target="_blank">New Data Support Role of Agendia BluePrint Test in Refining Breast Cancer Subtypes [Genome Web]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">In poster presentations at the American Society of Clinical Oncology's virtual annual meeting earlier this month, investigators presented two new studies of BluePrint classification patterns. The company highlighted both as illustrating how the test's molecular classifications can reveal different information about a breast cancer's aggressiveness or responsiveness to treatment than would be gleaned from traditional factors like HER2 and ER biomarker status.</span><br />
<div style="text-align: center;">
<br /></div>
<div style="text-align: center;">
<span style="font-family: Verdana, sans-serif;"><b>EHA</b></span></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://www.roche.com/media/releases/med-cor-2020-06-13.htm" target="_blank">Positive phase III results for Venclexta/Venclyxto combination in acute myeloid leukaemia presented at EHA 2020 [Roche]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">Phase III VIALE-A study showed Venclexta/Venclyxto plus azacitidine helped people with the most common type of aggressive adult leukaemia live longer compared to azacitidine alone.</span><br />
<br />
<span style="font-family: Verdana, sans-serif;"><a href="https://www.fiercepharma.com/pharma/eha-abbvie-roche-cement-venclexta-s-place-aml-survival-win" target="_blank">EHA: AbbVie, Roche cement Venclexta's place in AML with survival win [Fierce Pharma]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">The trial win is key for AbbVie and Roche, as it backs up a conditional AML approval the FDA doled out in late 2018 based on response rates. </span><br />
<br />
<span style="font-family: Verdana, sans-serif;"><a href="https://www.takeda.com/newsroom/newsreleases/2020/takeda-presents-positive-data-from-clinical-trial-evaluating-oral-ninlaro-ixazomib--in-multiple-myeloma-as-a-first-line-maintenance-therapy/" target="_blank">Takeda Presents Positive Data from Clinical Trial Evaluating Oral NINLARO™ (ixazomib) in Multiple Myeloma as a First-Line Maintenance Therapy [Takeda]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">Positive Phase 3 Data Evaluating NINLARO as a Maintenance Therapy (TOURMALINE-MM4) Shows Significant Improvement in Progression-Free Survival in Adult Patients Not Treated with Stem Cell Transplantation.</span><br />
<br />
<span style="font-family: Verdana, sans-serif;"><a href="https://investors.karyopharm.com/news-releases/news-release-details/karyopharm-presents-xpovior-selinexor-and-eltanexor-data-0" target="_blank">Karyopharm Presents XPOVIO® (selinexor) and Eltanexor Data at the European Hematology Association 2020 Virtual Annual Meeting</a> </span><br />
<span style="font-family: Verdana, sans-serif;">Selinexor Demonstrates a Significant Survival Benefit in Patients with Relapsed or Refractory DLBCL and Durable Responses in Important DLBCL Patient Subgroups, Including Those with Primary Refractory Disease and Regardless of Number of Prior Therapies.</span>OVEhttp://www.blogger.com/profile/16701670533772026788noreply@blogger.comtag:blogger.com,1999:blog-6449150757505425806.post-78234990751906630932020-06-12T11:37:00.000+02:002020-06-12T11:37:10.401+02:00Onco Actu du 12 juin 2020<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">DÉP., DIAG. & PRONO. - BIOPSIES LIQUIDES</span></b></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://www.nih.gov/news-events/news-releases/nih-scientists-develop-blood-test-help-improve-liver-cancer-screening" target="_blank">NIH scientists develop blood test to help improve liver cancer screening [NIH]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">The team checked for the footprints of more than 1,000 different viruses in blood samples from around 900 people, including 150 who had HCC. They identified a specific viral exposure signature that could accurately distinguish people with HCC from people with chronic liver disease and healthy volunteers. This signature contained footprints from 61 different viruses.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">TRAITEMENTS - PRÉ-CLINIQUE</span></b></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://www.sciencemag.org/news/2020/06/computer-algorithms-find-tumors-molecular-weak-spots" target="_blank">Computer algorithms find tumors’ molecular weak spots [Science]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">In 2015, Califano co-founded a company called DarwinHealth that uses his algorithms to guide doctors by identifying the key transcription factors in a patient’s tumor and suggesting drugs to target them.<br /> </span><br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">IMMUNOTHÉRAPIES - BIOTECH</span></b></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://endpts.com/fueled-with-a-fresh-cash-injection-cullinan-expands-its-pipeline-with-a-bid-to-develop-a-new-combination-drug-for-the-checkpoint-class/" target="_blank">Fueled with a fresh cash injection, Cullinan expands its pipeline with a bid to develop a new combination drug for the checkpoint class [EndPoints]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">As CSO and co-founder Baeuerle explains it, the MICA ligand plays a key role in allowing NK and other killer T cells to mount an attack on cancer cells. And patients with high levels of MICA have a particularly poor prognosis.</span><br />
<br />
<span style="font-family: Verdana, sans-serif;"><a href="https://endpts.com/juno-wuxi-jv-in-china-score-100m-in-fresh-funding-as-it-sets-stage-for-first-car-t-approval/" target="_blank">Juno, WuXi JV in China score $100M in fresh funding as it sets stage for first CAR-T approval [EndPoints]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">The Shanghai-based company, christened JW Therapeutics (an initial each from its root companies), was created to marry Juno’s CAR-T development experience and WuXi’s AppTec’s muscular manufacturing capacity.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">IMMUNOTHÉRAPIES - AMM</span></b></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><a href="https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-nivolumab-esophageal-squamous-cell-carcinoma" target="_blank">FDA approves nivolumab for esophageal squamous cell carcinoma [FDA]</a> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;">The Food and Drug Administration approved nivolumab (OPDIVO, Bristol-Myers Squibb Co.) for patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy.</span></div>
<span style="font-family: Verdana, sans-serif;"><br /></span><div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES, …</span></b></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://ucsdnews.ucsd.edu/pressrelease/putting-super-in-natural-killer-cells" target="_blank">Putting ‘Super’ in Natural Killer Cells [UCSD]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">Deleting an inhibitory gene in natural killer cells derived from induced pluripotent stem cells is found to boost their anti-tumor activity and persistence; researchers now seek to develop a clinical therapy.</span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">TRAITEMENTS - AMM</span></b></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://www.cancer.gov/news-events/cancer-currents-blog/2020/fda-olaparib-rucaparib-prostate-cancer" target="_blank">With Two FDA Approvals, Prostate Cancer Treatment Enters the PARP Era [NCI]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">The approvals are for the drugs olaparib (Lynparza) and rucaparib (Rubraca). They cover the use of the drugs in men whose prostate cancer has spread, or metastasized, and whose disease has stopped responding to standard hormone treatments, often called castration-resistant disease. </span><br />
<br />
<span style="font-family: Verdana, sans-serif;"><a href="https://investors.pfizer.com/investor-news/press-release-details/2020/FDA-Approves-Pfizers-Oncology-Supportive-Care-Biosimilar-NYVEPRIA-pegfilgrastim-apgf/default.aspx" target="_blank">FDA Approves Pfizer’s Oncology Supportive Care Biosimilar, NYVEPRIA™ (pegfilgrastim-apgf) [Pfizer]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">The FDA approval was based on the review of a comprehensive data package and totality of evidence demonstrating a high degree of similarity of NYVEPRIA to its reference product.</span><br />
<div style="text-align: center;">
<br /></div>
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">EHA</span></b></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><a href="https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2020/calquence-showed-long-term-efficacy-and-tolerability-for-patients-with-chronic-lymphocytic-leukaemia-in-two-trials.html" target="_blank">Calquence showed long-term efficacy and tolerability for patients with chronic lymphocytic leukaemia in two trials [AstraZeneca]</a> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;">Detailed results from both the Phase II ACE-CL-001 trial and the pivotal Phase III ASCEND trial showed the long-term efficacy and tolerability of Calquence (acalabrutinib) in chronic lymphocytic leukaemia (CLL), one of the most common types of adult leukaemia.</span></div>
<div style="text-align: center;">
<br /></div>
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">LUTTE CONTRE LES CANCERS - PUBLICATIONS</span></b></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><a href="http://news.mit.edu/2020/guided-by-open-access-principles-mit-ends-elsevier-negotiations-0611" target="_blank">MIT, guided by open access principles, ends Elsevier negotiations [MIT]</a> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;">Institute ends negotiations for a new journals contract in the absence of a proposal aligning with the MIT Framework for Publisher Contracts.</span></div>
<span style="font-family: Verdana, sans-serif;"><br /></span><div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">LUTTE CONTRE LES CANCERS - IMPLANTS MAMMAIRES</span></b></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://www.reuters.com/article/us-eu-court-france-implants/only-french-victims-of-faulty-breast-implant-may-claim-damages-eu-court-says-idUSKBN23I1IR" target="_blank">Only French victims of faulty breast implant may claim damages, EU court says [Reuters]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">“The regulation favours international exchanges of products, which is a good thing, but consumer protection stops at the border,” said Olivier Aumaitre, a lawyer for the association.</span><br />
<span style="font-family: Verdana, sans-serif;"><br /></span><div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">LUTTE CONTRE LES CANCERS - ASSOCIATIONS</span></b></div>
<span style="font-family: Verdana, sans-serif;"><a href="http://pressroom.cancer.org/2020reductions" target="_blank">American Cancer Society Reductions in Wake of Fundraising Drop from Coronavirus Pandemic [ACS]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">ACS is reducing its overall budget by approximately 30 percent, with cuts to both non-personnel and personnel expenses. Unfortunately, this included eliminating approximately 1,000 staff positions nationwide.</span> OVEhttp://www.blogger.com/profile/16701670533772026788noreply@blogger.comtag:blogger.com,1999:blog-6449150757505425806.post-18036685984908048232020-06-11T11:30:00.001+02:002020-06-11T11:30:30.820+02:00Onco Actu du 11 juin 2020<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">DÉP., DIAG. & PRONO. - GÉNOME </span></b></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://hospitals.jefferson.edu/news/2020/06/new-recommendations-on-genetic-testing-for-prostate-cancer.html" target="_blank">New Recommendations on Genetic Testing for Prostate Cancer [Thomas Jefferson University]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">Recommended priority genes for testing include BRCA2, BRCA1, and DNA mismatch repair genes in metastatic prostate cancer.</span><br />
<br />
<span style="font-family: Verdana, sans-serif;"><a href="https://www.genomeweb.com/cancer/cancer-experts-develop-precision-medicine-based-genetic-testing-framework-prostate-cancer" target="_blank">Cancer Experts Develop Precision Medicine-Based Genetic Testing Framework for Prostate Cancer [Genome Web]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">The panel recommended large germline panels and somatic testing for metastatic prostate cancer. They also recommended germline testing for metastatic disease or family history suggestive of hereditary prostate cancer. Additional family history and pathologic criteria garnered moderate consensus.</span><br />
<div style="text-align: center;">
<span style="font-family: Verdana, sans-serif;"><br /><b>IMMUNOTHÉRAPIES - ESSAIS</b></span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><a href="https://xconomy.com/new-york/2020/06/10/mercks-keytruda-fails-pivotal-bladder-cancer-study-sinks-first-line-hopes/" target="_blank">Merck’s Keytruda Fails Pivotal Bladder Cancer Study, Sinks First-Line Hopes [Xconomy]</a> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;">The Phase 3 study, KEYNOTE-361, enrolled 1,010 patients randomly assigned to receive pembrolizumab plus chemotherapy, pembrolizumab alone, or chemotherapy. The goals were to show improvement in how long patients lived overall as well as how long they lived without the cancer worsening.</span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><a href="https://www.fiercepharma.com/marketing/merck-s-keytruda-flops-bladder-cancer-trial-giving-roche-s-tecentriq-a-chance-at-bigger" target="_blank">Merck's Keytruda flops bladder cancer trial, giving Roche's Tecentriq an open shot [Fierce Pharma]</a> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;">Failure of the phase 3 Keynote-361 trial could endanger Keytruda’s conditional FDA approval for first-line bladder cancer in cisplatin-ineligible patients whose tumors express PD-L1 at a combined score of at least 10 or in patients who aren’t able to receive any platinum-containing chemo regardless of PD-L1 status. </span></div>
<span style="font-family: Verdana, sans-serif;"> </span><div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;"> </span></b></div>
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">IMMUNOTHÉRAPIES - PARTENARIATS</span></b></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><a href="https://endpts.com/abbvie-pays-750m-cash-to-ally-itself-with-genmab-on-a-pipeline-of-cancer-drugs-with-billions-more-on-the-table/" target="_blank">Analysts cheer as AbbVie pays $750M cash to ally itself with Genmab on a pipeline of cancer drugs, with billions more on the table [EndPoints]</a> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;">The big idea here is to marry up Genmab’s technology, designed to marshal a T cell attack on cancer cells, with AbbVie’s antibody-drug conjugate tech, which deposits a toxic payload into the cancer cells, sparing healthy cells.</span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><a href="https://ir.genmab.com/news-releases/news-release-details/genmab-and-abbvie-announce-broad-oncology-collaboration" target="_blank">Genmab and AbbVie Announce Broad Oncology Collaboration [Genmab]</a> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;">The collaboration combines Genmab’s world-class discovery and development engine and next-generation bispecific antibody therapeutic candidates with AbbVie’s deep clinical expertise, innovative antibody-drug conjugate (ADC) platform and global commercial leadership in hematological cancers.</span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><a href="https://www.biopharmadive.com/news/abbvie-genmab-cancer-drug-deal/579551/" target="_blank">AbbVie hands Genmab $750M in latest bid to grow cancer drug business [Biopharma Dive]</a> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;">For $750 million upfront, AbbVie gains rights to three early-stage Genmab drugs that can target two cell proteins at once, a type of treatment known as a bispecific antibody. The two companies will also work together to discover and advance four new antibody drugs for cancer.</span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><a href="https://xconomy.com/national/2020/06/10/abbvie-commits-750m-to-genmab-bispecific-antibody-cancer-drug-deal/" target="_blank">AbbVie Commits $750M to Genmab Bispecific Antibody Cancer Drug Deal [Xconomy]</a> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;">Genmab has a history of working with other companies to advance its experimental treatments, having inked a total of 18 strategic partnerships including the one announced Wednesday</span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><a href="https://www.fiercebiotech.com/biotech/abbvie-to-pay-genmab-750m-upfront-to-form-bispecific-r-d-pact" target="_blank">AbbVie to pay Genmab $750M upfront to form bispecific R&D pact [Fierce Biotech]</a> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;">The deal, which features up to $3.2 billion in milestones, positions AbbVie to race Regeneron to market with a bispecific antibody that could compete with CAR-T therapies.</span></div>
<span style="font-family: Verdana, sans-serif;"><br /></span><div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">IMMUNOTHÉRAPIES - BIOTECH</span></b></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://endpts.com/ipo-bound-art-krieg-and-the-checkmate-crew-collect-85m-to-back-up-their-1-drug-pipeline/" target="_blank">IPO bound? Five years in, Art Krieg and the Checkmate crew collect $85M to back up their 1-drug pipeline [EndPoints]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">The drug is CMP-001, which contains a CpG-A oligonucleotide that activates the TLR9 pathway to kick up an innate immune response to cancer — one of the most popular research strategies in the oncology handbook these days. </span><br />
<br />
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;">IMMUNOTHÉRAPIES - AMM</span></b></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://news.bms.com/press-release/corporatefinancial-news/us-food-and-drug-administration-approves-opdivo-nivolumab-trea" target="_blank">U.S. Food and Drug Administration Approves Opdivo® (nivolumab) for the Treatment of Patients with Advanced Esophageal Squamous Cell Carcinoma (ESCC) After Prior Fluoropyrimidine- and Platinum-based Chemotherapy [BMS]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">First approved immunotherapy in this patient population regardless of tumor PD-L1 expression level.</span> <br />
<div style="text-align: center;">
<br /></div>
<div style="text-align: center;">
<b><span style="font-family: Verdana, sans-serif;"> PHARMA - PARTENARIATS</span></b></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><a href="https://endpts.com/sanofi-sharpens-focus-on-bispecifics-and-china-with-alphamab-deal/" target="_blank">Sanofi sharpens focus on bispecifics, and China, with Alphamab deal [EndPoints]</a> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;">With the deal with Sanofi, the plan is to investigate the use of KN026 in combination with the French drugmaker’s chemotherapy Taxotere (Docetaxel) in patients with HER2+ breast cancer.</span></div>
<span style="font-family: Verdana, sans-serif;"><br /></span><div style="text-align: center;">
<span style="font-family: Verdana, sans-serif;"><b>LUTTE CONTRE LES CANCERS - PUBLICATIONS</b></span></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://www.forbes.com/sites/victoriaforster/2020/06/09/eight-fraudulent-cancer-research-studies-contained-same-copied-results-how-does-this-happen" target="_blank">Eight Fraudulent Cancer Research Studies Contained The Same Copied Results. How Does This Happen? [Forbes]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">The authors listed on the eight papers all appear to be Chinese with affiliations at Chinese hospitals and institutions. </span>OVEhttp://www.blogger.com/profile/16701670533772026788noreply@blogger.comtag:blogger.com,1999:blog-6449150757505425806.post-58355546406435775862020-06-10T11:53:00.001+02:002020-06-10T11:53:29.268+02:00Onco Actu du 10 juin 2020<div style="text-align: center;">
<span style="font-family: Verdana, sans-serif;"><b><span style="background-color: white;">BIOLOGIE - GÉNOME</span></b></span></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://www.genomeweb.com/sequencing/glioblastoma-genomes-point-non-coding-driver-mutations">Glioblastoma Genomes Point to Non-Coding Driver Mutations [Genome Web]</a> </span><br />
<span style="font-family: Verdana, sans-serif;">Along with alterations affecting coding genes linked to GBM previously, the team's analyses pointed to an over-representation of non-coding mutations falling near 78 GBM-related genes.<br class="Apple-interchange-newline" /></span><br />
<div style="text-align: center;">
<span style="font-family: Verdana, sans-serif;"><b>ETIOLOGIE</b></span></div>
<span style="font-family: Verdana, sans-serif;"><a href="https://www.helsinki.fi/en/news/health-news/researchers-have-found-a-molecular-explanation-to-a-longstanding-enigma-in-viral-oncology" target="_blank">Researchers have found a molecular explanation to a longstanding enigma in viral oncology [University of Helsinki]</a></span><br />
<span style="font-family: Verdana, sans-serif;">The oncogenic herpesvirus (HHV8 or KSHV) causes a cancer known as Kaposi’s Sarcoma. An international team of scientists led by the University of Helsinki has discovered key factors that control the genome maintenance and replication of a virus responsible for lymphatic vascular cancer.</span><br />
<br />
<div style="text-align: center;">
<span style="font-family: Verdana, sans-serif;"><b>PREVENTION</b></span></div>
<span style="font-family: Verdana, sans-serif;"><a href="http://pressroom.cancer.org/DietPhysicalActivity2020" target="_blank">American Cancer Society Updates Diet & Physical Activity Guideline for Cancer Prevention [ACS]</a></span><br />
<span style="font-family: Verdana, sans-serif;">More emphasis on reducing the consumption of processed and red meat and alcohol, and increasing physical activity.</span><br />
<span style="font-family: Verdana, sans-serif;"><br class="Apple-interchange-newline" /></span>
<div style="text-align: center;">
<span style="font-family: Verdana, sans-serif;"><b>DÉP., DIAG. & PRONO. - GÉNOME</b></span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><a href="https://www.dana-farber.org/newsroom/news-releases/2020/genomic-test-accurately-identifies-patients-with-smoldering-multiple-myeloma-at-high-risk-of-developing-myeloma--study-finds" target="_blank">Genomic test accurately identifies patients with smoldering multiple myeloma at high risk of developing myeloma, study finds [Dana-Farber Cancer Institute]</a> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;">Investigators collected bone marrow samples from 214 patients at the time of diagnosis with smoldering multiple myeloma and sequenced the DNA within the tumor cells. This was a multicenter cohort encompassing multiple centers from the United States and Europe.</span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><br class="Apple-interchange-newline" /></span></div>
<div style="text-align: left;">
<div style="text-align: center;">
<span style="font-family: Verdana, sans-serif;"><b>BIOPSIES LIQUIDES</b></span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><a href="https://www.businesswire.com/news/home/20200609005147/en/C2i-Genomics-Raises-12-Million-Series-Funding" target="_blank">C2i Genomics Raises $12 Million in Series A Funding [Business Wire]</a> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;">This novel genome-wide signature detection, coupled with proprietary mathematical inference models and machine learning techniques, provides ultra-sensitive quantification of the amount of circulating tumor DNA in the patient’s blood, accurately capturing the aggregate response of the heterogenic tumor.</span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><br class="Apple-interchange-newline" /></span></div>
<div style="text-align: center;">
<span style="font-family: Verdana, sans-serif;"><b>TRAITEMENTS</b></span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><a href="http://www.news.gatech.edu/2020/06/08/chemotherapy-and-cancer-gang-cause-neurological-side-effect-study-says" target="_blank">Chemotherapy and Cancer Gang up to Cause a Neurological Side Effect, Study Says [Georgia Tech]</a> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;">Contrary to common medical guidance, chemotherapy does not appear to be the only culprit in neuropathy, a neurological side effect of cancer treatment, a new study says. Cancer itself contributes heavily, too, and the stresses on neurons appear far worse than the sum of the two causes.</span></div>
<div style="text-align: left;">
<br /></div>
<div style="text-align: center;">
<span style="font-family: Verdana, sans-serif;"><b>TRAITEMENTS - PRÉ-CLINIQUE</b></span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><a href="https://www.garvan.org.au/news-events/news/precision-approach-for-lung-adenocarcinoma" target="_blank">Precision approach for lung adenocarcinoma [Garvan Institute]</a> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;">In cell culture and mouse models, the researchers discovered that when they inhibited P70S6K with a drug, or genetically reduced the enzyme’s levels, they could sensitise resistant lung adenocarcinoma cells to cisplatin. </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><br /></span><div style="text-align: center;">
<span style="font-family: Verdana, sans-serif;"><b>IMMUNOTHÉRAPIES - ESSAIS</b></span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><a href="https://www.reuters.com/article/us-merck-co-study/mercks-bladder-cancer-late-stage-study-fails-to-meet-main-goals-idUSKBN23G2YE" target="_blank">Merck's bladder cancer late-stage study fails to meet main goals [Reuters]</a> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;">Keytruda, which brought in sales of $3.28 billion in the first quarter, has already received three U.S. regulatory approvals for different types of bladder cancers.</span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><a href="https://endpts.com/king-keytruda-flounders-in-another-pivotal-cancer-study-and-that-may-spur-doubts-about-mercks-staying-power/" target="_blank">King Keytruda flounders in another pivotal cancer study. And that may spur doubts about Merck's staying power [EndPoints]</a> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;">With repeated snafus over the last 5 months, some analysts may start to wonder if the pharma giant is leaving itself vulnerable as the competition stacks up and new combos, including TIGIT, start to take center stage.</span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><a href="https://www.mrknewsroom.com/newsroom/news-releases/news-details/2020/Merck-Provides-Update-on-Phase-3-KEYNOTE-361-Trial-Evaluating-KEYTRUDA-pembrolizumab-as-Monotherapy-and-in-Combination-with-Chemotherapy-in-Patients-with-Advanced-or-Metastatic-Urothelial-Carcinoma/default.aspx" target="_blank">Merck Provides Update on Phase 3 KEYNOTE-361 Trial Evaluating KEYTRUDA® (pembrolizumab) as Monotherapy and in Combination with Chemotherapy in Patients with Advanced or Metastatic Urothelial Carcinoma [Merck]</a> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;">Results will be presented at an upcoming medical meeting and will be discussed with regulatory authorities.</span></div>
<div style="text-align: left;">
<div style="text-align: center;">
<span style="font-family: Verdana, sans-serif;"> </span></div>
<div style="text-align: center;">
<span style="font-family: Verdana, sans-serif;"><b>IMMUNOTHÉRAPIES - PARTENARIATS</b></span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><a href="http://innoventbio.com/en/#/news/190" target="_blank">Innovent and Roche Enter into A Strategic Collaboration to Discover and Develop Multiple Products including Cellular Therapies and Bispecific Antibodies [Innovent]</a> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;">The collaboration will focus on the discovery, clinical development and commercialization of bispecific antibodies and multiple cell therapies and will be directed to the treatment of hematological and solid cancers.</span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><a href="https://www.biopharmadive.com/news/roche-innovent-cancer-car-t-bispecific/579478/" target="_blank">China's Innovent buys rights to Roche cancer technology [Biopharma Dive]</a> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;">The deal involves Roche technology for "universal" CAR-T cell therapies, which wouldn't require the re-engineering of a patient's own immune cells that makes Novartis' Kymriah and Gilead's Yescarta so logistically complex.</span><div style="text-align: center;">
<span style="font-family: Verdana, sans-serif;"><br /><b>TRAITEMENTS - AMM</b></span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><a href="https://www.esmo.org/oncology-news/ema-recommends-granting-a-marketing-authorisation-for-biosimilar-trastuzumab" target="_blank">EMA Recommends Granting a Marketing Authorisation for Biosimilar Trastuzumab [ESMO]</a> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;">Zercepac is a biosimilar medicinal product. It is highly similar to the reference product Herceptin (trastuzumab), which was authorised in the EU on 28 August 2000.</span></div>
<div style="text-align: left;">
<div style="text-align: center;">
<span style="font-family: Verdana, sans-serif;"> </span></div>
<div style="text-align: center;">
<span style="font-family: Verdana, sans-serif;"><b>TRAITEMENTS - ÉCONOMIE</b></span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><a href="https://www.nice.org.uk/guidance/TA632" target="_blank">Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer [NICE]</a> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;">It is recommended only if the company provides trastuzumab emtansine according to the commercial arrangement.<br /><br /><a href="https://www.fiercepharma.com/pharma/sanofi-s-sarclisa-rollout-hits-snag-britain-s-cost-watchdogs" target="_blank">Sanofi's Sarclisa rejected by NICE over uncertainties on total benefit, cost-effectiveness [Fierce Pharma]</a> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;">The drug’s list price isn’t yet public. NICE's decision isn’t final and is subject to review and consultation. </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><br class="Apple-interchange-newline" /></span></div>
<div style="text-align: center;">
<span style="font-family: Verdana, sans-serif;"><b>ASCO</b></span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;"><a href="https://www.nature.com/articles/s41571-020-0402-2" target="_blank">From the ASCO20 Virtual meeting [Nature Reviews Clinical Oncology]</a> </span></div>
<div style="text-align: left;">
<span style="font-family: Verdana, sans-serif;">Although many will have missed out on networking opportunities and the collective excitement of witnessing the presentation of new, practice-changing data in person, the virtual format does have advantages.</span></div>
</div>
</div>
</div>
<span style="font-family: Verdana, sans-serif;"><b id="docs-internal-guid-215b377f-7fff-da0c-be8c-462bba0dd848" style="font-weight: normal;"><div dir="ltr" style="line-height: 1.38; margin-bottom: 0pt; margin-top: 0pt;">
<span style="background-color: white; color: black; font-size: 11pt; font-style: italic; font-variant: normal; font-weight: 400; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;"></span></div>
</b></span></div>
</div>
OVEhttp://www.blogger.com/profile/16701670533772026788noreply@blogger.comtag:blogger.com,1999:blog-6449150757505425806.post-20490192407008443612020-06-09T11:42:00.002+02:002020-06-09T11:42:19.134+02:00Onco Actu du 9 juin 2020<table style="-webkit-text-stroke-width: 0px; color: black; font-family: Times; font-size: medium; font-style: normal; font-variant-caps: normal; font-variant-ligatures: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-decoration-color: initial; text-decoration-style: initial; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
1. BIOLOGIE</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://medicine.utoronto.ca/news/when-cancer-cells-cant-make-their-own-fat-they-eat-more-it-u-t-study-finds" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
When Cancer Cells Can’t Make Their Own Fat, They Eat More Of It, U of T Study Finds [University of Toronto]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
The study, published this week in the journal Nature Metabolism, is the first to investigate global changes in cancerous cells as they adapt to a shortfall of critical nutrients such as fat molecules, or lipids, which make up the cell’s outer envelope.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
4.11 DÉP., DIAG. & PRONO. - OVAIRE</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.rcsi.com/dublin/news-and-events/news/news-article/2020/06/better-detection-of-a-type-of-ovarian-cancer-could-lead-to-better-treatments" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
RCSI research suggests that better detection of a type of ovarian cancer could lead to better treatments [RCSI]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Instead of having an inherited mutated BRCA1 gene, some patients have this gene modified in a way that is thought to silence it. The researchers analysed 2,636 patients with ovarian cancer from 15 international studies to see if those with this silenced BRCA1 gene had similar outcomes to those with the mutated gene.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.1 TRAITEMENTS - PRÉ-CLINIQUE</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.sbpdiscovery.org/news/preventing-pancreatic-cancer-metastasis-by-keeping-cells-sheltered-place" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Preventing pancreatic cancer metastasis by keeping cells “sheltered in place” [Sanford Burnham Prebys]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
In the study, the scientists used a mouse model of pancreatic cancer to show that, in response to glutamine deficiency, a protein called Slug drives metastasis by activating the epithelial-mesenchymal transition, or EMT—the process cells use to free themselves from tightly packed tissue.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.uc.edu/news/articles/2020/06/n20920867.html" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
UC research points to potential new treatment for pancreatic cancer [University of Cincinnati]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Researchers in this study have found that using a therapeutic compound, called SapC-DOPS, a nanovesicle (or a nanotechnology drug delivery system) made of microscopic components of a cell, to deliver a combined biomarker target therapy and standard chemotherapy for pancreatic cancer may show benefit to patients.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.12.1 IMMUNOTHÉRAPIES - PARTENARIATS</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.genomeweb.com/cancer/microbiotica-cambridge-researchers-study-microbiome-impact-immunotherapy-response" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Microbiotica, Cambridge Researchers to Study Microbiome Impact on Immunotherapy Response [Genome Web]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
For its part of the collaboration, Wellcome Sanger Institute spinout Microbiotica will use its microbiome profiling and analysis platform together with data from two CUH-led clinical studies, MelResist and MITRE, to identify gut bacterial signatures associated with treatment response or resistance.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.12.6 IMMUNOTHÉRAPIES - AMM</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.esmo.org/oncology-news/fda-approves-atezolizumab-plus-bevacizumab-for-unresectable-hepatocellular-carcinoma" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
FDA Approves Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma [ESMO]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Evidence for efficacy is based on the results from the IMbrave150 study.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.2.1 PHARMA - PARTENARIATS</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="http://www.alphamabonc.com/en/html/news/2093.html" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Alphamab Oncology and Sanofi Enter Collaboration on KN026 in HER2+ Breast Cancer [Alphamab]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
KN026 is an anti-HER2 bispecific antibody which can simultaneously bind two non-overlapping epitopes of HER2 and lead to a dual HER2 signal blockade, presumedly causing HER2 to aggregate on the cell surface and endocytose.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.2.3 PHARMA - ÉCONOMIE</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.fiercebiotech.com/special-report/top-10-pharma-r-d-budgets-2019" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
The top 10 pharma R&D budgets in 2019 [Fierce Pharma]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><div style="float: left;">
<img class="slider_img" id="relevance_171859_img" src="http://srv10-inca/amiei/img/slider_star_1.gif" style="margin: 0px 2px; vertical-align: bottom;" title="Niveau de pertinence" /></div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Looking through the main programs across all the top 10 companies, it’s immediately clear oncology is still the biggest therapeutic category when it comes to spending. Cancer R&D has traditionally been expensive, but the FDA’s willingness to approve treatments on more limited data is cutting costs and offering a quicker path to market.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
6.15 LUTTE CONTRE LES CANCERS - COVID-19</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.royalmarsden.nhs.uk/new-guidance-helps-select-breast-cancer-patients-urgent-surgery-or-chemotherapy-during-pandemic" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
New guidance helps select breast cancer patients for urgent surgery or chemotherapy during pandemic [Royal Marsden]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
The innovative algorithm, using data from multiple international trials, can identify postmenopausal patients with primary ER+HER2- breast cancer (c.70% of cases) who have less endocrine-sensitive tumours and who should be prioritised for early surgery or neoadjuvant chemotherapy.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://news.uci.edu/2020/06/08/global-oncology-pharmacists-face-restricted-access-to-essential-ppe-items-uci-study-finds/" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Global oncology pharmacists face restricted access to essential PPE items, UCI study finds [UCI]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
In the Journal of Oncology Pharmacy Practice, Alexandre Chan, department chair and professor clinical pharmacy practice, and Canadian and Australian colleagues of the International Society of Oncology Pharmacy Practitioners surveyed 42 pharmacy practice groups in 28 countries and regions (in both developed and developing countries) to determine pain points that this global pandemic has created for oncology pharmacy practitioners.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
</tbody></table>
OVEhttp://www.blogger.com/profile/16701670533772026788noreply@blogger.comtag:blogger.com,1999:blog-6449150757505425806.post-58102295062221776162020-06-08T10:56:00.004+02:002020-06-08T10:56:56.199+02:00Onco Actu du 8 juin 2020<table style="-webkit-text-stroke-width: 0px; color: black; font-family: Times; font-size: medium; font-style: normal; font-variant-caps: normal; font-variant-ligatures: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-decoration-color: initial; text-decoration-style: initial; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
2.5 ETIOLOGIE - GÉNOME</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.genomeweb.com/sequencing/secondary-tumor-risk-pediatric-cancer-survivors-linked-germline-variants-treatment-type" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Secondary Tumor Risk in Pediatric Cancer Survivors Linked to Germline Variants, Treatment Type [Genome Web]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
A team led by investigators at St. Jude Children's Research Hospital did whole-genome sequencing on blood samples from 4,402 pediatric cancer survivors in the St. Jude Lifetime Cohort, including 495 individuals who went on to develop more than 1,200 secondary neoplasms, focusing on pathogenic germline alterations affecting more than 100 genes from half a dozen DNA repair pathways.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5. TRAITEMENTS</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.birmingham.ac.uk/news/latest/2020/06/guidelines-for-treatments-for-hpv-positive-throat-cancer.aspx" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Experts release new guidelines for studies into most effective treatments for HPV-positive throat cancer [University of Birmingham]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Heightened caution is needed when considering de-escalation trials for patients with Human papillomavirus (HPV)-positive oropharyngeal cancer (OPC), to ensure minimal harm to patients, new guidelines from a group of international head and neck cancer experts have suggested.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.12.5.1 IMMUNOTHÉRAPIES - BIOTECH</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://xconomy.com/new-york/2020/06/05/legend-biotechs-upsized-ipo-lands-424m-for-multiple-myeloma-drug/" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Legend Biotech’s Upsized IPO Lands $424M for Multiple Myeloma Drug [Xconomy]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
The Legend drug targets a cancer protein called B-cell maturation antigen (BCMA). It’s found in abundance on the surface of multiple myeloma cells. There are no FDA-approved BCMA-targeting drugs yet, but the JNJ-4528 data make it a strong contender to become the first.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.biopharmadive.com/news/legend-biotech-ipo-car-t-multiple-myeloma/579291/" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Fresh off ASCO myeloma data, Legend Bio gets $424M in biotech's biggest IPO of 2020 [Biopharma Dive]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Legend Biotech, a subsidiary of Hong Kong firm GenScript, has become increasingly known in U.S. biotech circles since cutting a deal with Johnson & Johnson two and a half years ago.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://endpts.com/legend-fetches-424-million-emerges-as-biggest-winner-yet-in-pandemic-ipo-boom/" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Legend fetches $424 million, emerges as biggest winner yet in pandemic IPO boom as shares soar [EndPoints]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Legend Biotech, the Nanjing-based CAR-T developer, has raised $424 million on the Nasdaq. The biotech had originally filed for a still-hefty $350 million.<br />It didn’t stop there. Its shares rocketed up more than 60% on its first day of trading.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.12.8 IMMUNOTHÉRAPIES - ECONOMIE</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.cancerresearchuk.org/about-us/cancer-news/news-report/2020-06-05-immunotherapy-treatment-recommended-for-advanced-small-cell-lung-cancer" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Immunotherapy treatment recommended for advanced small cell lung cancer [Cancer Research UK]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><div style="float: left;">
<img class="slider_img" id="relevance_171841_img" src="http://srv10-inca/amiei/img/slider_star_1.gif" style="margin: 0px 2px; vertical-align: bottom;" title="Niveau de pertinence" /></div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
In trial involving 403 patients, patients taking atezolizumab lived for an average of 12.3 months, compared with 10.3 months in group taking a placebo and chemotherapy. But the long-term benefits of the combination are unclear, as clinical trial data did not suggest a significant survival benefit from adding atezolizumab beyond 30 months.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.2.2 PHARMA - FUSIONS & ACQUISITIONS</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://endpts.com/does-astrazeneca-ceo-pascal-soriot-really-want-to-merge-with-gilead-a-bloomberg-story-suggests-hes-interested/" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Does AstraZeneca CEO Pascal Soriot really want to merge with Gilead? A Bloomberg story suggests he’s interested -- but it's hard to see why [EndPoints]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
At this stage, there could only be 2 people who have the biggest share of the say here. One is AstraZeneca CEO Soriot and the other is Gilead CEO Dan O’Day. And they know each other well, having once held overlapping positions at Roche.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.4.2 TRAITEMENTS - ECONOMIE - IQWIG</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.iqwig.de/en/press/press-releases/ribociclib-in-breast-cancer-added-benefit-for-certain-women-after-menopause.13059.html" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Ribociclib in breast cancer: added benefit for certain women after menopause [IQWIG]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><div style="float: left;">
<img class="slider_img" id="relevance_171834_img" src="http://srv10-inca/amiei/img/slider_star_1.gif" style="margin: 0px 2px; vertical-align: bottom;" title="Niveau de pertinence" /></div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
According to the findings, an added benefit is not proven for initial endocrine therapy with ribociclib in combination with the aromatase inhibitor letrozole and for subsequent endocrine therapy with ribociclib plus fulvestrant. For initial endocrine therapy with ribociclib plus fulvestrant, in contrast, there is now an indication of a minor added benefit.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.5 ASCO</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://cancerletter.com/articles/20200605_6/" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Clifford Hudis: What a virtual meeting can accomplish—and what a virtual meeting cannot accomplish [The Cancer Letter]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><div style="float: left;">
<img class="slider_img" id="relevance_171836_img" src="http://srv10-inca/amiei/img/slider_star_3.gif" style="margin: 0px 2px; vertical-align: bottom;" title="Niveau de pertinence" /></div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
“Maybe this is ultimately why, like in the prior pandemics that have racked the world over the eons, humans still come back to the same behaviors they enjoy. And this is why I would expect that we will get back to face-to-face meetings when it is safe.”</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
6.15 LUTTE CONTRE LES CANCERS - COVID-19</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.nature.com/articles/d41586-020-01523-1" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Scientists’ worlds will shrink in the wake of the pandemic [Nature]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Researchers expect long-term changes that reduce travel for work and conferences: part 6 in a series on science after the pandemic.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://cancerletter.com/articles/20200605_8/" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
ASCO data will provide actionable insights from the COVID-19 pandemic—for every patient [The Cancer Letter]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
We also set out to collect data and, currently, have three lines of sight into the COVID-19 impact.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
</tbody></table>
OVEhttp://www.blogger.com/profile/16701670533772026788noreply@blogger.comtag:blogger.com,1999:blog-6449150757505425806.post-48309811169297221242020-06-05T12:18:00.002+02:002020-06-05T12:18:18.601+02:00Onco Actu du 5 juin 2020<table style="-webkit-text-stroke-width: 0px; color: black; font-family: Times; font-size: medium; font-style: normal; font-variant-caps: normal; font-variant-ligatures: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-decoration-color: initial; text-decoration-style: initial; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
1. BIOLOGIE</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://medicine.yale.edu/news-article/25136/" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Yale Cancer Center Scientists Reveal How Mutations in Metabolism Can Drive Cancers [Yale]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><div style="float: left;">
<img class="slider_img" id="relevance_171809_img" src="http://srv10-inca/amiei/img/slider_star_1.gif" style="margin: 0px 2px; vertical-align: bottom;" title="Niveau de pertinence" /></div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
In a paper published today in the journal Nature, Yale Cancer Center (YCC) scientists have identified mutations in metabolite-producing genes as a disruption of DNA repair. These mutation-driven “oncometabolites” may make cells more prone to developing cancer—but also more vulnerable to new cancer treatment strategies.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
3.3 PRÉVENTION - VACCINS</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://geiselmed.dartmouth.edu/news/2020/hpv-vaccines-that-work-in-u-s-women-may-miss-the-target-in-women-from-other-countries/" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
HPV Vaccines That Work in U.S. Women May Miss the Target in Women From Other Countries [Dartmouth]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Years of work in Honduras, led by Gregory J. Tsongalis, PhD, has shown a very different prevalence of hrHPV there compared to the U.S. The majority of cervical cancers are caused by persistent infection with hrHPV with different vaccines available to protect against HPV infection.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
4. DÉPISTAGE, DIAGNOSTIC ET PRONOSTIC</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://newsroom.ucla.edu/releases/study-reveals-some-types-of-prostate-cancers-may-not-be-as-aggressive-as-originally-thought" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Some types of prostate cancer may not be as aggressive as originally thought [UCLA]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Researchers at the UCLA Jonsson Comprehensive Cancer Center analyzed gene-expression patterns in the most aggressive prostate cancer grade group — known as Gleason grade group 5 — and found that this grade of cancer can actually be subdivided into four subtypes with distinct differences. The findings may affect how people are treated for the disease.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
4.2 DÉP., DIAG. & PRONO. - GÉNOME</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.prnewswire.com/news-releases/for-acute-myeloid-leukemia-genetic-testing-is-often-worth-the-wait-301070875.html" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
For Acute Myeloid Leukemia, Genetic Testing Is Often Worth the Wait [Blood]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Study suggests treatment delay does not increase risks and offers a window for selection of more personalized therapy.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.stjude.org/media-resources/news-releases/2020-medicine-science-news/identifying-survivors-at-high-risk-of-secondary-cancers.html" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Identifying survivors at high risk of secondary cancers [St. Jude Chldren's Research Hospital]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
The work relied on whole genome sequencing of DNA from blood samples gathered through the St. Jude Lifetime Cohort study (St. Jude LIFE). The team in St. Jude LIFE brings long-term childhood cancer survivors back to the hospital for regular health screenings throughout their adult lives.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5. TRAITEMENTS</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.mdanderson.org/newsroom/md-anderson-and-rakuten-medical-announce-strategic-alliance-to-advance-illuminox-platform-for-cancer-treatments.h00-159382734.html" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
MD Anderson and Rakuten Medical announce strategic alliance to advance Illuminox platform for cancer treatments [MD Anderson Cancer Center]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Illuminox is a technology combining drugs and laser device systems being evaluated for the treatment of different cancers.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.1 TRAITEMENTS - PRÉ-CLINIQUE</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.garvan.org.au/news-events/news/revealed-how-cancer-develops-resistance-to-treatment" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Revealed: how cancer develops resistance to treatment [Garvan Institute]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><div style="float: left;">
<img class="slider_img" id="relevance_171805_img" src="http://srv10-inca/amiei/img/slider_star_1.gif" style="margin: 0px 2px; vertical-align: bottom;" title="Niveau de pertinence" /></div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Cancer cells can turn on error-prone DNA copy pathways to adapt to cancer treatment, a breakthrough study published in the journal Science has revealed. Bacteria use the same process, termed stress-induced mutagenesis, to develop antibiotic resistance.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.12.11 IMMUNOTHÉRAPIES - PRÉ-CLINIQUE</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.ucsf.edu/news/2020/06/417666/tumors-disrupt-immune-system-throughout-body" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Tumors Disrupt the Immune System Throughout the Body [UCSF]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Different Tumor Types Have Distinct Effects on Mouse Immune System; Parallel Findings in Humans Suggest Applications for Cancer Immunotherapy.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://scienceblog.cancerresearchuk.org/2020/06/04/moves-and-countermoves-how-the-immune-system-responds-to-lung-cancers-tactics/" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Moves and countermoves: How the immune system responds to lung cancer’s ‘tactics’ [Cancer Research UK]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><div style="float: left;">
<img class="slider_img" id="relevance_171807_img" src="http://srv10-inca/amiei/img/slider_star_1.gif" style="margin: 0px 2px; vertical-align: bottom;" title="Niveau de pertinence" /></div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
“The therapeutic message out of that is that we believe that this tells us that we need to intervene as early as possible with immunotherapies when we have a younger immune system within the tumour.”</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.12.4 IMMUNOTHÉRAPIES - ESSAIS</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.gustaveroussy.fr/en/new-immunotherapeutic-agent-children-and-adolescents-advanced-lymphoma" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
A new immunotherapeutic agent for children and adolescents with advanced lymphoma [Gustave Roussy]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
The excellent results of the phase III international paediatric study, Inter-B-NHL ritux 2010, have been published today in the New England Journal of Medicine. This academic trial involved two international cooperative groups — the European Intergroup for Childhood Non-Hodgkin Lymphoma (EICNHL) and the Children’s Oncology Group (COG).</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.12.5 IMMUNOTHÉRAPIES - PHARMA</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://endpts.com/bristol-myers-is-cleaning-up-the-post-celgene-merger-pipeline-and-theyre-sweeping-out-an-experimental-checkpoint-in-the-process/" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Bristol Myers is cleaning up the post-Celgene merger pipeline, and they’re sweeping out an experimental checkpoint in the process [EndPoints]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
The big biotech’s leadership did a little housecleaning with a major pact it had forged with Jounce. Out went the $2.6 billion deal and a collaboration on ICOS and PD-1.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.12.6 IMMUNOTHÉRAPIES - AMM</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.cancer.gov/news-events/cancer-currents-blog/2020/fda-atezolizumab-bevacizumab-liver-cancer" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Atezolizumab Plus Bevacizumab Approved to Treat Liver Cancer [NCI]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
In the study that led to the approval, called IMbrave150, liver cancer patients treated with atezolizumab and bevacizumab lived substantially longer than those treated with sorafenib (Nexavar). They also lived longer without their cancer getting worse.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.2.1 PHARMA - PARTENARIATS</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.fiercebiotech.com/biotech/accent-astrazeneca-take-aim-at-rna-modifiers-55m-cancer-pact" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Accent, AstraZeneca take aim at RNA modifiers in $55M cancer pact [Fierce Biotech]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Accent is working on five programs of its own, including two it plans to push into the clinic in 2022: METTL3, an RNA methyltransferase that plays a role in acute myeloid leukemia and solid tumors, and ADAR1, an RNA editor for solid tumors.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.biopharmadive.com/news/astrazeneca-accent-rna-cancer-drug/579189/" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
AstraZeneca puts $55M into Accent as pharmas continue push to drug RNA [Biopharma Dive]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Accent aims to find and selectively block enzymes that might, for instance, lead to the production of proteins that drive tumor growth.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://endpts.com/jose-baselga-finds-promise-in-new-class-of-rna-modifying-cancer-targets-locking-in-3-preclinical-programs-with-55m/" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
José Baselga finds promise in new class of RNA-modifying cancer targets, locking in 3 preclinical programs with $55M [EndPoints]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Accent works in a burgeoning field sometimes referred to as epitranscriptomics, which features players such as Storm Therapeutics and Gotham Therapeutics. As with epigenetics, the goal is to control gene expression and function rather than altering the genetic code itself.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.2.6 PHARMA - BIOTECH</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://xconomy.com/boston/2020/06/04/cullinan-oncology-reels-in-98m-to-advance-cancer-drug-pipeline/" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Cullinan Oncology Reels In $98M to Advance Cancer Drug Pipeline [Xconomy]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
The two most advanced Cullinan programs are now in early-stage testing. A Cullinan subsidiary called Apollo is developing VK-2019, a small molecule designed to address Epstein-Barr virus, which is also linked to lympohomas, gastric cancers, and nasopharyngeal carcinoma.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://ir.genmab.com/news-releases/news-release-details/genmab-announces-european-marketing-authorization-subcutaneous" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Genmab Announces European Marketing Authorization for the Subcutaneous Formulation of DARZALEX® (daratumumab) for the Treatment of Patients with Multiple Myeloma [Genmab]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Approval follows positive opinion by European Committee for Medicinal Products for Human Use (CHMP) in April 2020 and applies to all current daratumumab indications in frontline and relapsed/refractory settings.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.5 ASCO</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.asco.org/about-asco/press-center/news-releases/asco-virtual-scientific-meeting-convened-record-number-onc-professionals" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
ASCO Virtual Scientific Meeting Convened Record Number of Oncology Professionals from across the Globe [ASCO]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
More than 42,700 attendees from 138 countries have participated thus far, learning virtually about new clinical cancer advances in every area of cancer research.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.5.15 ASCO (BIOPSIES LIQUIDES)</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.genomeweb.com/cancer/tumor-mutational-burden-blood-may-predict-immunotherapy-response-head-neck-cancer" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Tumor Mutational Burden in Blood May Predict Immunotherapy Response in Head, Neck Cancer [Genome Web]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
An analysis of retrospective data from the Phase III EAGLE study suggests that tumor mutational burden (TMB), as assessed through cell-free DNA in patients' blood plasma, may predict which head and neck squamous cell carcinoma patients are likely to respond to checkpoint inhibitors.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.9.3 EHA</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.gsk.com/en-gb/media/press-releases/gsk-announces-new-data-presentations-from-the-dreamm-programme/" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
GSK announces new data presentations from the DREAMM programme exploring investigational belantamab mafodotin in patients with relapsed/refractory multiple myeloma [GSK]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
16 presentations, including new analyses from the pivotal DREAMM-2 study and initial results from the DREAMM-4 study, will be presented at the European Hematology Association (EHA) Annual Congress.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
6.15 LUTTE CONTRE LES CANCERS - COVID-19</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.esmo.org/oncology-news/covid-19-mortality-in-uk-patients-with-cancer-on-anticancer-treatments-described" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
COVID-19 Mortality in UK Patients with Cancer on Anticancer Treatments Described [ESMO]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Results of the UK Coronavirus Cancer Monitoring Project.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
</tbody></table>
OVEhttp://www.blogger.com/profile/16701670533772026788noreply@blogger.comtag:blogger.com,1999:blog-6449150757505425806.post-41468350199542165722020-06-04T10:38:00.003+02:002020-06-04T10:38:52.240+02:00Onco Actu du 4 juin 2020<table style="-webkit-text-stroke-width: 0px; color: black; font-family: Times; font-size: medium; font-style: normal; font-variant-caps: normal; font-variant-ligatures: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-decoration-color: initial; text-decoration-style: initial; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
1. BIOLOGIE</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://news.cornell.edu/stories/2020/06/terminator-protein-halts-cancer-causing-cellular-processes" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
‘Terminator’ protein halts cancer-causing cellular processes [Cornell]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
The paper “TiPARP Forms Nuclear Condensates to Degrade HIF-1α and Suppress Tumorigenesis,” published in PNAS, establishes TiPARP as a turning-off mechanism for several important transcription factors.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
2.9 ETIOLOGIE - TABAC</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.upi.com/Health_News/2020/06/03/Cancer-risk-for-non-daily-smokers-4-times-higher-than-non-smokers/7421591194607/" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Cancer risk for non-daily smokers 4 times higher than non-smokers [UPI]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><div style="float: left;">
<img class="slider_img" id="relevance_171791_img" src="http://srv10-inca/amiei/img/slider_star_1.gif" style="margin: 0px 2px; vertical-align: bottom;" title="Niveau de pertinence" /></div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
For their study, researchers from the National Cancer Institute reviewed data on tobacco use and health outcomes for more than 505,000 U.S. adults over a 20-year period. Daily smokers in the study smoked roughly 20 cigarettes a day, while non-daily smokers smoked roughly 40 per month, the authors said.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
4.5 DÉP., DIAG. & PRONO. - COLORECTAL</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.nytimes.com/2020/06/02/well/live/colonoscopy-screening-colon-colorectal-cancer.html" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
How a Delay in Colonoscopy Screening May Affect Cancer Risk [NY Times]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><div style="float: left;">
<img class="slider_img" id="relevance_171790_img" src="http://srv10-inca/amiei/img/slider_star_1.gif" style="margin: 0px 2px; vertical-align: bottom;" title="Niveau de pertinence" /></div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
The analysis, in Annals of Internal Medicine, included 165,887 men and women aged 50 to 66 who had a single negative colonoscopy.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5. TRAITEMENTS</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://news.usc.edu/171028/antibody-drug-conjugates-cancer-treatment-usc-pharmacy/" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
New method of manufacturing targeted drugs could lead to better cancer treatments [USC]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
The current way to make a highly targeted type of drug called “antibody-drug conjugates” is lengthy and inefficient. Scientists at the USC School of Pharmacy have engineered something better.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.2.1 PHARMA - PARTENARIATS</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2020/astrazeneca-to-discover-and-develop-novel-therapies-targeting-rna-modifying-proteins-in-oncology-collaboration-with-accent-therapeutics.html" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
AstraZeneca to discover and develop novel therapies targeting RNA-modifying proteins in oncology collaboration with Accent Therapeutics [AstraZeneca]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
This collaboration focuses on targeting RMPs, proteins that control many aspects of RNA biology and represents a new approach for addressing the process disruptions that can lead to cancer and can cause resistance to medicines.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="http://ir.beigene.com/news-releases/news-release-details/beigene-announces-approval-brukinsatm-zanubrutinib-china" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
BeiGene Announces the Approval of BRUKINSA™ (Zanubrutinib) in China for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and Relapsed/Refractory Mantle Cell Lymphoma [BeiGene]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
First approvals for BRUKINSA in China and its first indication for relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.esmo.org/oncology-news/ema-recommends-extension-of-indications-for-olaparib" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
EMA Recommends Extension of Indications for Olaparib [ESMO]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
New indication concerns maintenance treatment of metastatic adenocarcinoma of the pancreas with germline BRCA1/2-mutations.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.5.4.5 ASCO (IMMUNOTHÉRAPIES-CAR-T, THÉRAPIES CELLULAIRES)</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://journals.lww.com/oncology-times/blog/onlinefirst/pages/post.aspx?PostID=2153" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Durable Remission, Rare Adverse Effects With Anti-CD19 CAR-T Therapy in CLL, Lymphoma [Oncology Times]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
"These long-term remissions raise the possibility, but do not prove that CAR T cells could be curative for some B-cell lymphomas, including diffuse large B-cell lymphoma, low-grade lymphomas, and CLL," first author Kathryn Cappell, MD, PhD, told Oncology Times.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
6.1 OBSERVATION</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="http://pressroom.cancer.org/ZhaoLostEarnings2020" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Study Puts Price Tag on Lost Earnings from Racial Disparities in Cancer Mortality [ACS]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
$3.2 Billion in lost earnings would be avoided in 2015 alone had mortality and earning been equal between blacks and whites.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
</tbody></table>
OVEhttp://www.blogger.com/profile/16701670533772026788noreply@blogger.comtag:blogger.com,1999:blog-6449150757505425806.post-88287922475954518782020-06-03T11:05:00.001+02:002020-06-03T11:05:04.476+02:00Onco Actu du 3 juin 2020<table style="-webkit-text-stroke-width: 0px; color: black; font-family: Times; font-size: medium; font-style: normal; font-variant-caps: normal; font-variant-ligatures: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-decoration-color: initial; text-decoration-style: initial; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
1. BIOLOGIE</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.eurekalert.org/pub_releases/2020-06/tmsh-dih052720.php" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Discovery in human acute myeloid leukemia could provide novel pathway to new treatments [EurekAlert!]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
In a study published in June in Cell Reports, the team described how they used induced pluripotent stem cells from a patient with AML to recreate leukemia stem cell biology in the lab, revealing that AML leukemia stem cells lose their leukemic properties once the transcription factor is knocked down or deleted. The researchers further showed that AML cells from other patients were RUNX1-dependent.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
4.12 BIOPSIES LIQUIDES</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.cancer.gov/news-events/cancer-currents-blog/2020/cancerseek-blood-test-detect-early-cancer" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Study Examines Whether Blood Test Can Identify Early Cancers [NCI]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><div style="float: left;">
<img class="slider_img" id="relevance_171777_img" src="http://srv10-inca/amiei/img/slider_star_1.gif" style="margin: 0px 2px; vertical-align: bottom;" title="Niveau de pertinence" /></div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Researchers led by Nickolas Papadopoulos, Ph.D., of Johns Hopkins University School of Medicine, designed the study to see whether it was possible to use such a blood test to detect cancers before symptoms developed. They also wanted to make sure the testing process did not cause participants distress or lead to many unnecessary diagnostic procedures.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.1 TRAITEMENTS - PRÉ-CLINIQUE</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://news.tulane.edu/pr/tulane-scientists-find-switch-flip-and-turn-breast-cancer-growth-and-spread" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Tulane scientists find a switch to flip and turn off breast cancer growth and spread [Tulane University]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
While targeting Rab27a delays progression of tumor growth, it fails to affect the spread of tiny amounts of cancer cells, or micrometastasis. On the contrary, targeting TRAF3IP2 suppresses tumor growth and spread, and interfering with it both shrinks pre-formed tumors and prevents additional spread.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.12.11 IMMUNOTHÉRAPIES - PRÉ-CLINIQUE</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://cancer.osu.edu/news/researchers-identify-key-immune-checkpoint-protein-that-operates-within-t-cells" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Researchers Identify Key Immune Checkpoint Protein That Operates Within T Cells [Ohio State University]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
“Our findings suggest that PCBP1 is a global intracellular immune checkpoint, and that targeting it would offer a way to influence antitumor responses during immune therapy.”</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.12.6 IMMUNOTHÉRAPIES - AMM</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.roche.com/media/releases/med-cor-2020-06-02.htm" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
FDA approves Roche’s Tecentriq in combination with Avastin for people with the most common form of liver cancer [Roche]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Tecentriq in combination with Avastin is the first and only cancer immunotherapy regimen approved for the treatment of unresectable or metastatic hepatocellular carcinoma.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.2.6 PHARMA - BIOTECH</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.fiercebiotech.com/biotech/hillhouse-leads-160m-round-for-chinese-antibody-maker-genor" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Hillhouse leads $160M round for Chinese antibody maker Genor [Fierce Biotech]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Founded in 2007, Genor is developing antibodies to treat a range of solid tumors and blood cancers as well as autoimmune diseases like rheumatoid arthritis. It counts more than 10 clinical-stage assets, several of which are in pivotal or phase 3 studies.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.sanofigenzyme.com/en/about-us/newsroom/2020/2020-06-02-11-50-00" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
European Commission approves Sarclisa® (isatuximab) for adults with relapsed and refractory multiple myeloma [Sanofi]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
EC approval based on data from first randomized Phase 3 trial (ICARIA-MM) to report results evaluating an anti-CD38 monoclonal antibody combined with pomalidomide and dexamethasone (pom-dex).</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.esmo.org/oncology-news/ema-recommends-granting-a-marketing-authorisation-for-alpelisib" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
EMA Recommends Granting a Marketing Authorisation for Alpelisib [ESMO]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Alpelisib is intended for the treatment of advanced breast cancer with a PIK3CA mutation.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.4 TRAITEMENTS - ECONOMIE</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.eurekalert.org/pub_releases/2020-06/bu-nfr060120.php" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
NIH funded research related to every new cancer drug approved from 2010-2016, totals $64B [EurekAlert!]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><div style="float: left;">
<img class="slider_img" id="relevance_171773_img" src="http://srv10-inca/amiei/img/slider_star_1.gif" style="margin: 0px 2px; vertical-align: bottom;" title="Niveau de pertinence" /></div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
The new report from the Center for Integration of Science and Industry, published in The Lancet Oncology, shows that the United States government invested $64 billion in research related to these 59 drugs.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.5.16 ASCO (MÉDECINE DE PRÉCISION)</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.genomeweb.com/cancer/evidence-targeted-treatment-builds-cancers-unknown-primary-randomized-data-pending" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Evidence for Targeted Treatment Builds in Cancers of Unknown Primary but Randomized Data Pending [Genome Web]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
New data presented over the weekend at the American Society of Clinical Oncology's virtual annual meeting, has added to growing evidence that genomic sequencing, in particular liquid biopsy tests, can identify actionable alterations in patients with cancers of unknown primary (CUP).</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.9.3 EHA</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.sanofigenzyme.com/en/about-us/newsroom/2020/2020-06-02-13-00-00" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Sarclisa® (isatuximab) combination therapy demonstrated superior progression free survival and clinically meaningful depth of response in patients with relapsed multiple myeloma [Sanofi]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Results from first planned interim analysis of the Phase 3 IKEMA trial selected as late-breaking presentation at EHA25 Virtual Congress.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
6.15 LUTTE CONTRE LES CANCERS - COVID-19</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.qmul.ac.uk/media/news/2020/smd/impact-of-covid-19-infection-in-blood-cancer-patients.html" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Impact of COVID-19 infection in blood cancer patients [Queen Mary University of London]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
The study, published in the British Journal of Haematology, looked at 35 adult patients with blood cancer who had tested positive for COVID-19 and monitored them for a minimum of 14 days. At the end of the observation period, 60 per cent of patients had recovered from COVID-19 infection.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
</tbody></table>
OVEhttp://www.blogger.com/profile/16701670533772026788noreply@blogger.comtag:blogger.com,1999:blog-6449150757505425806.post-38085583953138265522020-06-02T11:14:00.002+02:002020-06-02T11:14:15.426+02:00Onco Actu du 2 juin 2020<table style="-webkit-text-stroke-width: 0px; color: black; font-family: Times; font-size: medium; font-style: normal; font-variant-caps: normal; font-variant-ligatures: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-decoration-color: initial; text-decoration-style: initial; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
1. BIOLOGIE</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.crick.ac.uk/news/2020-06-01_cancer-cells-cause-inflammation-to-protect-themselves-from-viruses" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Cancer cells cause inflammation to protect themselves from viruses [Francis Crick Institute]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
In their study, published in Nature Cell Biology, the researchers identified a mechanism that protects cancer cells from oncolytic viruses, which preferentially infect and kill cancer cells.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.bcm.edu/news/resistance-to-immunosurveillance-favors-cluster-cancer-metastasis" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Resistance to immunosurveillance favors cluster cancer metastasis [Baylor College of Medicine]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
The researchers found that clusters of tumor cells are more resistant than single tumor cells to being killed by natural killer (NK) cells, immune cells that specialize in surveillance and destruction of tumor cells.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.genomeweb.com/sequencing/tumor-microbiome-appears-vary-cancer-type" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Tumor Microbiome Appears to Vary With Cancer Type [Genome Web]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
In an effort to take a closer look at these microbial communities, the team turned to 16S ribosomal gene sequencing and quantitative PCR to identify and quantify bacteria present in 1,010 tumor samples and more than 500 neighboring normal tissue samples.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
4.2 DÉP., DIAG. & PRONO. - GÉNOME</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.genomeweb.com/policy-legislation/acmg-offers-guidance-incorporating-genomic-data-electronic-health-records" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
ACMG Offers Guidance on Incorporating Genomic Data into Electronic Health Records [Genome Web]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Electronic health record systems (EHRs) have enabled physicians to more easily share patient data with each other to facilitate care as well as with patients themselves through patient portals. As genomic data increasingly informs patient care, it also needs to be incorporated in EHRs.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.1 TRAITEMENTS - PRÉ-CLINIQUE</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.icr.ac.uk/news-archive/mini-tumours-help-predict-how-cancer-handles-the-heat-of-innovative-cancer-treatments" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Mini tumours help predict how cancer handles the heat of innovative cancer treatments [Institute of Cancer Research]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
In a series of experiments, the researchers exposed mini tumours to 47 degrees C, radiation, and a combination of both. They repeated these treatments for standard cancer cells grown in dishes in the lab to allow them to compare the effects of the treatments between the two.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.10 TRAITEMENTS - ESSAIS</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.cancer.gov/news-events/cancer-currents-blog/2020/ruxolitinib-graft-versus-host-disease" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
More Evidence that Ruxolitinib Benefits Some Patients with Graft-Versus-Host Disease [NCI]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
The findings are from the first randomized clinical trial of a treatment for GVHD to yield positive results. And the study confirms findings from a smaller trial that, in 2019, led to the approval of ruxolitinib by the Food and Drug Administration (FDA) for some patients with GVHD.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.12.11 IMMUNOTHÉRAPIES - PRÉ-CLINIQUE</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="http://news.mit.edu/2020/boost-cancer-immunotherapy-0601" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
A boost for cancer immunotherapy [MIT]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
MIT engineers have now come up with a way to boost the effectiveness of one type of cancer immunotherapy. They showed that if they treated mice with existing drugs called checkpoint inhibitors, along with new nanoparticles that further stimulate the immune system, the therapy became more powerful than checkpoint inhibitors given alone.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.fiercepharma.com/manufacturing/wuxi-apptec-welcomes-veteran-celgene-s-troubled-cell-therapy-program-to-car-t" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
WuXi AppTec welcomes vet of Celgene's troubled cell therapy program to CAR-T leadership role [Fierce Pharma]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Chang will come to WuXi during a period of manufacturing concerns for the CAR-T field––not the least of which stem from his previous employer.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.12.6 IMMUNOTHÉRAPIES - AMM</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-atezolizumab-plus-bevacizumab-unresectable-hepatocellular-carcinoma" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
FDA approves atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma [FDA]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><div style="float: left;">
<img class="slider_img" id="relevance_171766_img" src="http://srv10-inca/amiei/img/slider_star_1.gif" style="margin: 0px 2px; vertical-align: bottom;" title="Niveau de pertinence" /></div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Efficacy was investigated in IMbrave150 (NCT03434379), a multicenter, international, open-label, randomized trial in patients with locally advanced unresectable or metastatic hepatocellular carcinoma who had not received prior systemic therapy.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://endpts.com/roche-nabs-frontline-ok-for-avastin-tecentriq-in-common-liver-cancer-besting-an-old-bayer-drug/" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Roche nabs frontline OK for Avastin/Tecentriq in common liver cancer, besting an old Bayer drug [EndPoints]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
The approval is a major boon for Roche’s immunotherapy program, which, while producing a blockbuster, has nonetheless long lagged behind the market-leading drugs from Bristol Myers Squibb and Merck.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.fiercepharma.com/pharma/roche-s-tecentriq-gets-a-green-light-to-challenge-bayer-first-class-liver-cancer-nod" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Roche's Tecentriq gets a green light to challenge Bayer with first-in-class liver cancer nod [Fierce Pharma]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
The FDA Friday cleared a combination of the checkpoint inhibitor and fellow Roche med Avastin for previously untreated patients with hepatocellular carcinoma, the most common form of the disease. The approval is the first for a member of the PD-1/L1 class, which has so far struggled to make inroads in liver cancer.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.2 PHARMA</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.fiercepharma.com/pharma/pfizer-s-ibrance-misses-shot-at-big-new-market-early-breast-cancer-failure" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Pfizer's Ibrance misses shot at big new market with early breast cancer failure [Fierce Pharma]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><div style="float: left;">
<img class="slider_img" id="relevance_171734_img" src="http://srv10-inca/amiei/img/slider_star_1.gif" style="margin: 0px 2px; vertical-align: bottom;" title="Niveau de pertinence" /></div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
In a result that could cost Ibrance access to a multibillion-dollar market, a planned futility analysis of the phase 3 Pallas trial determined that adding the drug to standard postsurgery endocrine therapy was unlikely to significantly lengthen patients’ time before invasive disease returned.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.pfizer.com/news/press-release/press-release-detail/pfizer-provides-update-phase-3-pallas-trial-ibrancer" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Pfizer Provides Update on Phase 3 PALLAS Trial of IBRANCE® (palbociclib) Plus Endocrine Therapy in HR+, HER2- Early Breast Cancer [Pfizer]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
“This result is not what we hoped for, but we are steadfast in our commitment to advancing the science and care for people living with breast cancer,” said Albert Bourla, Pfizer Chairman and CEO.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://endpts.com/in-a-stinging-setback-pfizers-cancer-blockbuster-ibrance-flops-in-key-adjuvant-setting/" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
In a stinging setback, Pfizer’s cancer blockbuster Ibrance flops in key adjuvant setting [EndPoints]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
The monitoring committee determined that Pfizer’s adjuvant study using Ibrance combined with standard endocrine therapy in an adjuvant setting for early-stage breast cancer has officially failed to make the cut.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.2.1 PHARMA - PARTENARIATS</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://news.abbvie.com/news/press-releases/abbvie-and-jacobio-announce-strategic-collaboration-to-advance-shp2-inhibitors.htm" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
AbbVie and Jacobio Announce Strategic Collaboration to Advance SHP2 Inhibitors [AbbVie]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Inhibition of SHP2 is believed to have dual effects by potentially reducing cancer cell growth and modulating immune responses to generate anti-tumor activities. Jacobio's early clinical stage SHP2 assets, JAB-3068 and JAB-3312, are oral small molecules designed to specifically inhibit SHP2 activity.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.fiercepharma.com/marketing/lilly-s-cyramza-after-split-decision-from-fda-advisers-wins-first-line-lung-cancer-nod" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Lilly's Cyramza, after split decision from FDA advisers, wins first-line lung cancer nod [Fierce Pharma]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
The decision was based on the phase 3 Relay trial, which showed the pairing could cut the risk of disease progression or death by 40% over Tarceva alone. Patients on the combo lived a median 19.4 months without disease progressing, compared with 12.4 months for those on Tarceva plus placebo.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-ramucirumab-plus-erlotinib-first-line-metastatic-nsclc" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
FDA approves ramucirumab plus erlotinib for first-line metastatic NSCLC [FDA]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><div style="float: left;">
<img class="slider_img" id="relevance_171765_img" src="http://srv10-inca/amiei/img/slider_star_1.gif" style="margin: 0px 2px; vertical-align: bottom;" title="Niveau de pertinence" /></div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Efficacy was evaluated in RELAY (NCT02411448), a multinational, randomized, double-blind, placebo-controlled, multicenter study in patients with previously untreated metastatic NSCLC whose tumors have EGFR exon 19 deletion or exon 21 (L858R) substitution mutations.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2020/lynparza-recommended-for-approval-in-eu-by-chmp-for-brca-mutated-metastatic-pancreatic-cancer.html" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Lynparza recommended for approval in EU by CHMP for BRCA-mutated metastatic pancreatic cancer [AstraZeneca]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Only PARP inhibitor to demonstrate patient benefit in a Phase III trial in this setting.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.reuters.com/article/us-astrazeneca-ema-lynparza/astrazeneca-merck-lynparza-gets-emas-positive-recommendation-idUSKBN2381EV" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
AstraZeneca-Merck Lynparza gets EMA's positive recommendation [Reuters]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
The recommendation from the EMA’s Committee for Medicinal Products for Human Use (CHMP) was based on positive results from a late-stage trial, where Lynparza nearly doubled the time patients with gBRCAm metastatic pancreatic cancer lived without the disease getting worse.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.novartis.com/news/media-releases/novartis-piqray-receives-positive-chmp-opinion-treat-hrher2-advanced-breast-cancer-pik3ca-mutation" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Novartis Piqray® receives positive CHMP opinion to treat HR+/HER2- advanced breast cancer with a PIK3CA mutation [Novartis]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Phase III trial showed Piqray plus fulvestrant nearly doubled median PFS (11.0 vs. 5.7 months) in this patient population, compared to fulvestrant alone.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.roche.com/media/releases/med-cor-2020-05-29b.htm" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
CHMP recommends EU approval of Roche’s Rozlytrek for people with NTRK fusion-positive solid tumours and for people with ROS1-positive, advanced non-small cell lung cancer [Roche]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Rozlytrek (entrectinib) has shown durable responses across multiple tumour types, including cancer that has spread to the brain, and could become Roche’s first tumour-agnostic therapy in Europe.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://investor.lilly.com/news-releases/news-release-details/lillys-cyramzar-ramucirumab-receives-fda-approval-first-line" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Lilly's CYRAMZA® (ramucirumab) Receives FDA Approval as First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer [Lilly]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
CYRAMZA regimen reduced the risk of disease progression or death by 41 percent compared to erlotinib in this patient population.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.astellas.com/en/news/15876" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
XTANDI® (enzalutamide) Approved by Japan MHLW for the Treatment of Prostate Cancer with Distant Metastasis [Astellas]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
The approval for mHSPC is based on results from the ARCHES trial, a randomized multi-national Phase 3 study which evaluated enzalutamide plus androgen deprivation therapy (ADT) versus placebo plus ADT in 1,150 men with mHSPC and met its primary endpoint of radiographic progression-free survival (rPFS).</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-may-2020" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 May 2020 [EMA]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Piqray (alpelisib) received a positive opinion from the CHMP for the treatment of locally advanced or metastatic breast cancer with a PIK3CA mutation.<br />The CHMP recommended granting a conditional marketing authorisation for Rozlytrek (entrectinib), for the treatment of patients whose solid tumours have a neurotrophic tyrosine receptor kinase gene fusion, or patients with ROS1-positive advanced non-small cell lung cancer.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.5.3 ASCO (PROSTATE)</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.icr.ac.uk/news-archive/asco-2020-uk-first-study-shows-feasibility-of-genetic-screening-for-prostate-cancer" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
ASCO 2020: UK-first study shows feasibility of genetic screening for prostate cancer [Institute of Cancer Research]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
The researchers collected DNA from saliva samples of 307 men and looked at for more than 130 genetic changes that can influence the risk of developing prostate cancer, each by a small amount.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.5.4.5 ASCO (IMMUNOTHÉRAPIES-CAR-T, THÉRAPIES CELLULAIRES)</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.biopharmadive.com/news/allogene-asco-study-results-car-t-therapy/578797/" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
With new Allogene data, same promise, questions surround 'off the shelf' CAR-T [Biopharma Dive]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><div style="float: left;">
<img class="slider_img" id="relevance_171731_img" src="http://srv10-inca/amiei/img/slider_star_1.gif" style="margin: 0px 2px; vertical-align: bottom;" title="Niveau de pertinence" /></div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Just like its initial peak, Allogene still reports that no patients developed graft-versus-host disease, a potentially deadly condition and a key worry with a treatment that puts foreign cells into the body.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
6. LUTTE CONTRE LES CANCERS</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.statnews.com/2020/05/30/earlier-diagnosis-big-impact-global-breast-cancer" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Early diagnosis, not cancer drug breakthroughs, is the best way to fix the global scourge of breast cancer [STAT]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Among the nearly 5,300 scientific abstracts being presented at the ASCO meeting, only about 10 focus on breast cancer in low- and middle-income countries, even though the death rate from breast cancer in those countries is almost double that of the U.S.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
6.1 OBSERVATION</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.bcm.edu/news/assessing-cancer-diagnosis-in-children-with-birth-defects" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Assessing cancer diagnosis in children with birth defects [Baylor College of Medicine]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
In this study led by Baylor College of Medicine and Texas Children’s Hospital, researchers compared about 13,000 children with cancer but no birth defects with nearly 1,600 children with cancer and one or more birth defects. The results were published in the journal Cancer.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
6.15 LUTTE CONTRE LES CANCERS - COVID-19</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.cancerresearchuk.org/about-us/cancer-news/press-release/2020-06-01-over-2-million-people-in-backlog-for-cancer-care" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Over 2 million people in backlog for cancer care [Cancer Research UK]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><div style="float: left;">
<img class="slider_img" id="relevance_171767_img" src="http://srv10-inca/amiei/img/slider_star_3.gif" style="margin: 0px 2px; vertical-align: bottom;" title="Niveau de pertinence" /></div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Delays to cancer screening have had the biggest impact on the total number, with a backlog of around 2.1 million people left waiting for breast, bowel or cervical screening. During this time, 3,800 cancers would normally be diagnosed through screening.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.theguardian.com/society/2020/jun/01/millions-in-uk-miss-cancer-screenings-tests-and-treatments-due-to-covid-19" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Millions in UK miss cancer screenings, tests and treatments due to Covid-19 [The Guardian]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Analysis by the charity has found there is a backlog of what it estimates to be 2.1 million people across the UK waiting to undergo screening for breast, bowel or cervical cancer because the NHS has not offered those appointments while hospitals have been busy tackling Covid-19.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
6.6 PUBLICATIONS, POLITIQUES SCIENTIFIQUES</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://retractionwatch.com/2020/06/01/nature-retracts-study-touted-as-step-toward-treatments-for-bone-diseases/" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Nature retracts study touted as step toward treatments for bone diseases [Retraction Watch]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Since being published in 2014 by researchers at UT Southwestern, MD Anderson and elsewhere, “miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2” has been cited more than 200 times, according to Clarivate Analytics’ Web of Science.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
6.7 DMP, BIG DATA & APPLIS</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.asco.org/about-asco/press-center/news-releases/new-cancerlinq-discovery-research-platform-may-2020" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
New CancerLinQ Discovery® Research Platform Offers Researchers Easy Access to Real-World Cancer Data [ASCO]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Using CancerLinQ Discovery, researchers can more easily access the collective experiences of patients and oncologists across the country, gaining from an unmatched pool of real-world information and potential insights.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
</tbody></table>
OVEhttp://www.blogger.com/profile/16701670533772026788noreply@blogger.comtag:blogger.com,1999:blog-6449150757505425806.post-47216614162141440512020-06-01T11:39:00.002+02:002020-06-01T11:39:20.220+02:00Onco Actu du 1er juin 2020<table style="-webkit-text-stroke-width: 0px; color: black; font-family: Times; font-size: medium; font-style: normal; font-variant-caps: normal; font-variant-ligatures: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-decoration-color: initial; text-decoration-style: initial; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.5.1 ASCO (GÉNÉRAL)</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://obroncology.com/blog/asco-2020-highlights-for-saturday/" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
ASCO 2020 Highlights for Saturday [OBR]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
The gastrointestinal cancer session featured four studies, one of which was a phase 2/3 trial that compared donafenib to sorafenib in liver cancer. HER2CLIMB and MINDACT were both discussed during the breast cancer session. Although not discussed this morning, the results of PHERGAIN dropped at this meeting and offer a de-escalation strategy for patients with early breast cancer.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://obroncology.com/blog/asco-2020-highlights-for-sunday" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
ASCO 2020 Highlights for Sunday [OBR]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Sunday’s live broadcast of the virtual scientific program of the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting featured late-breaking data from a phase 3 trial evaluating early local therapy in metastatic breast cancer and the results of the phase 3 ENDURANCE trial.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://medicalxpress.com/news/2020-05-drugs-headway-lung-prostate-colon.html" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
New drugs make headway against lung, prostate, colon cancers [Medical XPress]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
A big drawback: It and other newer drugs are extremely expensive—$150,000 or more a year. How much patients end up paying depends on insurance, income and other factors.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.5.1.1 ASCO (GÉNÉRAL) - INDUSTRIELS</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.reuters.com/article/us-astrazeneca-cancer-enhertu/astrazeneca-daiichi-niche-drug-shows-promise-beyond-breast-cancer-idUSKBN2351P4" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
AstraZeneca, Daiichi niche drug shows promise beyond breast cancer [Reuters]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Drugmakers are increasingly using biomarker-driven drugs to treat patients with rare tumours, and AstraZeneca made a $7-billion bet on the treatment when it partnered with Japan’s Daiichi last year to work on the drug in a direct challenge to Roche.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.5.10 ASCO (HÉMATO)</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.takeda.com/newsroom/newsreleases/2020/takeda-announces-compelling-data-from-the-phase-2-trial-of-pevonedistat-plus-azacitidine-in-patients-with-higher-risk-mds/" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Takeda Announces Compelling Data from the Phase 2 Trial of Pevonedistat Plus Azacitidine in Patients with Higher-Risk MDS [Takeda]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Pevonedistat Combination Demonstrates the Potential to Double Complete Remissions and Improve Outcomes in HR-MDS, With Safety Profile Similar to Azacitidine Alone.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.takeda.com/newsroom/newsreleases/2020/takeda-to-present-data-from-the-iclusig-ponatinib-clinical-trial-program-that-could-prove-practice-changing-for-the-treatment-of-chronic-phase-cml/" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Takeda to Present Data from the ICLUSIG® (ponatinib) Clinical Trial Program that Could Prove Practice-Changing for the Treatment of Chronic-Phase CML [Takeda]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Findings Support Response-Based Dosing Regimens of ICLUSIG Can Optimize Benefit-Risk Profile in Patients with Resistant / Intolerant Chronic-Phase CML.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://endpts.com/after-starring-at-ash-last-fall-gileads-new-forty-seven-crew-colors-in-more-promising-data-for-magrolimab-at-asco/" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
After starring at ASH last fall, Gilead’s new Forty Seven crew colors in more promising data for magrolimab at ASCO [EndPoints]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Researchers have data on 68 patients who have been treated with magrolimab plus azacitidine in a single arm study involving cases of untreated higher-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.nrgoncology.org/Home/News/Post/mtx-based-chemotherapy-combined-with-low-dose-whole-brain-radiotherapy-improves-progression-free-survival-for-patients-with-newly-diagnosed-cns-lymphoma" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
MTX-based Chemotherapy Combined with Low-Dose, Whole-Brain Radiotherapy Improves Progression-free Survival for Patients with Newly Diagnosed CNS Lymphoma [NRG Oncology]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
The study met its primary endpoint of demonstrating the improvements in progression-free survival. However, investigators cautioned that further neuropsychological testing and neuroimaging analyses are still ongoing to fully characterize cognitive decline associated with this treatment.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.5.11 ASCO (SNC]</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.fiercebiotech.com/biotech/asco-ziopharm-s-il-12-gene-therapy-boosts-survival-hard-to-treat-brain-cancer" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
ASCO: Ziopharm's IL-12 gene therapy boosts survival in hard-to-treat brain cancer [Fierce Biotech]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
The company tested the treatment, dubbed Controlled IL-12, in 95 patients as a monotherapy in two studies and in combination with a PD-1 inhibitor in a third study.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://ir.ziopharm.com/news-releases/news-release-details/ziopharm-oncology-presents-encouraging-clinical-data-0" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Ziopharm Oncology Presents Encouraging Clinical Data for Controlled IL-12 for the Treatment of Recurrent Glioblastoma at the 2020 American Society of Clinical Oncology [Ziopharma]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Controlled IL-12 in combination with PD-1 inhibitor has favorable safety profile and initial survival data are encouraging.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://endpts.com/early-survival-data-boost-ziopharms-controlled-il-12-immunotherapy-for-glioblastoma/" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Early survival data boost Ziopharm's 'controlled IL-12' immunotherapy for glioblastoma [EndPoints]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
On top of boosting its case as a monotherapy, the data can also bode well for a combination with Regeneron’s PD-1 inhibitor, Libtayo.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.5.15 ASCO (BIOPSIES LIQUIDES)</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.genomeweb.com/molecular-diagnostics/lucence-dx-liquid-biopsy-tech-detects-structural-rearrangements-breast-cancer" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Lucence Dx Liquid Biopsy Tech Detects Structural Rearrangements, Breast Cancer Mutations [Genome Web]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Lucence believes the studies support the clinical utility of using AmpliMark for detecting actionable mutations in the different cancer types, allowing for faster and more accurate testing than current approaches.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.genomeweb.com/liquid-biopsy/oncologists-make-progress-toward-showing-utility-brain-cancer-liquid-biopsy" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Oncologists Make Progress Toward Showing Utility for Brain Cancer Liquid Biopsy [Genome Web]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Brain cancers have emerged as somewhat of a conundrum for the liquid biopsy field, providing both a clear opportunity — because of the difficulty and danger in obtaining tissue samples from the brain relative to other organs — but also a significant challenge, as research has shown that brain tumors seem to shed DNA into the blood at much lower rates and quantities than other cancers.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.5.16 ASCO (MÉDECINE DE PRÉCISION)</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.genomeweb.com/cancer/pediatric-precision-oncology-study-matches-28-percent-patients-targeted-therapies" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Pediatric Precision Oncology Study Matches 28 Percent of Patients to Targeted Therapies [Genome Web]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Doctors from 72 sites in eight European countries submitted fresh, frozen tumor and blood for germline analysis from their patients with refractory, relapsed, progressive malignant disease for the study, van Tilburg said, noting that cases who were at exceptionally high risk at primary diagnosis could also participate in the study.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.genomeweb.com/molecular-diagnostics/germline-results-tumor-normal-sequencing-guides-precision-therapy-advanced" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Germline Results From Tumor-Normal Sequencing Guides Precision Therapy in Advanced Cancer Patients [Genome Web]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
In one study, involving 12,000 patients treated at Memorial Sloan Kettering Cancer Center, researchers identified nearly 600 patients with recurrent or metastatic cancer who had actionable germline mutations, and 44 percent of them received targeted drugs either as part of the standard of care or as part of a research protocol.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://media.bayer.com/baynews/baynews.nsf/id/Efficacy-Vitrakvi-larotrectinib-further-established-continued-response-rates-durable-response" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Efficacy of Vitrakvi™ (larotrectinib) further established with continued high response rates and durable response in updated analyses in adult patients and quality of life data in adult and pediatric patients with TRK fusion cancer [Bayer]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
71% overall response rate (ORR) per investigator assessment and median duration of response of 35.2 months shown in expanded data set of 116 adult patients with TRK fusion cancer.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.asco.org/about-asco/press-center/news-releases/tapur-study-shows-encouraging-results-olaparib-brca-mutated" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
TAPUR Study Shows Encouraging Results for Olaparib in BRCA-Mutated Advanced Prostate and Pancreatic Cancers [ASCO]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
In two small cohorts, olaparib treatment resulted in objective responses or stable disease for at least 16 weeks in more than two-thirds (68%) of patients with advanced prostate cancer and BRCA1/2 inactivating mutations, and nearly a third (31%) of patients with advanced pancreatic cancer and BRCA1/2 inactivating mutations.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.mdanderson.org/newsroom/targeted-therapy-pralsetinib-achieves-high-response-rates-in-advanced-cancers-with-ret-gene-fusions.h00-159381945.html" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Targeted therapy pralsetinib achieves high response rates in advanced cancers with RET gene fusions [MD Anderson Cancer Center]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
MD Anderson-led Phase I/II ARROW trial finds RET inhibitor to be well-tolerated with durable antitumor activity.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.5.16.2 ASCO (MÉDECINE DE PRÉCISION-SEIN)</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://myriad.com/investors/news-release/news-release-detail/?newsItemId=21216" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Myriad Presents New Data at ASCO Validating the Ability of riskScore® to Provide Personalized Breast Cancer Risk Information to Patients [Myriad]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
“The validation data we are presenting at ASCO this year will support a broader launch of riskScore to even more women in the coming year with more personalized information and the unique ability to modify carrier risk through a clinically validated tool.”</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.genomeweb.com/cancer/polygenic-risk-score-family-history-refine-breast-cancer-risk-assessment-chek2-mutation" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Polygenic Risk Score, Family History Refine Breast Cancer Risk Assessment in CHEK2 Mutation Carriers [Genome Web]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Overall, pathogenic CHEK2 mutations are thought to coincide with a moderate risk of breast cancer — in the 23 to 28 percent lifetime risk range — he explained, though that risk appears to be dialed up or down depending on broader genetic risk factors, an individual's family history, and certain environmental exposures.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.genomeweb.com/cancer/oncotype-dx-may-be-helpful-guiding-neoadjuvant-breast-cancer-treatment-decisions" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Oncotype DX May Be Helpful in Guiding Neoadjuvant Breast Cancer Treatment Decisions [Genome Web]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Given these updated guidelines, as well as the data from the three new ASCO studies, Shak believes there will be an "expanded use of the recurrence score in the [neoadjuvant] setting so that patients can get the right treatment before surgery."</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.exactsciences.com/newsroom/exact-sciences-showcases-continued-progress-in-cancer-diagnostics-at-asco-2020" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Exact Sciences Showcases Continued Progress In Cancer Diagnostics At ASCO 2020 [Exact Sciences]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
New data and society guidelines support value of Oncotype DX Breast Recurrence Score® test in guiding neoadjuvant treatment decisions for newly diagnosed patients.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.5.16.3 ASCO (MÉDECINE DE PRÉCISION-KRAS, HRAS)</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://endpts.com/kura-flashes-positive-hras-data-on-once-failed-jj-drug/" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Kura flashes positive HRAS data on once-failed J&J drug [EndPoints]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Now for the first time in the 15-plus year history of the compound, Kura has evidence that, when given to the right patients, the drug can help patients live longer.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="http://ir.kuraoncology.com/news-releases/news-release-details/kura-oncology-reports-overall-survival-data-phase-2-trial" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Kura Oncology Reports Overall Survival Data from Phase 2 Trial of Tipifarnib in HRAS Mutant Head and Neck Squamous Cell Carcinoma[Kura]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Median OS of 15.4 months, median PFS of 5.9 months and ORR of 50% observed in recurrent/metastatic HRAS mutant HNSCC.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.5.2 ASCO (SEIN)</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.nrgoncology.org/Home/News/Post/trastuzumab-achieves-slight-reduction-in-recurrence-for-women-with-her2-positive-ductal-carcinoma-in-situ-on-nrg-oncology-trial-nsabp-b-43" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Trastuzumab Achieves Slight Reduction in Recurrence for Women with HER2-Positive Ductal Carcinoma in Situ on NRG Oncology Trial NSABP B-43 [NRG Oncology]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
The addition of the monoclonal antibody therapy Trastuzumab to radiotherapy did not reach the protocol objective of a 36% reduction in the ipsilateral breast tumor recurrence rate for women with HER2-positive ductal carcinoma in situ (DCIS) on the NRG Oncology clinical trial NSABP B-43.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.5.3 ASCO (PROSTATE)</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.astellas.com/en/news/15881" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Final PROSPER Results Show XTANDI® (enzalutamide) Significantly Extends Overall Survival in Men with Non-Metastatic Castration-Resistant Prostate Cancer [Astellas]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
The median OS was 67.0 months (95% CI: 64.0 to not reached) for men who received XTANDI plus ADT compared to 56.3 months (95% CI: 54.4 to 63.0) with placebo plus ADT. OS was a key secondary endpoint of the trial.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://endpts.com/myovants-relugolix-wins-a-pivotal-prostate-cancer-showdown-with-an-old-standard-coming-down-to-the-wire-on-approvals/" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Myovant’s relugolix wins a pivotal prostate cancer showdown with an old standard — coming down to the wire on approvals [EndPoints]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
In this new data from Myovant, developers highlighted clearly superior results for the biotech’s drug over an old standard leuprolide (sold as Lupron), ringing three bells on efficacy, safety and quality of life.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://investors.myovant.com/news-releases/news-release-details/myovant-sciences-announces-additional-positive-efficacy-and" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Myovant Sciences Announces Additional Positive Efficacy and Cardiovascular Safety Data from Phase 3 HERO Study of Once-Daily, Oral Relugolix in Advanced Prostate Cancer and Publication in the New England Journal of Medicine [Myovant]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Presentation expands on previous results demonstrating superiority of relugolix to leuprolide acetate, with additional data on testosterone suppression and recovery, prostate-specific antigen (PSA) response, and cardiovascular safety.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.5.4.1 ASCO (IMMUNOTHÉRAPIES-REIN)</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.dana-farber.org/newsroom/news-releases/2020/study-reveals-factors-influencing-outcomes-in-advanced-kidney-cancer-treated-with-immunotherapy/" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Study reveals factors influencing outcomes in advanced kidney cancer treated with immunotherapy [Dana Farber Cancer Institute]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
The study showed that features that are typically linked to immunotherapy response or resistance in other types of cancer don’t work the same way in advanced clear cell renal cell cancer (ccRCC).</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.5.4.2 ASCO (IMMUNOTHÉRAPIES-COMBINAISONS)</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.fiercepharma.com/pharma/asco-merck-eisai-pad-case-for-liver-cancer-nod-keytruda-lenvima-combo-data" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
ASCO: Merck, Eisai pad case for liver cancer nod with Keytruda-Lenvima combo data [Fierce Pharma]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
While the trial, called Keynote-524, is a single-arm, phase 1b study, it’s already helped the duo nab a breakthrough therapy designation from the FDA.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.fiercepharma.com/pharma/has-astrazeneca-finally-found-a-place-for-long-plagued-i-o-candidate-tremelimumab" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
ASCO: Has AstraZeneca finally found a place for long-plagued I-O candidate tremelimumab? [Fierce Pharma]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
The performance may bode well for AstraZeneca’s phase 3 Himalaya study, set to read out in the second half of this year, where the British drugmaker is hoping its duo can replicate its success, this time in previously untreated patients—a group that has over the years proved difficult to treat.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2020/imfinzi-plus-tremelimumab-demonstrated-promising-clinical-activity-and-tolerability-in-patients-with-advanced-liver-cancer.html" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Imfinzi plus tremelimumab demonstrated promising clinical activity and tolerability in patients with advanced liver cancer [AstraZeneca]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Data presented at ASCO showed patients treated with a single, priming dose of tremelimumab plus Imfinzi achieved longest median survival among regimens tested.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.5.4.4 ASCO (IMMUNOTHÉRAPIES-POUMON)</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://endpts.com/as-tislelizumab-gains-traction-in-china-beigene-pulls-the-curtain-on-nsclc-data-supporting-the-pd-1-drug/" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
As tislelizumab gains traction in China, BeiGene pulls the curtain on NSCLC data supporting the PD-1 drug [EndPoints]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
The 360-patient trial, which tested the checkpoint inhibitor with two different chemo regimens against chemo alone, showed that the median time during which patients did not see disease progression in the tislelizumab combo groups was 7.6 months versus 5.5 months for chemo alone.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.5.4.5 ASCO (IMMUNOTHÉRAPIES-CAR-T, THÉRAPIES CELLULAIRES)</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://ir.allogene.com/news-releases/news-release-details/allogene-therapeutics-collaborator-servier-reports-positive" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Allogene Therapeutics, with Collaborator Servier, Reports Positive Results from its Phase 1 ALPHA Study of ALLO-501 in Relapsed/Refractory Non-Hodgkin Lymphoma at the American Society of Clinical Oncology Annual Meeting [Allogene]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
In the Ongoing Study, 22 Patients were Evaluable for Safety and 19 Patients Were Evaluable for Efficacy with at Least One Tumor Assessment as of Data Cutoff.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://endpts.com/headed-to-phii-allogene-ceo-david-chang-completes-a-positive-early-snapshot-of-their-off-the-shelf-car-t-pioneer/" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Headed to PhII: Allogene CEO David Chang completes a positive early snapshot of their off-the-shelf CAR-T pioneer [EndPoints]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
9 of the 12 responders remained in response at the data cutoff, offering a glimpse on durability that still has a long way to go before it can be completely nailed down.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.mdanderson.org/newsroom/adoptive-t-cell-therapy-adp-a2m4-targeting-mage-a4-shows-early-activity-in-patients-with-advanced-solid-tumors.h00-159381945.html" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Adoptive T-cell therapy ADP-A2M4 targeting MAGE-A4 shows early activity in patients with advanced solid tumors [MD Anderson Cancer Center]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
MD Anderson-led Phase I trial of Adaptimmune T-cell receptor therapy sees confirmed responses in multiple cancer types.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.5.4.6 ASCO (IMMUNOTHÉRAPIES-PEAU, MÉLANOME)</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.sanofi.com/en/media-room/press-releases/2020/2020-05-29-14-00-00" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Libtayo® (cemiplimab-rwlc) longer-term results in advanced cutaneous squamous cell carcinoma presented at ASCO 2020 show durable responses that deepen over time [Sanofi]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Across all groups combined, complete responses (CR) are now 16%; in the metastatic group with the longest follow-up, CRs are 20% representing a 200% increase over two years.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.5.4.7 ASCO (IMMUNOTHÉRAPIES- GASTRO-INTESTINAL)</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="http://www.vhio.net/en/immunotherapy-proves-effective-for-the-first-time-as-a-sole-treatment-for-a-subtype-of-metastatic-colorectal-cancer/" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Immunotherapy proves effective for the first time as a sole treatment for a subtype of metastatic colorectal cancer [VHIO]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
It is the first time a treatment using only the anti-PD1 antibody pembrolizumab and not including chemotherapy has proved effective as a first-line treatment in patients with colorectal cancer with microsatellite instability.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.ucl.ac.uk/news/2020/may/immunotherapy-bowel-cancer-could-change-clinical-practice" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Immunotherapy for bowel cancer could change clinical practice [University College London]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
For patients treated with pembrolizumab, progression-free survival was 55.3% at 12 months and 48.3% at 24 months. This compared with 37.3% and 18.6% respectively, for those on chemotherapy.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.5.5 ASCO (GASTRO-INTESTINAL)</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2020/enhertu-significantly-improved-tumour-response-rate-and-overall-survival-in-her2-positive-metastatic-gastric-cancer.html" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Enhertu significantly improved tumour response rate and overall survival in HER2-positive metastatic gastric cancer in Phase II DESTINY-Gastric01 trial [AstraZeneca]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
First HER2-directed medicine to show an improvement in overall survival for previously treated metastatic gastric cancer with a 41% reduction in the risk of death vs. chemotherapy.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2020/enhertu-achieved-a-tumour-response-rate-of-45p-in-patients-with-her2-positive-metastatic-colorectal-cancer-in-phase-ii-destiny-crc01-trial.html" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Enhertu achieved a tumour response rate of 45.3% in patients with HER2-positive metastatic colorectal cancer in Phase II DESTINY-CRC01 trial [AstraZeneca]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
The primary endpoint of confirmed objective response rate (ORR), assessed by independent central review, showed 45.3% of patients with HER2-positive (defined as IHC3+ or IHC2+/ISH+) advanced colorectal cancer treated with Enhertu (trastuzumab deruxtecan) monotherapy (6.4mg/kg) achieved a tumour response.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://endpts.com/astrazenecas-7b-adc-succeeds-where-roche-failed-improving-survival-in-gastric-cancer/" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
AstraZeneca’s $7B ADC succeeds where Roche failed, improving survival in gastric cancer [EndPoints]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
The positive results are particularly noteworthy because a key rival drug failed against gastric cancer. Kadcyla, Roche’s blockbuster HER2 targeting antibody drug conjugate, flopped 5 years ago in a Phase II/III trial in second-line patients.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.nrgoncology.org/Home/News/Post/trastuzumab-combined-with-trimodality-treatment-does-not-improve-outcomes-for-patients-with-her2-overexpressing-esophageal-cancer-on-nrg-oncology-trial" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Trastuzumab Combined with Trimodality Treatment Does Not Improve Outcomes for Patients with HER2-Overexpressing Esophageal Cancer on NRG Oncology Trial [NRG Oncology]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
The Phase III NRG-RTOG 1010 trial evaluated 203 HER2 positive patients with a median follow up of 5 years.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.5.6 ASCO (PEAU-MÉLANOME)</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.novartis.com/news/media-releases/novartis-announces-long-term-relapse-free-survival-benefit-high-risk-stage-iii-melanoma-patients-treated-tafinlar-mekinist-following-surgery" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Novartis announces long-term, relapse-free survival benefit for high-risk, stage III melanoma patients treated with Tafinlar® + Mekinist® following surgery [Novartis]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Study conclusions are drawn from the largest dataset and longest follow-up to date of patients with BRAF-mutated melanoma treated with targeted therapy following the surgical removal of their cancer.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.5.7 ASCO (GYNÉCO)</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.nrgoncology.org/Home/News/Post/combined-cediranib-and-olaparib-presents-similar-activity-to-standard-of-care-treatment-for-platinum-sensitive-ovarian-cancer" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Combined Cediranib and Olaparib Presents Similar Activity to Standard of Care Treatment for Platinum-Sensitive Ovarian Cancer [NRG Oncology]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
There were no overall survival differences between the treatment arms. Patients who received cediranib and olaparib in addition to the standard of care did experience a higher frequency of grade 3 or higher gastrointestinal, hypertension, and fatigue adverse events.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.5.8 ASCO (POUMON)</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2020/enhertu-demonstrated-meaningful-clinical-activity-in-patients-with-her2-mutant-non-small-cell-lung-cancer.html" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Enhertu demonstrated meaningful clinical activity in patients with HER2-mutant non-small cell lung cancer in interim analysis of Phase II DESTINY-Lung01 trial [AstraZeneca]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
61.9% of patients with HER2-mutant metastatic non-small cell lung cancer treated with Enhertu achieved a tumour response.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.mdanderson.org/newsroom/targeted-therapy-tepotinib-for-non-small-cell-lung-cancer-with-met-exon-14-skipping-mutation-shows-durable-response.h00-159381945.html" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Targeted therapy tepotinib for non-small cell lung cancer with MET exon 14 skipping mutation shows durable response [MD Anderson Cancer Center]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Phase II clinical trial shows 46.5% objective response rate.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.dana-farber.org/newsroom/news-releases/2020/study-shows-comprehensive-genomic-profiling-identified-co-occurring-alterations-that-may-cause-treatment-resistance-in-patients-with-metex14-altered-non-small-cell-lung-cancer/" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Study shows comprehensive genomic profiling identified co-occurring alterations that may cause treatment resistance in patients with METex14-altered non-small cell lung cancer [Dan Farber Cancer Insitute]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Alterations that cause skipping of exon 14 on the MET gene (METex14) are drivers of a type of lung cancer with a poor prognosis, but that is treatable with a recently approved MET inhibitor.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.5.9 ASCO (AUTRES ORGANES)</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://endpts.com/pfizer-merck-kgaa-cement-bavencio-bladder-cancer-win-with-os-data-while-carving-another-niche-in-rare-cancer/" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Pfizer, Merck KGaA cement Bavencio bladder cancer win with OS data — while carving another niche in rare cancer [EndPoints]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
All 700 patients in the trial completed chemotherapy before getting randomized to either maintenance therapy with Bavencio or regular checking. Those on the drug arm saw mOS of 21.4 months, compared with 14.3 months on the comparator group.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
</tbody></table>
OVEhttp://www.blogger.com/profile/16701670533772026788noreply@blogger.comtag:blogger.com,1999:blog-6449150757505425806.post-47711431603317280492020-05-29T12:31:00.004+02:002020-05-29T12:31:25.332+02:00Onco Actu du 29 mai 2020<table style="-webkit-text-stroke-width: 0px; color: black; font-family: Times; font-size: medium; font-style: normal; font-variant-caps: normal; font-variant-ligatures: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-decoration-color: initial; text-decoration-style: initial; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
2.13 ETIOLOGIE - NDMA</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.fda.gov/news-events/press-announcements/fda-alerts-patients-and-health-care-professionals-nitrosamine-impurity-findings-certain-metformin" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
FDA Alerts Patients and Health Care Professionals to Nitrosamine Impurity Findings in Certain Metformin Extended-Release Products [FDA]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
The agency is in contact with five firms to recommend they voluntarily recall their products.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
4.10 DÉP., DIAG. & PRONO. - POUMON</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.cancerresearchuk.org/about-us/cancer-news/press-release/2020-05-27-ai-could-predict-risk-of-lung-cancer-coming-back" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
AI could predict risk of lung cancer coming back [Cancer Research UK]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
The paper was published in Nature Medicine and is showcased alongside 8 other TRACERx publications on the Nature website.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.1 TRAITEMENTS - PRÉ-CLINIQUE</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://news.uthscsa.edu/cancer-drugs-cause-large-cells-that-resist-treatment-scientist-aims-to-stop-it/" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Cancer drugs cause large cells that resist treatment; scientist aims to stop it [University of Texas]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Dr. Mahadevan found that two cancer-causing genes, called c-Myc and BCL2, are operative in “double-hit” high-grade lymphomas, which are incurable. “These genes are part of the problem, because when they are present, they help the lymphoma cells to live longer and prime them to become large cells with treatment,” he said.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://penntoday.upenn.edu/news/blocking-tumor-signals-can-hinder-cancers-spread" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Blocking tumor signals can hinder cancer’s spread [Penn Medicine]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Using an inhibitor of the enzyme known as p38α kinase (p38), they successfully reduced the spread of melanoma in a mouse model, significantly prolonging survival time.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.12 IMMUNOTHÉRAPIES</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.sciencemag.org/news/2020/05/designer-antibodies-fight-cancer-tethering-immune-cells-tumor-cells" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Designer antibodies fight cancer by tethering immune cells to tumor cells [Science]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><div style="float: left;">
<img class="slider_img" id="relevance_171652_img" src="http://srv10-inca/amiei/img/slider_star_3.gif" style="margin: 0px 2px; vertical-align: bottom;" title="Niveau de pertinence" /></div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Those new players in immunotherapy are no panacea yet. For some blood cancers, the bispecific antibodies aren’t giving patients the long-lasting remissions often seen with CAR T cells. As happened with CAR T cells, several patients have died in trials testing bispecific antibodies, possibly from overzealous immune responses sparked by the drugs.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.2.1 PHARMA - PARTENARIATS</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.fiercebiotech.com/biotech/bristol-myers-jumps-into-synthetic-lethality-65m-repare-deal" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Bristol Myers jumps into synthetic lethality with $65M Repare deal [Fierce Biotech]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Repare’s CRISPR-based platform identifies synthetic lethal gene pairs, which cause cell death when both genes are inactivated. In cancer cells, one of these genes is inactivated by a mutation; the other will be switched off by a drug.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.cancer.gov/news-events/cancer-currents-blog/2020/fda-sacituzumab-govitecan-triple-negative-breast-cancer" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Sacituzumab Govitecan Approved for Metastatic Triple-Negative Breast Cancer [NCI]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
The new approval was based on findings from a phase 2 clinical trial that was sponsored by Immunomedics, the drug’s manufacturer. The trial enrolled 108 patients with metastatic triple-negative breast cancer, and all the participants received sacituzumab govitecan.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.5.1 ASCO (GÉNÉRAL)</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://obroncology.com/blog/sneak-peek-at-asco-2020-plenary-sessions/" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Sneak Peek at ASCO 2020 Plenary Sessions [OBR]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><div style="float: left;">
<img class="slider_img" id="relevance_171660_img" src="http://srv10-inca/amiei/img/slider_star_1.gif" style="margin: 0px 2px; vertical-align: bottom;" title="Niveau de pertinence" /></div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Late-breaking data dropped for three potentially practice-changing studies that will be presented during Sunday’s Plenary Session: JAVELIN Bladder 100, KEYNOTE-177, and ADAURA.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://obroncology.com/blog/asco-2020-late-breakers-showcase-impact-of-covid-19-on-cancer-and-more/" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
ASCO 2020 Late-Breakers Showcase Impact of COVID-19 on Cancer and More [OBR]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
The studies cover new data from two cancer registries (CCC19 and TERAVOLT) assessing the impact of COVID-19 on patients with cancer, and results from the TROPHIMMUN trial and INFORM registry.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.5.10 ASCO (HÉMATO)</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.mdanderson.org/newsroom/combination-therapy-well-tolerated-and-highly-effective-for-patients-with-idh1-mutated-acute-myeloid-leukemia-aml.h00-159381945.html" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Combination therapy well-tolerated and highly effective for patients with IDH1-mutated acute myeloid leukemia (AML) [MD Anderson Cancer Center]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Findings suggest AML treatments may be tailored to individual molecular profiles.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.5.14 ASCO (VESSIE ET VOIES URINAIRES)</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.asco.org/about-asco/press-center/news-releases/immunotherapy-following-chemotherapy-offers-extended-survival" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Immunotherapy Following Chemotherapy Offers Extended Survival to Patients with Advanced Urothelial Cancer [ASCO]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
When combined with best supportive care, avelumab treatment resulted in a median overall survival of 21.4 months compared with 14.3 months for best supportive care alone.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.5.16 ASCO (MÉDECINE DE PRÉCISION)</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.asco.org/about-asco/press-center/news-releases/large-scale-precision-medicine-approach-successfully-applied" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Large Scale Precision Medicine Approach Successfully Applied to Pediatric Cancers With Poor Prognosis [ASCO]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
In all, 149 patients received targeted treatment based on the targets identified using the algorithm at the discretion of their clinical pediatric oncologist.<br />There were no clinically relevant differences in overall survival.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.5.18 ASCO (OBSERVATION)</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.asco.org/about-asco/press-center/news-releases/early-data-show-cancer-progression-associated-increased-risk" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Early Data Show Cancer Progression Associated With Increased Risk of Death in Patients With COVID-19 [ASCO]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><div style="float: left;">
<img class="slider_img" id="relevance_171644_img" src="http://srv10-inca/amiei/img/slider_star_3.gif" style="margin: 0px 2px; vertical-align: bottom;" title="Niveau de pertinence" /></div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Treatment with combination of hydroxychloroquine and azithromycin also strongly associated with greater risk of death.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.asco.org/about-asco/press-center/news-releases/chemo-within-3-months-covid-19-diagnosis-associated-increased" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Chemo Within 3 Months of COVID-19 Diagnosis Associated With an Increased Risk of Death in Patients With Thoracic Cancer [ASCO]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Only patients treated with chemotherapy (alone or in combination with other therapies) within 3 months of COVID-19 diagnosis had a significantly increased risk (64%) of dying from the virus compared with patients not receiving chemotherapy.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.5.19 ASCO (REIN)</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.mdanderson.org/newsroom/novel-targeted-drug-induced-positive-response-for-patients-with-von-hippel-lindau-disease-associated-kidney-cancer.h00-159381945.html" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Novel targeted drug induced positive response for patients with von Hippel-Lindau disease–associated kidney cancer [MD Anderson Cancer Center]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
MD Anderson led Phase II study may lead to first systemic therapy for VHL disease.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.5.4 ASCO (IMMUNOTHÉRAPIES)</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.mrknewsroom.com/news-release/asco/keytruda-pembrolizumab-plus-lenvima-lenvatinib-combination-demonstrated-clinically" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Combination Demonstrated Clinically Meaningful Tumor Response Rates in Unresectable Hepatocellular Carcinoma and Advanced Renal Cell Carcinoma [Merck]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Analyses from KEYTRUDA Plus LENVIMA Trials to be Presented at 2020 ASCO Annual Meeting.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.5.4.7 ASCO (IMMUNOTHÉRAPIES- GASTRO-INTESTINAL)</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.fiercepharma.com/pharma/asco-merck-s-keytruda-doubles-time-to-disease-progression-certain-colorectal-cancer-patients" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
ASCO: Merck's Keytruda doubles time to disease progression in certain colorectal cancer patients [Fierce Pharma]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
“These long-awaited trial results will change clinical practice,” lead study author Thierry André, M.D., said in a statement.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.mrknewsroom.com/news-release/asco/mercks-keytruda-pembrolizumab-superior-standard-care-chemotherapy-patients-msi-h-c" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Merck’s KEYTRUDA® (pembrolizumab) Superior to Standard of Care Chemotherapy in Patients with MSI-H Colorectal Cancer [Merck]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
KEYNOTE-177 is the First Positive Head-to-Head Phase 3 Trial of a Single-Agent, Anti-PD-1 Therapy Compared to Chemotherapy as First-Line Treatment for Patients with MSI-H Colorectal Cancer.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.asco.org/about-asco/press-center/news-releases/pembrolizumab-doubles-time-disease-progression-patients" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Pembrolizumab Doubles Time to Disease Progression in Patients With Advanced Colorectal Cancer With Specific DNA Mutations [ASCO]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Progression-free survival with first-line pembrolizumab was 16.5 months compared with 8.2 months with chemotherapy with or without targeted therapy, establishing pembrolizumab as the new standard of care for patients with microsatellite instability high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal carcinoma.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.5.7 ASCO (GYNÉCO)</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.fiercepharma.com/pharma/asco-pfizer-merck-kgaa-s-bavencio-posts-win-rare-gynecological-cancer" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
ASCO: Pfizer, Merck KGaA's Bavencio posts win in rare gynecological cancer [Fierce Pharma]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
While the data aren’t practice-changing—doctors will need more evidence before switching up the way they treat the disease, lead author Benoit You, M.D., Ph.D said—"these are highly promising results.”</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.asco.org/about-asco/press-center/news-releases/immunotherapy-avelumab-shows-potential-rare-gynecologic-cancer" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Immunotherapy Avelumab Shows Potential in Rare Gynecologic Cancer Resistant to Chemotherapy [ASCO]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
This is the first trial exploring use of immunotherapy in patients with gestational trophoblastic tumors (GTT) and suggests that avelumab may be a new therapeutic option for these patients.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.5.8 ASCO (POUMON)</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.roche.com/media/releases/med-cor-2020-05-29.htm" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Updated data demonstrate Roche’s Alecensa increases overall survival rate for people with ALK-positive non-small cell lung cancer [Roche]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
ALEX study is the first global phase III study to show a clinically meaningful benefit in overall survival at five years (62.5% with Alecensa), compared with crizotinib (45.5%).</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.5.8 ASCO (POUMON) - OSIMERTINIB</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.biopharmadive.com/news/astrazeneca-tagrisso-aduara-lung-cancer-asco-results/578801/" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
AstraZeneca bid to expand lung cancer drug's use boosted by trial data [Biopharma Dive]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
The British drugmaker is now preparing to ask the Food and Drug Administration to clear Tagrisso for use in this setting, called adjuvant treatment. An approval could boost sales of the medicine, which at more than $3 billion a year is AstraZeneca's top-selling product.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.fiercepharma.com/pharma/asco-astrazeneca-s-tagrisso-headed-for-big-sales-boost-cuts-lung-cancer-recurrence-by-83" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
ASCO: AstraZeneca's Tagrisso, headed for big sales boost, cuts lung cancer recurrence by 83% [Fierce Pharma]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
“This trial is a home run. It exceeded our expectations,” lead study author Roy Herbst, M.D., PhD., said in a statement.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://endpts.com/astrazeneca-trumpets-the-good-data-they-found-for-tagrisso-in-an-adjuvant-setting-for-nsclc-but-many-of-the-experts-arent-cheering-along/" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
AstraZeneca trumpets the good data they found for Tagrisso in an adjuvant setting for NSCLC — but many of the experts aren’t cheering along [EndPoints]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><div style="float: left;">
<img class="slider_img" id="relevance_171653_img" src="http://srv10-inca/amiei/img/slider_star_1.gif" style="margin: 0px 2px; vertical-align: bottom;" title="Niveau de pertinence" /></div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
The disease-free survival numbers look good, the skeptics concede, but when you’re out to cure patients at this stage, it’s the overall survival data you want in hand to make a call like this. And when researchers jumped early, the OS data weren’t on hand, just evidence of a trend in the drug’s favor — which doesn’t count among biostatisticians.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2020/tagrisso-demonstrated-unprecedented-disease-free-survival-in-the-adjuvant-treatment-of-stage-ib-iiia-patients-with-egfr-mutated-lung-cancer.html" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Tagrisso demonstrated unprecedented disease-free survival in the adjuvant treatment of Stage IB-IIIA patients with EGFR-mutated lung cancer [AstraZeneca]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Phase III ADAURA trial showed treatment with Tagrisso after surgery with curative intent reduced the risk of disease recurrence or death by c. 80%.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.ajmc.com/conferences/asco-2020/osimertinib-after-surgery-keeps-cancer-at-bay-for-nsclc-patients-with-key-mutation" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Osimertinib After NSCLC Surgery Keeps Cancer at Bay for Patients With Key Mutation [AJMC]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
The results have important implications for managed care. Many patients in the study who today would receive surgery and chemotherapy would see a recurrence. In addition, the ability to treat these patients more effectively at earlier stages raises new questions about the need to conduct more lung cancer screening.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.asco.org/about-asco/press-center/news-releases/post-surgery-osimertinib-delays-disease-recurrence-patients" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Post-Surgery Osimertinib Delays Disease Recurrence in Patients With Localized Non-Small Cell Lung Cancer [ASCO]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Results of the multinational randomized controlled phase III ADAURA trial were compelling enough that the independent data monitoring committee recommended early unblinding.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
</tbody></table>
OVEhttp://www.blogger.com/profile/16701670533772026788noreply@blogger.comtag:blogger.com,1999:blog-6449150757505425806.post-41164536400349126982020-05-28T15:46:00.004+02:002020-05-28T15:46:57.534+02:00Onco Actu du 28 mai 2020<table style="-webkit-text-stroke-width: 0px; color: black; font-family: Times; font-size: medium; font-style: normal; font-variant-caps: normal; font-variant-ligatures: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-decoration-color: initial; text-decoration-style: initial; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
1. BIOLOGIE</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.cshl.edu/pregnancy-reprograms-breast-cells-reducing-cancer-risk/" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Pregnancy reprograms breast cells, reducing cancer risk [Cold Spring Harbor Laboratory]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
“You have cancer genes being shut down at the same time that genes leading this cell to a kind of a precipice, like they’re going to jump out and die, get turned on. We believe these signals are the key players for why these cells do not turn into cancer.”</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://medicalxpress.com/news/2020-05-gene-inactivation-pten-cancer-predisposition.html" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Gene inactivation of PTEN drives cancer predisposition [Medical XPress]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
In a new study published in the New England Journal of Medicine, a research team found that mutations to the gene WWPI may be an additional genetic driver of PHTS-associated cancer.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
1.1 BIOLOGIE - GÉNOME</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.broadinstitute.org/news/international-gnomad-consortium-releases-its-first-major-studies-human-genetic-variation" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
International gnomAD Consortium releases its first major studies of human genetic variation [Broad Institute]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Analyses of the largest publicly available catalog of human genomic data reveal new details on rare types of genetic variation and provide better tools for genetic disease diagnosis and drug development.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.nature.com/articles/d41586-020-01551-x" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
A milestone in human genetics highlights diversity gaps [Nature]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><div style="float: left;">
<img class="slider_img" id="relevance_171633_img" src="http://srv10-inca/amiei/img/slider_star_3.gif" style="margin: 0px 2px; vertical-align: bottom;" title="Niveau de pertinence" /></div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Landmark study identifies the genes that it seems people can and cannot live without and highlights ongoing challenges in making data sets more representative of the world’s population.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.genomeweb.com/sequencing/gnomad-consortium-details-range-human-genetic-variation-large-dataset" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
GnomAD Consortium Details Range of Human Genetic Variation From Large Dataset [Genome Web]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
In a series of papers appearing on Wednesday in Nature, Nature Communications, and Nature Medicine, the gnomAD team showed how the dataset could be used to improve rare variant interpretations, evaluate potential drug targets, and more.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5. TRAITEMENTS</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.nature.com/articles/d41586-020-01347-z" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Take lessons from cancer evolution to the clinic [Nature]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><div style="float: left;">
<img class="slider_img" id="relevance_171619_img" src="http://srv10-inca/amiei/img/slider_star_3.gif" style="margin: 0px 2px; vertical-align: bottom;" title="Niveau de pertinence" /></div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
The first long-term study of how lung cancer evolves is revealing that therapies targeting multiple proteins in tumour cells could help to outpace the disease.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.12.1 IMMUNOTHÉRAPIES - PARTENARIATS</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.fiercebiotech.com/biotech/gilead-pens-2b-arcus-pact-for-immuno-oncology-targets-past-and-future" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Gilead pens $2B Arcus pact for immuno-oncology targets of the past and future [Fierce Biotech]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
The headline part of the deal sees Gilead join companies including Merck and Roche in the race to bring an anti-TIGIT antibody to market, which could be the future of immuno-oncology, while also gaining a hand in the checkpoint inhibitor research space.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://xconomy.com/san-francisco/2020/05/27/gilead-gains-foothold-in-solid-tumors-with-375m-10-year-arcus-bio-pact/" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Gilead Gains Foothold in Solid Tumors With $375M, 10-Year Arcus Bio Pact [Xconomy]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
The Arcus collaboration gives Gilead immediate access to zimberelimab, an antibody drug that blocks PD-1, a checkpoint protein on immune cells that keep them from targeting cancer cells.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.biopharmadive.com/news/gilead-arcus-cancer-drug-deal/578669/" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Gilead puts $375M into Arcus in latest push to broaden cancer business [Biopharma Dive]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
The deal broadens Gilead's research and development of drugs for solid tumors. It's also a bet by Gilead that Arcus can help it develop treatment combinations that boost the benefits of first generation immunotherapies.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://endpts.com/gilead-leases-partner-rights-to-tigit-pd-1-in-a-2b-deal-with-arcus-now-comes-the-hard-part/" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Gilead leases partner rights to TIGIT, PD-1 in a $2B deal with Arcus. Now comes the hard part [EndPoints]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Hotly rumored for weeks, the 2 players have formalized a 10-year alliance that starts with rights to the PD-1, zimberelimab.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.12.11 IMMUNOTHÉRAPIES - PRÉ-CLINIQUE</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.pennmedicine.org/news/news-releases/2020/may/new-cancer-immunotherapy-targeting-myeloid-cells-slows-tumor-growth" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
New Cancer Immunotherapy Targeting Myeloid Cells Slows Tumor Growth [Penn Medicine]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
The team showed that in c-Rel-deficient mice tumor size and weight were reduced by up to 80 percent, and that administering the c-Rel inhibitor drug in another set of mice shrank tumors by up to 70 percent, compared to controls.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.pennmedicine.org/news/news-releases/2020/may/new-blueprint-of-exhausted-t-cell-lifespan-could-help-build-better-immunotherapies" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
New “Blueprint” of Exhausted T Cell Lifespan Could Help Build Better Immunotherapies [Penn Medicine]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Penn researchers identified four stages of exhausted T cell development.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.12.6 IMMUNOTHÉRAPIES - AMM</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://endpts.com/bristol-myers-squibb-finally-gets-in-the-frontline-nsclc-game-dominated-by-merck-adding-a-second-opdivo-yervoy-based-option/" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Bristol Myers Squibb finally gets in the frontline NSCLC game dominated by Merck, adding a second Opdivo/Yervoy-based option [EndPoints]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
While it marks a clear win for Bristol Myers after some setbacks — including an ill-fated campaign to stratify patients by tumor mutational burden — establishing a place in the lung cancer market will remain a challenge for the commercial team.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.12.8 IMMUNOTHÉRAPIES - ECONOMIE</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.nice.org.uk/news/article/nice-recommends-treatment-for-type-of-small-cell-lung-cancer" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
NICE recommends treatment for type of small-cell lung cancer [NICE]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><div style="float: left;">
<img class="slider_img" id="relevance_171625_img" src="http://srv10-inca/amiei/img/slider_star_1.gif" style="margin: 0px 2px; vertical-align: bottom;" title="Niveau de pertinence" /></div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
In new draft guidance, atezolizumab (also called Tecentriq and made by Roche) with carboplatin and etoposide has been recommended as an option for untreated extensive-stage small-cell lung cancer (ES-SCLC).</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.2.2 PHARMA - FUSIONS & ACQUISITIONS</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://endpts.com/in-latest-cancer-deal-bristol-myers-squibbs-new-bd-chief-bets-80m-in-search-for-more-targets-like-parp/" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
In latest cancer deal, Bristol Myers Squibb's new BD chief bets $65M in search for more targets like PARP [EndPoints]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Synthetic lethality is the theme at Versant-backed Repare Therapeutics, which is getting $50 million in cash and $15 million in equity investment to discover new targets for Bristol.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://endpts.com/sanofi-ceo-paul-hudson-has-23b-burning-a-hole-in-his-pocket-and-here-are-some-hints-on-how-he-plans-to-spend-that/" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Sanofi CEO Paul Hudson has $23B burning a hole in his pocket. And here are some hints on how he plans to spend that [EndPoints]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Porges is expecting some quick movement on the buyout front following Hudson’s deal to acquire Synthorx for $2.5 billion — putting them on the trail for more oncology assets to go with the new R&D strategy.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.4 TRAITEMENTS - ECONOMIE</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.nice.org.uk/guidance/ta630" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Larotrectinib for treating NTRK fusion-positive solid tumours [NICE]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
More evidence on larotrectinib is being collected until there are enough data to address the committee’s uncertainties. After this NICE will decide whether or not to recommend it for use on the NHS and update the guidance. It will be available through the Cancer Drugs Fund until then.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.5.10 ASCO (HÉMATO)</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.fiercebiotech.com/biotech/asco-gsk-s-anti-bcma-antibody-gets-a-data-boost-ahead-fda-decision" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
ASCO: GSK's anti-BCMA antibody gets a data boost ahead of FDA decision [Fierce Biotech]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Of the 97 patients that received the lower dose of the treatment, belantamab mafodotin, 31 had their tumors shrink and five patients saw them vanish—two more than were reported in December.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://endpts.com/gsk-adds-to-its-trove-of-positive-data-for-multiple-myeloma-contender-as-rivals-continue-to-command-the-spotlight/" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
GSK adds to its trove of positive data for multiple myeloma contender as rivals continue to command the spotlight [EndPoints]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Combined with bortezomib/dexamethasone, belantamab mafodotin hit an overall response rate of 78% among patients who had received one or more previous therapies.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.5.2 ASCO (SEIN)</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.novartis.com/news/media-releases/novartis-kisqali-shows-overall-survival-benefit-hrher2-advanced-breast-cancer-consistent-findings-patients-more-aggressive-disease" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Novartis Kisqali® shows overall survival benefit in HR+/HER2- advanced breast cancer with consistent findings in patients with more aggressive disease [Novartis]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Subgroup analysis shows Kisqali plus endocrine therapy extended life compared to endocrine therapy for patients with liver metastases – showing ~47% and 37% reduction in the risk of death in MONALEESA-7 (M7) and MONALEESA-3 (M3), respectively.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
6.1 OBSERVATION</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://medicalxpress.com/news/2020-05-breast-cancer-pre-invasive-disease.html" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Study sheds light on risks of breast cancer after pre-invasive disease [Medical XPress]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Women who are diagnosed with ductal carcinoma in situ (known as DCIS) during breast screening go on to experience higher risks of developing breast cancer and of death from breast cancer, compared with the general population, finds a study published by The BMJ today.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
6.15 LUTTE CONTRE LES CANCERS - COVID-19</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://edition.cnn.com/2020/05/27/opinions/unexpected-side-effect-less-medical-care-covid-19-welch-prasad/index.html" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
The unexpected side effect of Covid-19 [CNN]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><div style="float: left;">
<img class="slider_img" id="relevance_171613_img" src="http://srv10-inca/amiei/img/slider_star_1.gif" style="margin: 0px 2px; vertical-align: bottom;" title="Niveau de pertinence" /></div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Suspending cancer screening is another important area to study. There is little doubt, for example, that the decline in mammography will lead to fewer breast cancers diagnosed. But is that a bad thing or good thing? One opportunity is to study what happens to US cancer statistics when screening is resumed.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.nytimes.com/2020/05/26/well/live/coronavirus-cancer-diagnosis-treatment-cure.html" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Finding, and Curing, Cancers May Be Another Casualty of Coronavirus [NY Times]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
As the death tolls rise to the coronavirus pandemic, those of us who specialize in oncology are bracing for another wave of victims: People not yet diagnosed with cancer.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
</tbody></table>
OVEhttp://www.blogger.com/profile/16701670533772026788noreply@blogger.comtag:blogger.com,1999:blog-6449150757505425806.post-39520752386951403362020-05-27T12:22:00.002+02:002020-05-27T12:22:31.759+02:00Onco Actu du 27 mai 2020<table style="-webkit-text-stroke-width: 0px; color: black; font-family: Times; font-size: medium; font-style: normal; font-variant-caps: normal; font-variant-ligatures: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-decoration-color: initial; text-decoration-style: initial; text-indent: 0px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
1. BIOLOGIE</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.massgeneral.org/news/press-release/lymph-node-metastases-versus-distant-metastases" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Lymph Node Metastases Form Through a Wider Evolutionary Bottleneck than Distant Metastases [Mass. General Hospital]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><div style="float: left;">
<img class="slider_img" id="relevance_171599_img" src="http://srv10-inca/amiei/img/slider_star_1.gif" style="margin: 0px 2px; vertical-align: bottom;" title="Niveau de pertinence" /></div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Reconstructing the evolutionary histories of dozens of primary colorectal cancers and their metastases, the team showed that lymph node metastases are a genetically highly diverse group. Their pronounced heterogeneity indicates that they can be seeded by many different primary tumor sub-lineages.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
1.1 BIOLOGIE - GÉNOME</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.genomeweb.com/sequencing/colorectal-cancer-study-reveals-tumor-mutation-immune-microenvironment-relationships" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Colorectal Cancer Study Reveals Tumor Mutation, Immune Microenvironment Relationships [Genome Web]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
An international research team has uncovered apparent ties between tumor mutational patterns and immune features in the surrounding microenvironment in dozens of colorectal cancer (CRC) patients from Korea and Belgium.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
4.5 DÉP., DIAG. & PRONO. - COLORECTAL</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.reuters.com/article/us-health-coronavirus-usa-cancer-exclusi/exclusive-research-finds-concerning-drop-in-u-s-colorectal-cancer-screenings-and-surgeries-idUSKBN2330EH" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Exclusive: Research finds concerning drop in U.S. colorectal cancer screenings and surgeries [Reuters]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Research by the health data firm Komodo Health and exclusively shared with Reuters found new colorectal cancer diagnoses declined more than 32%, while the number of performed colonoscopies and biopsies fell by nearly 90% from mid-March to mid-April, compared with the same period last year.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.1 TRAITEMENTS - PRÉ-CLINIQUE</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://massey.vcu.edu/about/news-center/2020-archive/anti-malarial-drug-shows-promise-for-brain-cancer-treatment/" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Anti-malarial drug shows promise for brain cancer treatment [Massey Cancer Center]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Innovative screening strategies for Fli-1 inhibitors identified lumefantrine as a prospective agent that could bind to Fli-1, inactivate it and thereby suppress expression of important genes regulating growth, survival and oncogenicity (ability to cause tumors) of glioblastoma multiforme.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.10 TRAITEMENTS - ESSAIS</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.cancer.gov/news-events/press-releases/2020/burkitt-lymphoma-adult" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Study confirms effective, less toxic alternative to standard treatment for adults with Burkitt lymphoma [NCI]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
In addition to being better tolerated, the regimen, called dose-adjusted (DA) EPOCH-R, is already an option for diffuse large B-cell lymphomas and can be administered in an outpatient setting. The findings were published May 26, 2020, in the Journal of Clinical Oncology.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.12.6 IMMUNOTHÉRAPIES - AMM</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.fiercepharma.com/pharma/bms-grabs-another-green-light-for-opdivo-yervoy-first-line-lung-cancer-time-alongside-chemo" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Bristol Myers Squibb's Opdivo, Yervoy score another lung cancer OK, this time alongside chemo [Fierce Pharma]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><div style="float: left;">
<img class="slider_img" id="relevance_171605_img" src="http://srv10-inca/amiei/img/slider_star_1.gif" style="margin: 0px 2px; vertical-align: bottom;" title="Niveau de pertinence" /></div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
The go-ahead comes just 11 days after the agency cleared Opdivo and Yervoy for use sans chemo in PD-L1-positive patients.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://news.bms.com/press-release/corporatefinancial-news/us-food-and-drug-administration-approves-opdivo-nivolumab-ye-2" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) + Yervoy® (ipilimumab) Combined with Limited Chemotherapy as First-Line Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer [BMS]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Approval marks sixth indication for Opdivo + Yervoy-based combinations across five types of cancer.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.12.8 IMMUNOTHÉRAPIES - ECONOMIE</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.cancerresearchuk.org/about-us/cancer-news/news-report/2020-05-26-immunotherapy-for-triple-negative-breast-cancer-approved-for-nhs-in-england" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
Immunotherapy for triple-negative breast cancer approved for NHS in England [Cancer Research UK]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
The final decision comes in response to the company that developed atezolizumab submitting new data analysis and an amended price, after the drug was initially rejected by NICE in October last year.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
5.5 ASCO</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://news.vumc.org/2020/05/26/asco-press-program-highlights-covid-19-outcomes-in-lung-cancer-patients/" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
ASCO press program highlights COVID-19 outcomes in lung cancer patients [VUMC]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
“The data on the first 200 patients was primarily from France, Italy and Spain,” Horn said. “The outcomes were pretty shocking. There was 35% mortality in patients with a thoracic malignancy. Almost three-quarters of the patients required hospital admission.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="center" height="20" style="background-color: #e3e3e3; font-family: Helvetica, Arial, sans-serif; height: 20px; line-height: 20px; padding: 0px;"><h3 style="color: #666666; font-size: 12px; font-weight: bold; line-height: 12px; margin: 0px; padding: 0px; text-transform: uppercase;">
6.15 LUTTE CONTRE LES CANCERS - COVID-19</h3>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td colspan="3" style="margin: 0px; padding: 0px;" valign="top"><table border="0" cellpadding="0" cellspacing="0" style="color: #717171; font: 11px Helvetica, Arial, sans-serif; margin: 0px; padding: 0px; width: 508px;"><tbody>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td align="left" style="border-bottom: 1px solid rgb(233, 233, 233); padding: 5px 0px 0px;"><a href="https://www.statnews.com/2020/05/27/coronavirus-mother-son-confront-cancer/" style="text-decoration: none;"><h2 style="color: #0b5394; font-family: Helvetica, Arial, sans-serif; font-size: 16px; font-weight: bold; line-height: 26px; margin: 0px; padding: 0px;">
‘Forced to retract completely into ourselves,’ a mother and son confront cancer in the age of Covid-19 [STAT]</h2>
</a></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td valign="top"><div style="float: left;">
<img class="slider_img" id="relevance_171603_img" src="http://srv10-inca/amiei/img/slider_star_3.gif" style="margin: 0px 2px; vertical-align: bottom;" title="Niveau de pertinence" /></div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 10px 0px 8px;" valign="top"><div class="newsletter_summary" style="color: #767676; font-family: Helvetica, Arial, sans-serif; font-size: 12px; font-weight: normal; line-height: 20px; margin: 0px; padding: 0px;">
Amy and Landen, two generations fighting cancer, are united by something else: They are going through the most frightening and painful moments of their lives without the family warmth and support that was standard practice at the nation’s medical centers — until Covid-19.</div>
</td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
<tr><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td><td style="padding: 5px 0px 0px;" valign="top"><br /></td><td style="font-size: 1px; line-height: 1px;" width="22"><br /></td></tr>
</tbody></table>
</td></tr>
</tbody></table>
OVEhttp://www.blogger.com/profile/16701670533772026788noreply@blogger.com